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ABSTRACT 
Structural and Functional Characterization of the LDP3 (VHZ)  
Protein Tyrosine Phosphatase 
 
 by  
Vyacheslav I. Kuznetsov, Doctor of Philosophy 
Utah State University, 2013 
Major Professor: Alvan C. Hengge 
Department: Chemistry and Biochemistry  
 
 PTPs represent a large family of enzymes responsible for the intracellular 
dephosphorylation. Together with protein tyrosine kinases (PTKs), PTPs control the level 
of protein phosphorylation which modulates numerous aspects of cell life.  VHZ, a 
recently discovered PTP, expresses in most fetal tissues and is associated with several 
types of cancer. It was originally classified as a dual specificity phosphatase (DUSP23) 
and named after the prototypical member as VH1 related protein member Z.  Our 
preliminary screening assays of VHZ performed with 360 phosphopeptides have revealed 
a number of phosphotyrosine containing substrates, but no activity toward 
phosphothreonine or phosphoserine substrates, thus strongly suggesting that this enzyme 
is not related to DUSPs.  We solved a crystal structure to 1.1 Å resolution, which, 
together with sequence analysis showed that VHZ is more related to classical PTPs rather 
than DUSPs.  The crystal structure revealed an unusual metavanadate (VO3) ion in the 
iv 
 
active site of VHZ which has never been observed in the aqueous environment. Its 
appearance in our crystal structure, together with computational studies, allowed us to 
propose a mechanism by which PTPs can enzymatically interconvert different non-
inhibiting vanadate species dominating at physiological pH to generate the inhibiting 
metavanadate ion observed in our structure. We also evaluated VHZ catalytic properties 
by several techniques including steady-state and pre-steady-state kinetics, kinetic isotope 
effects, kinetic inhibition studies combined with site-directed VHZ modification, and 
computer modeling. We found that the catalytic activity of VHZ was significantly 
underestimated by previous researchers. Unlike any other PTP, VHZ has evolved with 
two general acids in the active site – a phenomenon that was expedited by two substrate 
binding orientations. Finally, we show that VHZ is capable of performing hydrolysis as 
well as alcoholysis of its phosphate monoester substrates. We were able to identify a 
single mutation in the area of the active site responsible for this unusual 
phosphotransferase behavior. Considering that the level of intracellular phosphorylation 
affects a number of normal and pathological physiological processes, our finding may 
explain the relation of VHZ to several types of cancer and justify this enzyme as a 
promising drugable target.  
 
 
 
(219 pages) 
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PUBLIC ABSTRACT 
 
Structural and Functional Characterization of the LDP3 (VHZ) 
Protein Tyrosine Phosphatase 
by Vyacheslav I. Kuznetsov 
Utah State University, 2013 
 
Protein phosphorylation is as an important regulatory mechanism that controls a large 
number of physiologically important cellular processes.  Proteins are phosphorylated on 
aliphatic (serine and threonine) as well aromatic (histidine and tyrosine) residues 
predominantly located on sterically accessible loops. Phosphorylation affects three-
dimensional structures of proteins resulting in conformational changes which activate or 
deactivate enzymatic functions. Because of the ability of protein phosphorylation to 
modulate a multitude of diverse cellular processes, it became an appealing and promising 
target for drug therapy.  
Attachment of phosphate is accomplished by kinases, whereas the removal of the  
phosphoryl group is performed by protein phosphatases. Traditionally, protein kinases 
have been studied more intensely than protein phosphatases due to the earlier belief that 
they confer fine regulation to protein phosphorylation, whereas protein phosphatases act 
to nonspecifically remove phosphate groups. In recent years the protein phosphatases 
were subjected to thorough analysis to reveal a number of diverse properties which 
formed the basis for phosphatase classification. The family of protein tyrosine 
phosphatses (PTPs) represents the largest group of protein phosphatases known today.    
We focused our study on the 150 amino acids VHZ phosphatase, which was originally 
classified as a dual-specificity enzyme which can dephosphorylate aliphatic (phospho 
serine, phospho threonine) and aromatic (phospho tyrosine) residues.  We solved a crystal 
structure of VHZ refined to 1.1 Å resolution and performed an extensive structural, 
biological and kinetic analysis which revealed that this enzyme is not a dual specificity 
phosphatase. Activity screening with 360 biologically relevant peptides indicated strict 
phospho-tyrosine specificity and provided important information about its physiological 
substrates. Mechanistic studies using steady-state and pre-steady state kinetics, as well as 
inhibition studies and kinetic isotope effects (KIE) explain the significantly reduced 
catalytic parameters of VHZ, and contribute to our understanding of the PTP catalytic 
mechanism in general.  
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CHAPTER 1 
INTRODUCTION 
1-1. Introduction to protein phosphorylation 
 Within cellular signaling, protein phosphorylation is one of the most abundant 
posttranslational modifications. Protein phosphorylation/dephosphorylation (Figure 1-1) 
is recognized as an important regulatory mechanism affecting cell physiology, health and 
pathology (1, 2). It controls inter- and intracellular communication, gene transcription, 
tissue homeostasis, organ development and immune response.  Proteins are 
phosphorylated on aliphatic (1, 3) as well aromatic (histidine and tyrosine) residues 
located primary on sterically accessible loop regions. Phosphorylation affects three 
dimensional structures of proteins resulting in conformational changes which activate or 
deactivate enzymatic function or/and triggers protein-protein interaction. Protein kinases 
and protein phosphatases regulate the level of intracellular phosphorylation and hereby 
considered to be the main players in this dynamic process. Because of their importance 
protein kinases and phosphatases are often called Yin and Yang of the phosphatome (2).  
 
 
1-2. Classification of protein phosphatases 
The crucially important step in understanding newly discovered enzymes is their 
proper characterization and classification. Protein phosphatases are classified based upon 
catalytic mechanism, presence of cofactors, structural arrangement, sequence similarities 
(signature motifs, often related to the mechanism), subcellular localization, and substrate 
specificity. Figure 1-2 shows the classification of protein phosphatases. 
Phosphoserine/phosphothreonine specific enzymes are grouped into the PPP and 
PPM families (4). Proteins in this family require metal cofactors to support activity and 
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are also known as metallophosphatases (5). They utilize a multi-subunit architecture 
which contains a small catalytic subunit that binds regulatory and/or targeting subunits in 
vivo. Enzymes in this family have evolved to selectively target protein sites containing 
serine and threonine-phosphorylated residues. The further discussion of this family lies 
outside of the scope of the present work.  
Another family of protein tyrosine phosphatase (PTPs) requires no cofactor to 
support activity. It is subdivided into Class I, Class II, Class III, and Class IV 
phosphatases based on evolutionary relation revealed by the amino acid and structural 
similarities, which, in turn, are often associated with the scope of potential substrates and 
biological functions. Class I, Class II, and Class III enzymes utilize the same catalytic 
mechanism, which is shown in Figure 1-2.  
The largest class, Class I, consists of the tyrosine specific (classical PTPs) and 
dual specificity phosphatases, the latter which target both phosphoserine, 
phosphothreonine as well as phosphotyrosine residues. It comprises 99 members that are 
divided into 38 classical tyrosine-specific PTPs and 61 DSPs.  They could have 
potentially evolved from a common ancestor due to the high structural similarity of 
catalytic domains, which are easily superimposable, despite the fact they share very little 
(<30%) primary sequence similarity (4). Classical PTPs can be further subdivided into 
two groups of 21 and 17 genes encoding receptor PTPs (PTP-Rs) and non-receptor PTPs 
(PTP-NRs), respectively. The DSP subfamily is divided into seven different groups 
including  PTEN phosphatases, slingshot phosphatases (SSHs), MKPs, and 
myotubularins (MTMRs).  
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Figure 1-1.  Catalytic mechanism utilized by Class I, Class II, and Class III PTPs.  
 
 
The Mitogen Activated Protein Kinase phosphatases (MKPs) are specific (11 
proteins) which target ERK, JNK and p38 kinases (6).  These MAPKs are simultaneously 
phosphorylated on threonine and tyrosine residues within a TXY activation loop region 
required for full activity (7). The complete inactivation by MKPs requires 
dephosphorylation at both sites as well. Although MKPs have very little sequence 
similarity to classical PTPs, they share a very similar structural fold and are highly 
superimposable with catalytic domains of classical PTP enzymes.  
There are 16 atypical VH1-related DSPs, which are highly similar to MKPs, 
except for lacking CH2 homology domain and represented by a sole catalytic subunit (8).  
They are named after the first enzyme cloned – the VH1 protein from Vaccinia Virus. 
They target MAPK and STAT1, but an increasing amount of evidence indicates the 
substrate scope is not restricted to these enzymes. Because atypical DSPs contain no 
additional regulatory or targeting domains these enzymes likely interact with additional 
subunits in vivo, and, similar to serine/threonine specific phosphatases, utilize a 
multisubunit arrangement. Similar to MKPs, atypical DSPs have dual specificity and can 
dephosphorylate both pY and pT residues (8). It was shown, however, that VHR has a 
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2000-fold preference for phosphotyrosine over phosphoserine/ phosphothreonine residues 
(9).  
PTEN phosphatases target phosphatidylinositol (3,4,5)-trisphosphate  
phospholipids to generate phosphatidylinositol 4,5-bisphosphate (PIP2) which directly 
opposes PI3 - kinase activity. It is a crucial part of many signaling pathways (10). Its 
structure containing a CH2 targeting domain has been described (11). 
There are 16 myotubularins, which, similar to the PTEN phosphatases, can 
dephosphorylate phosphatidylinositol (3,4,5)-trisphosphate and are highly conserved 
from yeast to human (12-15). The physiological role of these enzyme remains unclear, 
however, it was shown that more than a half of the known enzymes in this group lack 
catalytically important cysteine, arginine and aspartic acid residues and are thus 
catalytically inactive. 
The PRL family of phosphatases contains the PRL-1, PRL-2, and PRL-3 
enzymes. These enzymes contain a conserved PTP catalytic domain as well as C-terminal 
CAAX region which is required for post-translational farnesylation of these enzymes 
(16). These enzymes are believed to localize close to the cell membrane but the actual 
role and biological functions remains largely unknown.   
The only Class II enzyme found in humans is a Low Molecular Weight (LMW) 
protein tyrosine phosphatase.  Despite sharing the same mechanism as classical PTPs and 
DSPs, LMW-PTPs have a strikingly different catalytic domain topology and cannot be 
superimposed with classical PTP or DSPs. With the exception of the C(X5)R(S/T) 
catalytic signature motif highly conserved in all PTPs, and the catalytic aspartic acid 
required for catalysis (17), LMWs share no sequence homology with other PTPs. They 
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are related to evolutionary conserved bacterial type II phosphatases. LMW PTPs target a 
number of tyrosine kinases, and similar to classical PTPs can only dephosphorylate pY 
residues (18). 
Class III is exemplified by three p80 CDC25 phosphatases – CDC25A, CDC25B 
and CDC25C. These enzymes are known cell cycle regulators which specifically target 
Cdc2 kinase by dephosphorylating tyrosine and threonine residues located on the (pT)-P-
(pY) phosphorylation lip. This dual dephosphorylation activates Cdks promoting cell 
division cycle progression. Similar to Class II enzymes, Class III is structurally distinct 
from other PTP family members (19) and with the exception of the PTP signature motif 
share no sequence homology (3). Despite sharing the catalytic PTPase motif the enzymes 
are not inhibited by oxyanions suggesting their mechanism is more related to the bacterial 
rhodanese (20) which catalyzes transfer of sulfane sulfur from thiosulfate to cyanide 
generating thiocyanate and sulfite. What is remarkable about Class III enzymes is that, 
working as phosphatases, they are themselves dependent on phosphorylation of 
conserved tyrosine residues near the active site.  
All PTPs except for class IV utilize the same two step double displacement 
mechanism and contain a consensus catalytic signature (H/V)CX5R(S/T) motif in which 
cysteine and arginine residues are invariant and essential for enzymatic activity of all 
members. By contrast, the class IV members contain a conserved (DXDXT/V) domain 
and use an aspartic acid as a key element for catalysis (21). The class IV enzymes have 
been demonstrated to display pS or pY phosphatase activity as well (22). EyA (eye 
absent) tyrosine specific phosphatases and HAD (haloacid dehydrogenase) are pY or pS 
specific and target various substrates including proteins, phospholipids and sugars.  
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Most of the PTPs, unlike S/T-phosphatases have a modular structural architecture. 
In other words, 79 out of 107 known PTPs contain at least one additional non-catalytic 
(extracatalytic) domain which is important for enzyme-substrate interaction, or 
intracellular localization and represents a part of the same polypeptide chain which is 
permanently attached to the catalytic subunit (23). For example, receptor type PTPs 
contain a SH2 domain that consists of 100 residues and contains a pY binding site. MAP 
kinase phosphatases contain a N-terminal CH2 (CDC25 homology) domain which targets 
them to their natural substrates – ERK and JNK kinases (24-26). Myotubularins contain 
an N-terminal PH (pleckstrin homology) domain and C-terminal coil domain which 
targets these enzyme to specific subcellular location. Only a group of small atypical 
VH1-related DSPs and Class II Low Molecular PTPs contains no additional 
extracatalytic domains. As was exemplified by the SHP-1 PTP, the extracatalytic domain 
may modulate the activity of the catalytic domain (27).  
 
1-3. Association of PTPs with pathological processes  
Protein phosphorylation plays an important role in multiple biological processes 
such as proliferation, differentiation, adhesion and metabolic homeostasis. Because of the 
crucial importance of the phosphorylation/dephosphorylation several PTPs were found to 
be associated with cancer, diabetes, and immune deficiencies.  Type II diabetes or 
diabetes mellitus is characterized by reduced insulin sensitivity (insulin resistance, IR) in 
insulin target organs. Human PTP1B is responsible for the dephosphorylation of insulin 
receptor kinase which generates a potent insulin mimetic effect and has been viewed as a 
very potential target for anti-diabetes drugs (28). Somatic mutations in human cancer 
specifically target PTEN at a high frequency, resulting in increased activity of the PI3K 
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pathways that are associated with cell survival and tumor development and metastasis 
(29, 30).  Yersinia PTP (YopH, Yop51) is the known virulence factor in the bacterium 
responsible for bubonic plague and is one of the most active phosphatases known to date 
Figure 1-2. Classification of protein phosphatases. Metal containing phosphatases are 
represented by PPM and PPP families. Protein tyrosine phosphatases (PTPs) require no 
cofactor for catalysis and represented by aspartate-based PTPs, utilizing aspartic acid as a 
nucleophilic residue, and more abundant cysteine based PTPs, containing nucleophilic 
cysteine in the active site.   
 
(25, 31). All three PRL members were found to overexpress in a variety of cancer cells 
leading to cell proliferation and migration (32). While the presence of LMW PTP has 
been correlated with a number of diseases such as rheumatoid arthritis, asthma, diabetes, 
cardiomyopathy and Alzheimer’s disease, the physiological role of these enzymes is yet 
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to be discovered (33, 34). Mutations in myotubularins were associated with 
neuromuscular disease (35-37). Several MKPs were found to play an important role in 
negative regulation of the inflammatory response (38, 39) as well as responsible for 
several types of cancer (40).  Atypical DSPs were found to overexpress in multiple cancer 
cell lines including prostate cancer, breast cancer and colon cancer (41).  
Unfortunately, the physiological functions of the individual PTPs are poorly 
understood, owing to the lack of information about the genuine substrates of the 
respective PTPs. Genetic and epigenetic alterations in genes encoding PTPs result in 
changes to the equilibrium of kinase–phosphatase activity that might have deleterious 
effects, including abnormal cell proliferation, which could ultimately lead to cancer. It 
was noted that the mutations affecting the catalytic domain are known to be associated 
with highly conserved regions. They were found to have an oncogenic effect and 
simultaneously decrease the authentic phosphatase activity. In order to better understand 
the effect of genetic alteration and mutations, the catalytic principles of individual PTPs 
must be better understood. For example, it is not clear why different PTPs which share 
the same catalytic protein fold and utilize the same mechanism differ by as much as four 
orders of magnitude in their catalytic activity.  
 
1-4. VHZ as a newly member of  PTP superfamily 
Human VHZ (also known as DUSP23 or LDP3) was cloned and characterized by 
several research groups in recent years (23, 42, 43). Because of its small size stipulated 
by the absence of any extracatalytic domains it was immediately tagged as an atypical 
DSP and named VH1 related member Z.  Its mRNA overexpresses in all fetal tissues, but 
it is only present in adults’ testis and colon.  The VHZ sequence is evolutionarily 
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conserved and did not alter significantly as revealed by its orthologues from frog, fish, 
fly, and the Archaea, indicating an important physiological role which is yet to be 
discovered.  It was found to overexpress in several cancer cell lines, indicating it may 
play some role in the tumor development process (44).  The kinetic characterization of 
this newly discovered phosphatase revealed it was one of the least active protein 
phosphatases known to date. The research however stumbled over an unexpected 
problem when VHZ was tested to identify its natural substrates from the list of MAPK 
known to be atypical DSP targets (45). The results yielded conflicting reports and failed 
to provide consistent evidence.  The only crystal structure of VHZ in complex with 
malate ion in the active site trapped from the crystallization cocktail was used to present 
additional evidence for VHZ being a VH1 related DSP (46). The fact that the malate ion 
was neither substrate nor product analogue for this class of enzymes (but was 
nevertheless treated as such), and was involved in several unspecific interactions was 
completely ignored.  It was obvious that there was no consistent and reliable information 
about VHZ that could be used to guide further research or make affirmative conclusions 
about its biological role. At the same time its evolutionary conservation, expression in 
several human tissues, and association with cancer development and progression made it 
a particularly promising target for the future research.   
In the following chapters we address important aspects of VHZ in more detail. In 
Chapter 2 we show that from the very beginning its classification as a VH1 related DSP 
was incorrect and was detrimental for essentially all subsequent research conducted with 
this enzyme. We present a crystal structure of VHZ (PDBID 4ERC) with a 
physiologically relevant metavanadate transition state analogue which allowed us to draw 
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several important conclusions and revise the original classification of VHZ. Our 
conclusions were consistent with the kinetic evidence obtained with a multi-peptide 
library which indicated that VHZ reveals an exclusive phospho tyrosine specificity and 
hereby cannot be treated as DSP. In Chapter 3 we show that VHZ has very unique, 
unprecedented kinetic properties and significantly more active than it was previously 
believed. We use SsoPTP from the thermophilic organism Sulfolobus solfataricus which 
is structurally related to VHZ to show that the observed kinetic behavior was not 
accidental but stipulated by the uniqueness of the structure.  In Chapter 4 a potential 
mechanism by which PTPs are inhibited by vanadate oxyanions is proposed and 
discussed. It addresses the long lasting and controversial topic of how PTPs are inhibited 
by complex mixtures of vanadate oxyanion, how closely vanadate mimics transition state 
of PTP catalyzed reaction, and the nature of vanadate interaction with this family of 
enzymes. 
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CHAPTER 2 
NEW ASPECTS OF THE PHOSPHATASE VHZ REVEALED BY A HIGH 
RESOLUTION STRUCTURE WITH VANADATE 
AND SUBSTRATE SCREENING
1
 
 
Abstract 
The recently discovered 150-residue human VHZ (VH1 related protein, Z 
member) is one of the smallest protein tyrosine phosphatases (PTPs) known, and contains 
only the minimal structural elements common to all PTPs.   We report a substrate 
screening analysis and a crystal structure of the VHZ complex with vanadate at 1.1 Å 
resolution, with a detailed structural comparison with other members of the protein 
tyrosine phosphatase family, including classical tyrosine-specific protein tyrosine 
phosphatases (PTPs) and dual specific phosphatases (DSPs).  A screen with 360 
phosphorylated peptides shows VHZ efficiently catalyzes the hydrolysis of phospho-
tyrosine(pY)-containing peptides, but exhibits no activity toward phospho-serine (1) or 
phospho-threonine (pT) peptides.  The new structure reveals a deep and narrow active 
site more typical of the classical tyrosine specific PTPs.  Despite the high structural and 
sequence similarities between VHZ and classical PTPs, its general acid IPD-loop is most 
likely conformationally rigid, in contrast to the flexible WPD counterpart of classical 
PTPs.  VHZ also lacks substrate recognition domains and other domains typically found 
on classical PTPs.  It is therefore proposed that VHZ is more properly classified as an 
atypical PTP rather than an atypical DSP, as has been suggested. 
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Introduction 
Protein tyrosine phosphatases (PTPs) are involved in multiple physiological 
processes including cell growth and proliferation, control of the cell cycle, cytokine 
activation and cytoskeletal integrity (2, 3). PTPs share the conserved signature motif 
HCXXGXXR(S/T) that binds the substrate and provides transition state stabilization, and 
a two-step catalytic mechanism with a cysteinyl-phosphate intermediate (4-6). PTP 
family members are further subdivided into several subfamilies based on substrate 
specificity and sequence similarity.  In-vivo protein phosphorylation most commonly 
occurs on hydroxyl containing aliphatic (serine/threonine) or aromatic (tyrosine) side 
chains, and the classical PTPs (often referred to as tyrosine specific PTPs) hydrolyze only 
phosphotyrosine containing polypeptides. The dual-specificity phosphatases (DSPs) 
constitute a subset of (PTPs) that are characterized by the ability to dephosphorylate 
phosphoserine and phosphothreonine residues in addition to phosphotyrosine (7, 8).  
The active sites of all PTP family members are structurally similar and utilize an 
invariant triad of amino acids to catalyze phosphate monoester hydrolysis, which includes 
a nucleophilic cysteine; an arginine that, along with backbone amides, binds substrate and 
provides transition state stabilization; and an aspartic acid that protonates the leaving 
group.  In the classical, tyrosine-specific PTPs the latter catalytic residue resides on a 
flexible loop referred to as the WPD loop (9).  In the DSPs, the general acid is believed to 
reside on a structurally rigid element.  
Despite the high structural similarities of catalytic domains, superimposable 
active sites, and common mechanism, PTPs are selective for particular biological targets.  
The accurate identification of substrate preference and the correct assignment of these 
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enzymes into the various PTP subfamilies associated with different biological pathways 
and pathological states is one of the most important goals of human phosphatome 
research. The recently discovered 150-residue human VHZ (also designated as atypical 
DSP 23) is one of the smallest PTP family members known to date, which contains only 
the minimal set of secondary structural elements common to all PTPs (10-12). Because of 
its small size and the absence of substrate targeting domains, it has been classified as an 
atypical VH-1 related DSP (12) - a subfamily of cysteine based PTPs that regulates 
mitogenic signaling pathways and cell cycle process (7, 13). Atypical DSPs have been 
linked to cancer, but despite numerous studies knowledge about these enzymes still 
remains contradictory and incomplete (1, 14).  The attempts to identify the physiological 
substrates of VHZ have provided conflicting and inconsistent evidence (10, 15, 16). It is 
known, however, that VHZ is highly expressed in fetal tissues, and recent reports 
associated VHZ with breast cancer (17). 
The only crystal structure of VHZ published to date is a complex with malate 
trapped in the active site (18). Malate ion is an important part of VHZ crystallization 
conditions, but represents neither a substrate nor a product analogue. Potential resulting 
distortions on the local geometry of the active site motivated us to seek a structure with a 
physiologically relevant reaction analogue.  We report a high-resolution X-ray structure 
of VHZ complexed with the physiologically relevant transition state analogue 
metavanadate which allows us to compare VHZ structurally with a number of classical 
PTP and atypical DSP protein-ligand complexes.  This analysis suggests that VHZ bears 
more resemblance to the classical PTPs rather than DSPs, but probably lacks a movable 
loop. These conclusions from the crystal structure support the results of a phosphopeptide 
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substrate screen, which revealed that phosphotyrosine, but not phosphoserine or 
phosphothreonine-containing peptides, are substrates for VHZ. The collected results 
strongly suggest that VHZ is more related to the classical PTPs rather than the atypical 
DSP subfamily, and in order to more properly guide future research in the biological 
roles of VHZ, its current classification should be re-considered.  
 
Experimental Procedures (Materials and Methods) 
All buffer solids, EDTA, malic acid, ammonium sulfate and sodium 
orthovanadate were obtained from Fisher. Chromatography columns were purchased 
from GE Healthcare. Protease K was from Sigma. Polyethyleneimine (Mw 50000) was 
from Acros Organics. A set of standard FastDigest restriction enzymes, DNA Pfu Turbo 
Polymerase, dNTP master mix were obtained from Fermentas. Custom primer 
oligonucleotides were synthesized by IDT.  The phosphatase substrate screen was from 
GPT Innovative Peptide Solution. DTT, antibiotics and protease inhibitors were from 
GoldBio.  
 
Protein cloning  
The human VHZ WT gene was amplified using a two-step PCR strategy from a 
GST-tagged version on a plasmid that was a generous gift of Dr. Subramanyam 
Swaminathan (18).  In the first step the gene was amplified using the following primers: 
Fwd1: GAAAACCTGTATTTTCAGGGCGTGCAGCCCCCC, Rev1: 
GGAGAGCTCTTATTTCGTTCGCTGGTAGA to incorporate TEV cleavage site (in 
bold) immediately upstream of the first N-terminal GGC codon (methionine excluded). 
At the same time SacI restriction site (GAGCTC) was added at the end of the sequence. 
In the second PCR step, the product of the first step was used as a template and a KpnI 
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restriction site was added upstream of the TEV protease cleavage sequence using the 
following set of primers: Fwd2:CGGGGTACCGAAAACCTGTAT, Rev1:  GGAGA 
GCTCTTATTTCGTTCGCTGGTAGA. The PCR product was digested with KpnI and 
SacI restriction enzymes (Fermentas) and inserted into the pet-45(B+) vector (Novagen). 
The obtained pet 45B+TEV-VHZ construct was successfully expressed in BL21-codon+ 
(DE3)-RIL cells and purified with Ni-Fast Flow High affinity resin (GE Healthcare). 
Unfortunately, the resulting fusion protein was resistant to TEV cleavage of the poly-
histidine tag and the tagged protein was unstable at low pH. Insertion of a short spacer 
arm following the histidine tag did not improve TEV cleavage (19). A tagless enzyme 
construct was prepared by removal of the histidine tag and TEV-cleavage site from the 
pET 45b-TEV-VHZ construct using one-step overlap-extension PCR (20) using the 
following primers: Fwd: TATACCATGGGCGTGCAGCCC; 
Rev:CGTGCACGCCCATGGTATATCT. The resulting construct was used to express 
tagless VHZ WT in BL-21 DE-3 (codon+) cells.   
 
Protein preparation 
Tagless VHZ WT was expressed in BL21-codon+(DE3)-RIL cells. The cells were 
grown at 37
o
C to an OD600 = 1.2-1.5. Protein expression was induced with IPTG 
(100mg/L) and cell culture flasks were transferred to room temperature shaker for 20 
hours before harvesting. The cells were harvested by centrifugation for fifteen minutes 
and re-suspended in the lysis buffer containing 50 mM HEPES, 150 mm NaCl, 1mM 
EDTA, 10 mM DTT, 5% glycerol pH 7.4 (4
o
C).  Cells were disrupted by sonication on 
ice and the pellet was separated by centrifugation. The supernatant was transferred into a 
separate beaker and a 10 % w/v solution of polyethyleneimine (PEI, Mw50000, pH 8.0) 
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was added dropwise to the supernatant at 4
o
C to reach a final PEI concentration of 0.5% 
(w/v). A white precipitate formed immediately and was separated by centrifugation. 
Ammonium sulfate was added to the supernatant (to 65% saturation), precipitated protein 
was collected and re-suspended in 150 mL of SP-loading buffer containing 100 mM 
sodium acetate, 1mM DTT, 1mM EDTA, 10 % glycerol, pH 5.6. The solution was 
filtered and 15 mL of Hi-Trap SP-HP cation exchange resin (GE-Healthcare) pre-
equilibrated with SP-loading buffer were added to the protein (4
o
C). The resin was 
transferred into a column and washed with SP-loading buffer (2ml/min) to reach a stable 
baseline. Protein was eluted using 120 mL linear gradient with elution buffer containing 
100 mM sodium acetate, 1mm DTT, 1mM EDTA, 600 mM sodium chloride, 10 % 
glycerol, pH 5.6. Fractions containing phosphatase activity toward para-
nitrophenylphosphate (pNPP) were collected, concentrated to a volume of 3-5 mL and 
loaded on a Superdex 75 26/60 gel filtration column (GE-Healthcare) pre-equilibrated 
with buffer containing 10 mM HEPES, 150 mM NaCl, 1 mM methionine, 3 mm DTT, 10 
% glycerol pH 7.5  (4 
o
C, 0.3 ml/min). The single peak correspondent to VHZ WT was 
collected and estimated to be >98% pure based on the SDS PAGE analysis.  Protein was 
concentrated to 20 mg/mL as determined by UV using an A
280
1 mg/ml= 0.68.   
 
Determination of substrate specificity 
The commercial phosphopeptide screen from JPT Innovative Peptide 
Technologies (product code PhSS-360-250) was used. The full list of the 
phosphopeptides comprising this screen is available at the manufacturer web site 
(http://jpt.com) and is included in Supporting Information as Table A-1.  25 μL of buffer 
containing 100 mM sodium acetate 0.5 mM DTT, 150 mM NaCl (pH5.5) and 0.25 units 
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of VHZ WT (0.55mg/ml) were added in each well of 384-well microtiter plate containing 
360 phosphopeptides (250 pmol per well) derived from human phosphorylation sites 
together with 10 calibration standards. After incubation for two hours at 25 
o
C, 5 μL of 
protease K (Sigma, 200 μg/ml) was added to digest the enzyme and prevent enzyme 
precipitation after addition of the malachite green reagent. After 15 minutes, 30 μL of the 
malachite green solution (Promega) were added and color developed for 10 minutes. The 
absorbance at 600 nm was measured to quantify the amount of free inorganic phosphate 
released by the enzyme using a standard curve.  This was converted to a % of total 
hydrolysis using the supplier-provided information for amounts of substrate in each well.  
Subsequently, kcat and KM were measured for two peptide substrates, one that exhibited 
among the highest percent of hydrolysis (QREAEpYEPETV) and one from the group 
exhibiting the least (DADEpYLIPQQG). In a control experiment, incubation of pY-
containing peptides under the assay conditions without enzyme exhibited no measurable 
hydrolysis after 48 hours. 
 
Co-crystallization with sodium vanadate  
 All crystallization experiments were carried out at room temperature using the 
sitting drop vapor diffusion method. VHZ WT concentrated to 20 mg/mL in the 
crystallization buffer was mixed with 50 mM solution of sodium vanadate (final vanadate 
concentration 10 mM, Ki=2.7 μM) prepared as previously described (21). One μL of 
protein-vanadate complex was mixed with an equal volume of well solution containing 
150 mM L-Malate, pH 7.0 and PEG3350 (15-20 %). 1M stock solution of sodium malate 
was prepared by titration of malic acid with sodium hydroxide. Crystals grew within one 
week.  
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Data collection and processing 
The crystal in the droplet was transferred to a cryosolution containing the well 
solution supplemented with 10% v/v glycerol and 10mM sodium vanadate for 10 min and 
flash-frozen in liquid nitrogen. Diffraction data were collected at the Stanford 
Synchrotron Radiation Lightsource (SSRL) on the beam line 9-2. The collection and 
refinement statistics are shown in Table 2-1. Molecular replacement was performed with 
Phenix (22) using the previously published VHZ structure (PDBID 2img) as a search 
model with malate ion in the active site removed. Coot (23) and MolProbity (24) were 
used for model building and validation. Phenix was used for model refinement. PyMol 
(25) was used to prepare figures and superimpose structures. Structure factors and 
coordinates have been deposited in the Protein Data Bank under accession code 4ERC. 
 
Results 
Substrate specificity of VHZ 
The substrate specificity of VHZ was assessed using a phosphatase substrate set 
containing 360 peptides, correspondent to natural in vivo phosphorylation sites 
monophosphorylated on serine, threonine, or tyrosine.  Amino acids adjacent to the 
phosphorylation site play an important role in the substrate recognition by different PTPs 
(26).  The structural diversity of JPT screen eliminates the bias resulting from adverse 
binding effects caused by unfavorable amino acids proximal to the phosphorylated site, 
which allows a reliable assessment of the comparative effectiveness of VHZ in catalyzing 
the hydrolysis of pS, pT and pY containing peptides.  Because the goal of this experiment 
was to determine whether VHZ was a DSP or a PTP, reactions were given a sufficiently 
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Table 2-1. Data collection and refinement statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
long time to incubate before assay to insure that even substrates yielding very low 
activity would be detected.  After two hours, enzymatic activity was observed in every 
well containing a pY-phosphorylated peptide, with an average hydrolysis completion of 
50-60%. No activity was observed in wells containing either pS or pT-phosphorylated 
peptides. In particular, no activity was observed in the wells containing serine/ threonine 
 VHZ-VO3 
Data collection SSRL 
    Beamline 9-2 
          Wavelength (Å) 0.97946 
Resolution range (outer shell) (Å) 50.00-1.15 (1.19 -1.15) 
No. of reflections  
                Unique 94,449 
                Total 1,237,514 
Average redundancy 13.1 (12.2) 
Mean I/σ(I) 31.3 (3.8) 
Completeness (%) 99.6 (99.4) 
Rsym (%) 6.8 (66.6) 
Space group P 21 21 21 
Unit cell dimensions (a, b, c (Å); α = β =γ 
90° ) 
33.0, 79.9, 99.7 
  
Refinement  
Rwork/Rfree (%) 12.8/14.5 
Atoms in the structure 5312 
    Protein 4838 
       Waters 466 
    Ligands/ions 8 
Average B-factors (Å
2
)  
    Protein 13.6 
    Water 26.6 
R.M.S.D. bond (Å)/angle (degrees) 0.008 /1.245 
Protein geometry  
    Ramachandran favored (%) 96.07% 
    Ramachandran outliers (%) 0.66 
        Rotamer outliers (%) 1.57% 
    Protein Data Bank entry 4ERC 
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monophosphorylated peptides corresponding to the previously tested MBP (myelin 
binding protein) and common DSP substrates containing TXY activation loop of MAPK 
8—MAPK11.  The peptide sequences that resulted in hydrolysis yielding greater than the 
average are presented in Table A-2 of Supporting Information.  In subsequent 
experiments, kcat and KM were determined for the substrate QREAEpYEPETV, one of the 
substrates exhibiting the highest percent of hydrolysis, and for DADEpYLIPQQG, which 
was among those that exhibited the lowest activity.  These kinetic results are shown in 
Table 2-2.  
 
General structure description 
The crystal structure of VHZ complexed with metavanadate was solved to 1.1 Å 
resolution (Figure 2-1). The structure was refined to an Rwork/Rfree of 12.8/14.5% (Table 
2-1). Two molecules of VHZ are contained in the asymmetric unit. The final model 
includes the protein residues 1-150 and a metavanadate (VO3) ligand present in each 
active site. VHZ  is a single domain protein consisting of a central, twisted, five-stranded 
β sheet surrounded by six α helices, two on one side and four on the other side (Figure 2-
1). The conserved phosphate-binding loop (P-loop) connects the β5 strand and the α4 
helix, and general acid loop (referred as IPD-loop (12) by analogy to the conserved WPD 
loop of the classical PTPs) connects α3 and β4 elements. The D residue of the IPD motif 
(D65) acts as the general acid during catalysis. The Q-loop (connecting α6 and α5) 
further defines the active site cleft. The overall VHZ structure represents a typical for the 
PTP family α/β domain. Both molecules in the asymmetric unit adopt a similar protein 
conformation. The guanidinium side chains of R60 and R62 from the symmetry related 
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VHZ molecule is observed in the area of the active sites of molecule A and molecule B, 
respectively  (Figure 2-2 A,C). 
\ 
Comparison with VHZ-Malate structure 
The structure of the VHZ-VO3 transition state complex differs in several important 
details from the previously published VHZ-malate complex. In the VHZ-Mal structure 
(not shown), the malate ion makes four hydrogen bonds to the backbone of the P-loop, 
two hydrogen bonds to the side chain of R101, and one hydrogen bond to the backbone 
of the IPD-loop. The catalytic acid D65 (in the IPD loop) and E134 (in the Q-loop) are 
turned away from the active site (presumably repelled by the negative charge of the 
malate carboxylate groups). As a result, the IPD-loop adopts a catalytically unfavorable 
conformation in which D65 hydrogen bonds to the side chain of the conserved 
phosphate-binding residue R101. Additionally, this catalytically unviable conformation 
imparted by malate distorts the VHZ active site into a shallow and broad crevice 
reminiscent of DSPs.  In the VHZ-Mal complex the side chain of Y136 from the 
symmetry related molecule is trapped in the active site, which, together with the rest of 
 
Table 2-2.  Kinetic constants for peptide hydrolysis. Two substrates selected from the 
substrate screen of differing percentages of hydrolysis.  The last column shows the 
percent of hydrolysis observed in the long time course general substrate screen. 
 
Peptide Sequence kcat (s
-1
) KM (mM) 10
-3
 kcat/KM (M
-1
s
-1
) % hydrolysis 
QREAEpYEPETV 0.56 ± 0.02 1.9 ± 0.2 0.3 100% 
DADEpYLIPQQG 0.53 ± 0.06 4.2 ± 0.4 0.12 50% 
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Figure 2-1. Structure of the VHZ-VO3 complex. Cartoon representation of the VHZ-VO3 
structure reveals a classical PTP α/β fold with central region composed of β sheet (green) 
surrounded by α helices (brown).  The important active site residues and hydrogen bond 
network (dashed lines) surrounding the VO3 oxyanion are shown. 
 
the molecule, makes five additional crystal contacts in the area of the active site, further 
complicating the interpretation of this structure.  
In the VHZ- VO3 structure, the active site contains a region of distinct electon 
density corresponding to a low B-factor water molecule. The water is located whithin 
hydrogen bond distance from the equatorial oxygens of VO3, the side chains of E134 (Q- 
loop), Q138 (Q-loop), and D65 (IPD-loop), and the backbone amide nitrogen of F66 
(Figure 2-1). It is absent in the VHZ-Mal structure due to interactions of the malate ion, 
but a water in this position is consistently observed in X-ray structures of classical PTPs 
such as Yersinia PTP and PTP1B. It represents an important node coordinating the 
primary active site elements in classical PTPs but not in VH1 related DSPs. 
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Figure 2-2. Comparison of the VHZ-VO3 complex with analogous PTP1B structures. (A) 
The VO3 molecule at the VHZ active site in Chain A coordinated by P-loop hydrogen 
bonds. The structural water Ws shown in Figure 2-1 has been omitted for the sake of 
clarity. Hydrogen bond distances (in red) are in Å. The vanadium-sulfur distance is 
similar to that observed in PTP1B structure PDBID 3I7Z (shown in B) with a bound 
vanadyl peptide. The R60 side chain belongs to the symmetry related VHZ molecule  
trapped near the active site. (B) A transition state analog structure for the first catalytic 
step of PTP1B (PDBID 3I7Z), consisting of the enzyme bound to the tyrosyl vanadyl 
ester of the peptide DADEYL; (C) The VO3 moiety at the VHZ active site in Chain B. 
(D) A crystal structure of YopH with bound nitrate, taken as a transition state analogue 
for the second catalytic step of the PTP mechanism (PDBID 1YPT). The R62 side chain 
nitrogen atom from a symmetry related VHZ molecule near the active site in Chain B in 
(C) assumes a position that is analogous to the nucleophilic water molecule (WATNU). 
 
The VHZ-VO3 complex (Figure 2-2) reveals the active site arrangement observed 
in many classical PTP structures where all of the catalytic elements are properly 
positioned for catalysis. The electron density in the active site region clearly reveals the 
[VO3]
-
 ion is coordinated in each active site to the P-loop amide backbone as well as to 
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the side chain of R101. The sulfur of C95 is 2.4 Å from the central vanadium atom. The 
electron density indicates 100% occupancy of the [VO3]
-
 ion bound to one of the VHZ 
molecules (chain A) but only 86% occupancy in the second molecule (chain B).  The 
guanidinium moiety of R101 makes bidentate hydrogen bonds with the bound 
metavanadate, which is a transition state analog of the transferring phosphoryl group.  
The general acid D65 is located in a position suitable for protonation of the scissile 
oxygen atom, as is commonly observed in similar ligand-containing PTP structures.  The 
nucleophilic cysteine sulfur atom is in an apical position relative to the central VO3 
moiety.  
 Interestingly, a gap in electron density exists between the C95 and the vanadate 
in both the 2Fo-Fc difference map and in an unbiased composite omit map (Figure 2-3 A, 
C). Modeling and refinement of a covalently bound cysteinyl-vanadate adduct resulted in 
a large negative electron density peak in the region between the sulfur and vanadium 
(Figure 2-3 B), whereas relaxation of the geometry constraints during refinement yielded 
the original model with a non-covalent sulfur-vanadium interaction. This suggests a 
primarily electrostatic interaction rather than a covalent bond between cysteine 95 and the 
vanadium atom, which has been confirmed by a computational analysis (27). 
 
Functional analysis of VHZ active site  
The active site of classical PTPs is formed by the phosphate binding loop (P-
loop), a glutamine-bearing loop (Q-loop), general acid loop (WPD-loop), and substrate 
binding (recognition) loop. VHZ lacks a substrate recognition loop, which is normally  
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Figure 2-3. The electron density at the VHZ active site. It reveals a non-covalently bound 
vanadate molecule. (A) 2Fo-Fc (blue) contoured at 1.5 σ around catalytic C95, 
metavanadate, and neighboring residues in the refined model. The arginine from the 
symmetry related molecule was omitted for the sake of clarity. (B) 2Fo-Fc (1.5 σ) (blue) 
and Fo-Fc (±3.0 σ) maps (green is positive; red is negative) produced after refining with a 
covalently bound cysteinyl-vanadate model. (C) An unbiased composite omit map 
contoured at 1.5 σ in the same orientation as (A). 
 
located at the N- terminus of classical PTPs.  These loop regions in VHZ, compared with 
PTPs and DSPs, are discussed separately. 
 
P-loop interactions (VHZ residues 95-102)  
The P-loop interactions with bound VO3 in VHZ are presented in Figure 2-1. The 
backbone amides of five P-loop residues make hydrogen bonds to the [VO3]
-
 ion.  The 
amide of conserved G98 makes a catalytically important hydrogen bond to the side chain 
of the nucleophilic C95 (28). The side chain of T102 also donates a hydrogen bond to the 
C95 sulfur, assisting the breakdown of the phosphoenzyme intermediate in the second 
step of the overall reaction, another conserved feature of the PTP family (29). The 
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carbonyl oxygen of G98 makes a hydrogen bond to the side chain of R129, which, 
together with the side chain of N7, provides conformational stability to the P-loop. This 
arginine is highly conserved in all PTPs, and mutation leads to the loss of enzymatic 
activity (30). In atypical DSPs, in addition to the structural role, this residue is important 
for recognition of bisphosphorylated peptide substrates, providing a positive charge in the 
second docking site on the protein surface (30). In classical PTPs this arginine is shielded 
from the surface by protein structural elements and plays no role in the substrate 
recognition.  In VHZ, as in classical PTPs, R129 is shielded from the surface by the side 
chain of N7 (Figure 2-1). The guanidinium R101 side chain, which binds the phosphate 
moiety of the substrate, makes two hydrogen bonds to the metavanadate equatorial 
oxygens, the carbonyl oxygen of I63 (in the IPD-loop) and to the carboxyl oxygen of 
E44.  
 
Q-loop interactions (residues 127-138) 
In classical PTPs this region is characterized by two conserved Q residues and 
participates in catalysis by activation and orientation of the nucleophilic water in the 
second step (31, 32).  Important Q-loop interactions are presented in Figure 2-1. The Q-
loop motif in VHZ is identical to that in classical PTPs with exception of the substitution 
of the first Q by E, which, however, resulted in no functional changes in YopH (32). The 
side chains of E134 and Q138 are directed toward the active site, and together with D65 
(from the IPD-loop) serve to position the incoming nucleophilic water. The analogous N-
loop region in atypical DSPs (Figure 2-4) is positioned such that it provides a broad and 
shallow active site opening required for dual specificity that has no conserved 
glutamines.  
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IPD-loop interactions (residues 61-71) 
The general acid loop in VHZ has been termed the IPD loop, by analogy with the 
conserved WPD loop in the classical PTPs (18). This loop carries the D65 general acid 
that protonates the leaving group in the first step, and acts as a general base in the second 
step activating the nucleophilic water (16, 33, 34). The interactions involving IPD loop 
residues are shown in Figure 2-1 and Figure 2-2.  The IPD loop position corresponds with 
the closed, catalytically active position of the WPD loops in classical PTPs. The side 
chain of I63 docks in a hydrophobic pocket created by the aliphatic part of R101 and side 
chains of M105, V93 and P69, providing hydrophobic interactions similar to those 
involving the conserved W in classical PTP (35).  Similar to clasical PTPs, the carbonyl 
oxygen of I63 makes a hydrogen bond to R101 retaining its side chain in the catalyticaly 
favourable substrate binding conformation. Additional hydrogen bonds occur between the 
carboxyl oxygen of D65 and structural water WS as well as between carbonyl oxygen of 
C67 and side chain nitrogen of Q138. Such interactions are characteristic in the WPD- 
loop stabilization in classical PTPs (Figure2-4, A) but not of atypical DSPs (Figure 2-4, 
B) (36). The structural water molecule is absent in all atypical DSP structures reported to 
date. Instead, general acid positioning is provided by the side chain of a conserved 
asparagine from the N-loop motif and the conserved serine from the P-loop. As the result, 
the general acid position in relation to the leaving group differs in PTPs compared to 
DSPs and protonation occurs from different angles (Figure 2-4, A and B). 
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Figure 2-4. Important distinctions between atypical DSPs and classical PTPs. The 
catalytic general acids are D356, D92 and D65 in YopH, VHR and VHZ respectively; all 
structures are viewed at the same angle in relation to the structurally superimposable P-
loop. Topology and hydrogen bond network of the general acid loop and Q-loop in 
YopH-1YTW  (A), VHR-1J4X (B) and VHZ-VO3 (C) reveal important distinctions 
between classical PTPs (represented by YopH ) and atypical DSPs (represented by 
VHR):  1) Stabilization of general acid WPD-loop in classical PTPs (Panel A) and 
atypical DSPs (Panel B) is obviously different. In particular, the structural water (Ws) 
provides stabilization to the general acid loop in YopH and VHZ, but is never observed in 
atypical DSPs. In VHR (and other atypical DSPs) the general acid loop is stabilized by 
the cluster of highly conserved serine/asparagine residues (S129/N163 in VHR, Panel B). 
As a result, the position of the general aspartic acid in PTPs and DSPs is different and the 
leaving group protonation occurs at different angles; 2) Classical PTPs use invariant Q-
loop residues (Q446 and Q450, Panel A) to orient the incoming nucleophilic water (not 
shown in the figures). The analogous E134 and Q138 residues are present in VHZ (Panel 
C). The analogous region in VHR, named N-loop, has no analogous residues and bears 
the invariant structural asparagine (N163, Panel B); 3) Glycine residue in YopH (G408, 
Panel A) and VHZ (G100, Panel C) provides the important access of Q446 and E134 into 
the active site, whereas the invariant structural serine is present in VHR (S129, Panel B) 
and other atypical DSPs.  
 
Sequence analysis of VHZ 
With the goal of ascertaining where VHZ fits in the PTP-DSP continuum, we 
carried out sequence and structural comparisons between VHZ and several classical PTPs 
and VH1-related DSPs.  Because of significant size differences and little conservation 
outside of the following regions, alignments were confined to the general acid-loop, P-
loop, and Q-loop as the three most important catalytic regions. The results, shown in 
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Appendix A, Figure A-1, A and B, reveal both significant resemblance of VHZ to the 
classical PTPs, and important distinctions from atypical DSPs.  
 
Sequence analysis of the P-loop 
The general PTP family signature motif (P-loop motif) contains the 
HCXXGXXR(S/T) sequence (2, 37). As can be seen from the sequence alignments in 
Figure A-1, (A and B), the conserved motif in classical PTPs is HCXXGXGRT whereas 
in atypical DSPs this sequence is HCXXGXSRS.  The H+6 position (in bold) is 
exclusively occupied by glycine in classical PTPs and by serine in atypical DSPs.  The 
serine at this position in atypical DSPs donates a hydrogen bond to the general acid 
(Figure2-4 B) contributing to its correct positioning for catalysis. Mutation of S129 to G 
in VHR abolishes general acid catalysis by D92 (data not shown).  In classical PTPs, 
glycine occupies the analogous position (Figure 2-4, A), which permits conserved Q-loop 
glutamine residues (Q446 and Q450 in YopH) to access the active site and participate in 
the second step of the reaction by positioning the nucleophilic water (32, 38).  VHZ 
(Figure 2-4, C) resembles classical PTPs in having glycine (G100) rather than serine in 
this position, which allows the E134 side chain to access the active site. 
 
The sequence analysis of the Q-loop 
 In classical PTPs (Figure A-1, A) this region contains the motif 
(V/I)Q(R/T)XXQ. The region is named after two catalytically important Q residues that 
serve to orient and activate the nucleophilic water molecule in the second step (32, 38).  
The corresponding N-loop in atypical DSPs characterized by the highly conserved 
PNXXFXXQL sequence contains a conserved asparagine residue (N163 in VHR), which 
together with the conserved S residue in the P-loop (S129 in VHR), forms a hydrogen 
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bond with the general acid and stabilizes its catalytically favorable conformation (Figure 
2-4, B).  
 
The sequence analysis of the IPD-loop 
In the atypical DSPs the general acid-bearing loop has no sequence conservation 
(Figure A-1,B) with exception of the catalytic aspartic acid, and unlike the WPD-loop, 
does not undergo conformational changes (36).  The sequence alignment of VHZ with 
classical PTPs (Figure A-1,A) shows its IPD-loop is highly analogous to the WPD-loop 
in classical PTPs with the exception of I63 in place of the conserved W.  The MOTIF 
server was used to search the RSCB database for structures that simultaneously contain 
the PTP family HCXXXXR[S/T] motif and a variable general acid XXDXXP loop region 
(Figure A-1, C) but not the highly conserved PNXXXF N-loop sequence, thus allowing 
us to eliminate atypical DSPs.  The goal was to identify proteins that, like VHZ, are 
related to classical PTPs but with variability of the general acid loop region.  Alignment 
of the retrieved structures (e.g. VSP (3AWF), PTEN (1D5R), KAP1 (1FPZ), PhyA 
(3F41), SsoPTP (2I6I), CDC14B(1OHC) revealed the common PTP α/β-fold with 
general acid XXD-loops superimposable with the IPD-loop in VHZ and WPD-loop in 
classical PTPs (Figure A-1,C). These proteins share the active site architecture of 
classical PTPs with substitutions for W in the general acid loop. Based on the sequence 
alignment analysis and structural and functional information of the retrieved proteins, 
VHZ is most closely related to S.solfataricus PTP rather than VSP, PTEN, KAP1, PhyA 
or CDC14B.   
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Discussion 
Identification of VHZ Substrate specificity.   
The substrate specificity of VHZ has been the subject of several conflicting 
studies. In one study VHZ was found to effectively dephosphorylate ERK, but not JNK 
or p38 (11).  In another study, VHZ was found to effect JNK and p38 with no apparent 
effect on ERK (10).  These substrates are common ones among DSPs. The substrate 
screen used in the present study contained several sequences corresponding to activation 
loops of MAPK 8, MAPK 9, MAPK 10 and ERK1 monophosphorylated on pT or pS. No 
activity was detected in these wells, indicating that if VHZ targets the reported proteins, it 
may dephosphorylate only the phosphotyrosine of the pTXpY activation loops, unlike the 
DSP VHR, which targets both sites (30). The observed dephosphorylation pattern is 
characteristic of classical tyrosine-specific PTPs, which result in monophosphorylated 
MAPK forms and retain reduced but significant activity compared to the bi-
phosphorylated proteins (39). DSPs have a preference, but not specificity for, 
bisphosphorylated substrates, and have the ability to act on singly phosphorylated pS and 
pT-peptides. As described above, because R129 is shielded by the side chain of N7, it is 
unlikely that VHZ has a preference for bisphosphorylated substrates (30, 40). These 
results suggest that VHZ is phosphotyrosine specific PTP rather than a DSP.  
Two substrates, one from among those showing the highest hydrolysis percentage 
and one from the lowest, were chosen for more detailed kinetic analysis.  Table 2-2 
shows the kcat, KM, and kcat/KM for the substrates QREAEpYEPETV and 
DADEpYLIPQQG.  The substrates differ in KM but have similar kcat values.  The kcat 
values are higher than a reported value of kcat of 0.009 with pNPP (12).  Related enzymes 
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(VH1, VHX, and VHY) show kcat values in the range 0.2 to 0.9 s
-1
 with pNPP (12).   The 
substrate DADEpYLIPQQG has also been tested with YopH and PTP1B.  At pH 6.6 and 
30 C with YopH, kcat = 1314 ± 18 s
-1
 and KM  = 59 ± 4 µM; with PTP1B, kcat = 75.7 ± 1.0 
s
-1
 and KM  = 2.63 ± 0.37 µM (41).  Both YopH  and PTP1B exhibit very similar kcat 
values for a range of phosphopeptide substrates regardless of sequence.  The same trend 
is apparent in these two VHZ substrates, where the difference in hydrolysis arises from 
KM rather than kcat.  Such consistency in turnover number is a common feature of PTPs, 
although kcat varies over several orders of magnitude among enzymes within the PTP 
family.  The lower kcat observed for the peptide substrates in this study for VHZ relative 
to YopH and PTP1B parallels the lower rate reported for VHZ catalysis of pNPP (12).  A 
thorough search for substrate sequences with particularly strong affinity for VHZ is 
beyond the scope of this study.   
The apparent disagreement between our assay results and those of previous 
reports of VHZ as a DSP led us to consider potential explanations.  In one of the previous 
reports, a commercial kit was used to estimate the phosphatase activity (11). Our 
previous experiments with commercial kits based on malachite green assays have shown 
a tendency to give false positives with some proteins, depending on the quantity of 
protein used. In these cases addition of the acidic malachite green solution causes protein 
precipitation, forming turbidity that is not always visible to the naked eye in the darkly 
colored solution. The resulting light scattering can register as absorbance over the blank 
where no protein is added. We avoided this problem by digesting the enzyme with a 
phosphate-free protease prior to adding the malachite green solution.  
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In another study, MBP (myelin basic protein) phosphorylated by protein kinase A 
(PKA) was used in a dephosphorylation assay that followed radioactively labeled 
phosphate release (10). The reported pS/pT dephosphorylation rate (0.0073 pmol/min) 
was 1500 times lower than pY hydrolysis (1.1 pmol/min). Despite the fact that serine and 
threonine are the predominant phosphorylation sites, the PKA phosphorylation of MBP is 
not 100% specific, and produces detectable quantities of pY in addition to pS and pT 
(42). A small incorporation of phosphotyrosine into MBP may explain the low activity of 
VHZ detected with this substrate. 
Finally, the VHZ used in these previous reports contained an N-terminal GST tag. 
The N-terminal region in classical PTPs contains an important substrate recognition loop.  
The GST tag alone showed no phosphatase activity, but its proximity to the active site 
may affect substrate specificity.  In order to avoid potential complications with N-
terminal tags, all experiments in the present study used untagged VHZ. 
 
Is the IPD loop of VHZ mobile?   
The mobility of the WPD loop in classical PTPs has been extensively documented 
(9, 43-47). In solution the loop is dynamic, and substrate/oxyanion binding shifts the 
equilibrium to favor the closed conformation that brings the general acid into position 
favorable for catalysis (9, 48). The crystal structure of the VHZ-VO3 complex shows the 
IPD-loop is properly positioned for catalysis, and superimposes with the closed WPD-
loop conformation observed in classical PTPs. Because the highly conserved W residue is 
important for WPD-loop dynamics (49), we searched for related proteins containing 
substitutions for W in this position. Like VHZ, most of the sequences resulting from this 
search (Figure A-1 C) contain isoleucine. Two of these proteins, the S. solfataricus PTP 
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and the CDC14 B PTP (containing an IPD-loop and FAD-loop, respectively) have been 
crystallized in both apo (PDBID 2I6I and 1OHC) and tungstate bound forms (PDB ID 
2I6M and 1OHD).   These structures reveal no difference in the loop position in ligand-
free and ligand-bound forms, which contrasts with classical PTPs. Additionally, the 
crystal structures of phytase (PDB IDs 2PS2 and 3D1H) obtained with no ligand bound 
has the identical closed loop position. These findings suggest the general acid loop is not 
a mobile element in these enzymes.  To seek a further rationale for the apparent single 
conformation of the IPD-loop in VHZ, we aligned the VHZ-VO3 complex with the YopH 
WT ligand-free structure (PDB ID1YPT) where the loop occupies its open conformation. 
The alignment revealed that, were the IPD loop of VHZ to adopt an open conformation, 
D65 would clash with the anionic side chain of E44, which corresponds to the smaller 
and neutral S287 in YopH  (Figure A-2).  The S. solfataricus PTP and phytase contain 
analogous E37 and E132 residues in this location.  In all, there is no evidence or 
likelihood that these enzymes undergo conformational changes in their general acid loop.  
We conclude that, although VHZ is likely related to the classical PTPs in other structural 
aspects and in substrate preference, its IPD loop probably does not undergo 
conformational changes in the process of catalysis.  
 
The shape of the active site  
The active site width and depth are primary factors defining substrate specificity 
in the PTP family. In Figure 2-5 the active sites of two DSPs (CDC14B (A) and VHR 
(B)), the classical PTP YopH (C), and VHZ(D) are rendered as surface models. Two 
peptide substrates containing pY and pS are modeled in the catalytically favorable 
orientation.  In this position the equatorial oxygens are stabilized by hydrogen bonds 
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from the P-loop, and the scissile phosphate monoester oxygen is located within hydrogen 
bond distance of the general acid.  These common determinants allow one to model 
substrates into the active sites of PTPs and DSPs with little ambiguity. Atypical DSPs are 
characterized by shallow and/or broad active sites that allow them to accommodate the 
aliphatic side chains of pS (2.63Å distance between phosphorus and the alpha-carbon) 
and pT (3.76 Å), in addition to longer pY (7.44Å) residues (Figure 2-5 A and B). In 
contrast, classical PTPs have a deep and narrow active site pocket that accommodates 
pY-containing peptides (Figure 2-5 C and D). Modeling shows that the pT and pS side 
chains of a polypeptide substrate are too short to reach the nucleophilic cysteine at the 
bottom of the active site, consistent with their lack of activity by classical PTPs, although 
low activity with monomeric alkyl phosphate esters has been reported (50).  With its 
shallower active site depth of 6 Å, the DSP VHR already displays a 2000-fold preference 
for pY over pS/pT-containing substrates.  The active site of VHZ is deeper than that of  
VHR and is close to those of classical tyrosine specific PTPs (Figure 2-5 B, C, D). The 
depth of the active site is a required but not exclusive factor that provides PTPs with the 
ability to discriminate between aliphatic and aromatic substrates. For example, CDC14B 
reveals a deep 8Å active site crevice but specifically targets cyclin-dependent kinases 
phosphorylated on serine (51). This ability is provided by the greater width of its active 
site, which renders dual specificity to some enzymes in the family.  The active site of 
VHZ is both narrow and deep, similar to classical PTPs. This provides a structural 
rationale for the absence of activity toward pS and pT-containing peptides observed in 
the substrate screen. 
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In conclusion, a new structure of VHZ complexed with the physiologically 
relevant inhibitor vanadate has been solved. This structure reveals important structural 
evidence that, together with the results of broad phosphopeptide screening, allows the 
following conclusions to be made:   
 
Figure 2-5. The effect of active site geometry on PTP substrate specificity. The width and 
depth, which explains the substrate selectivity observed in different PTP subfamilies 
exemplified by: A) CDC14B (DSP), B) VHR(DSP), C) YopH (PTP) and D) VHZ (blue). 
The active site dimensions are presented in angstroms.  Phosphoserine (orange) and 
phosphotyrosine (green) containing peptides are modeled in the active sites such as  the 
P-loop stabilized  phosphate moiety is in the  catalytic proximity to the nucleophilic 
cysteine, and the scissile bridging oxygen on the leaving group is within hydrogen bond 
distance from the catalytic general acid. The importance of the active site depth on the 
substrate selectivity is illustrated in the top row, whereas the bottom row reveals the 
effect of the width. The backbone of phospho serine - containing peptide in C and D is 
buried below the protein surface indicating it clashes with several residues on the edge of 
the active site. At the same time the binding of the phospho tyrosine containing peptide 
reveals no such problem due to the longer side chain. The importance of this clash for the 
substrate selectivity is consistent with the reported ability of classical enzymes to catalyze 
monomeric alkyl phosphate esters but not when a part of a peptide (50).  
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 (a) VHZ is a viable catalyst for the hydrolysis of pY-containing peptides. In 
contrast, no activity toward pS or pT residues was observed.  This tendency is that of a 
classical PTP rather than a DSP. 
(b) Classical PTPs have a deep and narrow active site cavity consistent with the 
observed specificity for pY-containing substrates. Atypical DSPs have a broader and 
shallower active site in order to accommodate phosphoserine/threonine side chains.  The 
active site of VHZ more closely resembles those of classical PTPs. 
(c) VHZ lacks the secondary positively charged binding site characteristic of 
atypical DSPs that confers a preference for bis-phosphorylated substrates (30). A 
conserved arginine residue characterizes this binding site. A correspondent R129 residue 
in VHZ is in an analogous position as in the secondary binding pockets of atypical DSPs 
(30), but it is blocked from the surface by the N7 side chain. 
(d) In classical PTPs, a structural water molecule is seen in crystal structures that 
stabilizes the position of the general acid loop. No such water molecule is observed in 
DSP structures, where this structural role is fulfilled by the asparagine residue from the 
N-loop and a serine residue from the P-loop.  As a result of differences in the positioning 
of the general acid loop, protonation of the leaving group occurs from different angles.   
In both respects VHZ resembles PTPs rather than DSPs. 
(e) The Q-loop motif containing two catalytically important glutamines 
(QXXXQ) is present in all classical PTPs.  Atypical DSPs contain the N-loop in the 
analogous position. Its conserved PNXXF motif stabilizes the general acid and defines 
the wide and shallow active site of atypical DSPs.  Analogous to the classical PTPs , the 
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Q-loop in VHZ contains E134 and Q138 residues superimposable with Q446 and Q450 
in YopH. It is concluded that the Q-loop in VHZ operates as in classical PTPs. 
While sharing a number of similarities, VHZ also bears several important 
distinctions from the classical PTPs: 
(a) In addition to the catalytic domain, classical PTPs contain multiple domains 
defining substrate specificity and subcellular localization. The VHZ protein is comprised 
of only a catalytic domain, and lacks the N-terminal extension containing a substrate 
recognition loop found in all classical PTPs (26, 52).   
(b) The general acid IPD-loop in VHZ, unlike the WPD-loop in classical PTPs, is 
not mobile.    
On total, the data suggest that VHZ does not fit the profile of an atypical DSP, but 
rather is structurally and functionally more closely related to tyrosine-specific PTPs. 
However, the absence of a substrate recognition loop and additional domains is not  
consistent with its placement as either a receptor or non-receptor type classical PTP.  It is 
similar in size to the Class II low-molecular weight (LMW) phosphatases which display 
the same phosphotyrosine specificity; however, significant sequence, functional, and 
structural distinctions exist between the LMW family and VHZ (53, 54).  We propose 
that a separate category designated “atypical PTPs,” shown in the shaded box in Figure 2-
6, is more appropriate for VHZ.  Other analogous phosphatases, including that from S. 
solfataricus, and others identified in section C of Figure A-1, may also prove to belong in 
this category. The shaded box, is more appropriate for VHZ and probably for similar 
enzymes in Figure A-1. PTPs are classified based on the basis of sequence similarity and 
substrate specificity, as well as protein size and subcellular localization.  Structural and  
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Figure 2-6. A classification of PTP family members (2).  On the basis of early reports 
VHZ has been suggested to belong to the atypical DSP group. The evidence reported here 
suggests VHZ is structurally and functionally more closely related to classical tyrosine-
specific PTPs. However, the absence of a substrate recognition loop and additional 
domains is not consistent with its placement as either a receptor or non-receptor type 
classical PTP. We propose that a separate category designated “atypical PTPs”.  
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functional distinction between classical PTPs and atypical PTPs can be used to 
discriminate between the two subfamilies. The identification and proper classification of 
VHZ will assist subsequent research into its biological role and its physiological 
substrates. 
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CHAPTER 3 
NEW FUNCTIONAL ASPECTS OF THE ATYPICAL PROTEIN TYROSINE 
PHOSPHATASE VHZ
2
 
Abstract 
LDP3 (VHZ) is the smallest classical protein tyrosine phosphatase (PTP) 
known to date, and was originally misclassified as an atypical dual specificity 
phosphatase (DSP).  Kinetic isotope effects, steady state and pre-steady-state 
kinetics of native VHZ and its mutants with para-nitrophenol phosphate (pNPP) 
have revealed several unusual properties. VHZ is significantly more active than 
earlier reported, but remains one of the least active PTPs.  Highly unusual for a 
PTP, VHZ possesses two acidic residues (E134 and D65) near the active site.  
D65 occupies the position corresponding to the typical general acid in the PTP 
family.  However, VHZ primarily utilizes E134 as the general acid, with D65 
taking over this role when E134 is mutated.  This unusual behavior is facilitated 
by two coexisting, but unequally populated, substrate binding modes.  Unlike 
most of the classical PTPs VHZ exhibits phosphotransferase activity.  Despite the 
presence of the Q-loop that normally prevents alcoholysis of the phosphoenzyme 
intermediate in other classical PTP family members, VHZ readily phosphorylates 
ethylene glycol.  Although mutations to Q-loop residues affect this 
phosphotransferase activity, mutations on the IPD-loop that contains the general 
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acid exert more control over this process.  A single P68V substitution on this loop 
completely abolishes phosphotransferase activity. The ability of native VHZ to 
catalyze transphosphorylation may lead to an imbalance of intracellular 
phosphorylation, which could explain why its overexpression has been correlated 
with several types of cancer.  
Introduction 
The protein tyrosine phosphatases (PTPs) are a large family of enzymes 
responsible for intracellular dephosphorylation. Together with protein tyrosine kinases 
(PTKs), PTPs control the level of protein phosphorylation which modulates numerous 
aspects of cell life, such as growth, proliferation, metabolism, intercellular interaction, 
immune responses, and gene transcription (1).  PTPs contain a highly conserved 
HCXXGXXRS/T signature sequence motif but share very little sequence similarities 
outside of the conserved regions, which are comprised of the phosphate binding loop (P-
loop); the general acid loop, often referred to as the WPD-loop; and the Q-loop that bears 
conserved glutamine residues that orient the water nucleophile in classical PTPs and 
prevent phosphotransferase activity to other potential nucleophiles. 
All PTPs utilize a two-step double-displacement mechanism of phosphate 
monoester hydrolysis (Scheme 3-1) mediated by an invariant cysteine-arginine-aspartic 
acid triad of catalytic residues (2).  The mechanism proceeds through a phosphoenzyme 
intermediate with the second chemical step often being rate limiting (3). In the first step, 
the P-loop orients the substrate as the nucleophilic cysteine attacks phosphorus with 
simultaneous expulsion of the leaving group protonated by the catalytic general acid.  In 
the second step, the phosphoenzyme intermediate is attacked by a water molecule  
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Scheme 3-1. Top, the chemical steps in the reaction catalyzed by PTPs.  In the first 
chemical step a nucleophilic cysteine attacks the phosphate ester with simultaneous 
protonation of the leaving group by the conserved aspartic acid.  In the second chemical 
step water attacks the phosphoenzyme intermediate liberating inorganic phosphate and 
free enzyme.  Forward rate constants are numbered with odd subscripts, and reverse rate 
constants are shown with even subscripts.  The Q-loop which is only present in classical 
PTPs serves to orient the incoming nucleophilic water and most commonly contains a 
catalytic glutamine residue marked with a star. This residue is represented by isosteric 
glutamic acid E134 in VHZ.  
 
 
directed by the aspartic acid residue that served as the general acid in the first step and Q-
loop glutamine residues. 
 The PTP family is subdivided into several groups based on the substrate 
specificity, subcellular localization, and size (4).  The classical PTPs selectively 
hydrolyze phosphotyrosine containing peptides and includes the well-studied bacterial 
effector protein YopH responsible for the virulence of notorious Y.pestis, and human 
PTP1B, which plays an important role in the insulin signaling pathway (5).  Classical 
PTPs have a modular organization, and in addition to the catalytic phosphatase domain, 
contain non-catalytic domains which control subcellular localization and protein-  
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Figure 3-1. Side-by-side comparison of (A) VHZ/PTP (PDB ID 4ERC), and  (B), SsoPTP 
(PDB ID 2I6J).  The proteins are very similar in size and structure, and both contain a 
rigid IPD-loop (highlighted in red) in contrast to the conserved WPD-loop in classical 
PTPs.  Both proteins lack an N-terminal substrate recognition loop and contain no 
additional extracatalytic domains.    
 
substrate interactions.  All classical PTPs are tyrosine specific enzymes. The members of 
the dual-specificity phosphatases (DSPs) subfamily hydrolyze phosphoserine and 
phosphothreonine in addition to phosphotyrosine containing target sites.  Within the DSP 
subfamily, the atypical DSPs are smaller and contain only a catalytic domain (6).  The 
classical PTPs and DSPs also differ in their phosphotransferase ability.  In classical PTPs 
the phosphoenzyme intermediate is attacked only by water due to the shielding effect of 
conserved Q-loop residues, named for the presence of conserved glutamines (2).  In 
contrast, DSPs such as VHR, and the low-molecular weight LMW-Ltp1, both of which 
lack the Q-loop, display significant phosphotransferase ability (3).  On this basis, it has 
been concluded that the presence of the Q-loop prevents phosphotransferase activity.   
  VHZ, and the closely related phosphatase S.solfataricus PTP (SsoPTP), are among 
the smallest classical PTPs known to date.  The SsoPTP (161 amino acids) is similar to 
VHZ (150 amino acids) in size and catalytic activity (Figure 3-1).  Both VHZ and 
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SsoPTP consist of a single, catalytic domain that is more similar to classical PTPs than 
DSPs (1, 7) and contain identical secondary structural elements, but, unlike most classical 
PTPs, lack an N-terminal extension that forms a substrate recognition/binding loop.  Like 
VHZ, the general acid in SsoPTP resides on a rigid IPD-loop, which, unlike the flexible 
WPD-loop in classical PTPs, permanently occupies a closed conformation. Unlike VHZ, 
and like classical PTPs, SsoPTP/WT contains no additional general acid in its Q-loop 
region.  VHZ was originally classified as an atypical DSP and named after its 
prototypical member as VH1-related protein member Z. In previous work, we presented 
results indicating that VHZ should be classified as a PTP rather than a DSP, on the basis 
of a structural analysis and results of a phosphopeptide substrate screen in which VHZ 
showed activity against pY–containing peptides but not toward pS- or pT-peptides (1). 
 
 
Scheme 3-2. Partitioning of the enzyme-phosphate intermediate [E-P] between hydrolysis 
and alcoholysis pathways.  Alcohols, or a water nucleophile, in two competing pathways 
attack the phosphoenzyme intermediate formed in the first step.  
 
 In the present work, we show that the catalytic activity of VHZ was significantly 
underestimated in previous reports, as a result of pronounced product inhibition, and the 
inhibitory effect of certain buffers.  Despite much in common with classical PTPs, VHZ 
is highly unusual in possessing two acidic residues in the active site, D65 and E134.  Our 
results indicate that under certain circumstances either of these residues can serve as the 
general acid in the first step of the reaction.  We also present results demonstrating that 
VHZ, despite the presence of a Q-loop, catalyzes phosphoryl transfer to alcohols 
(alcoholysis) in addition to water (hydrolysis) (Scheme 3-2). 
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The mutagenesis of several residues in VHZ in parallel with SsoPTP has revealed 
that, in addition to the Q-loop, particular residues in the general acid IPD-loop play a 
crucial role in nucleophilic selectivity.  A combination of kinetics and mutagenesis 
experiments have revealed unusual aspects of the kinetic behavior of VHZ and given 
insights into factors that control the phosphotransferase activity of VHZ, and possibly in 
other PTPs. 
 
Experimental Procedures (Materials and Methods) 
Protein cloning, expression and purification:  
VHZ mutants were made using the Qiagen QuikChange Lightning Site-Directed 
Mutagenesis Kit. VHZ and mutants were purified as previously described (1).  A His-
tagged version of VHR was prepared as follows.  In the first step the gene of VHR was 
amplified from pT7-7 plasmid using the following primers: Fwd1: GAA AAC CTG 
TAT TTT CAG GGC ATGTCGGGCT CGTTCGAGCT, Rev1: GGA GAG CTC CTA 
GGG TTT CAA CTT CCC CTC CTT GGC TAG to incorporate TEV protease cleavage 
site (Fwd1,in bold) immediately upstream of the protein gene, and  Sac-I restriction site 
(Rev1, in bold) was added at the end of the gene sequence. In the second step, the product 
of the first PCR step was used as a template and a KpnI restriction site was added 
upstream of the TEV protease cleavage sequence using the following set of primers: 
Fwd2: CGGGGTACCGAAAACCTGTAT, Rev1: GGA GAG CTC CTA GGG TTT 
CAA CTT CCC CTC CTT GGC. The resulting PCR product was digested with Kpn-I 
and Sac-I (Fermentas) and ligated into the pet-45(B+) vector (Novagen) pre-digested 
with the same set of restriction enzymes.  The E.coli DH5α competent cells were 
transformed with 5 μL of the ligation mixture and plated on an ampicillin-containing agar 
 
 
 
                                                                                                                                                                  60 
plate. DNA sequencing confirmed the presence of the desired gene. BL-21 DE-3 
(codon+) E.coli competent cells were transformed with the peT-45(B+) -VHR vector. 10 
mL of LB media were inoculated with a single colony and incubated at 37
o
C on a shaker 
overnight.  1L of 2xYT media containing ampicillin and chloramphenicol were 
inoculated with 10 mL of overnight cell growth. The cells were grown at 37
o
C until 
OD600nm reached 1.2-1.5 a.u.  100 mg of IPTG were added (final concentration 100 
mg/L), the flask was transferred to a room temperature shaker and incubated for 18-20 
hours. The cells were harvested by centrifugation and re-suspended in Ni loading buffer 
containing 50 mM Tris, 500 mM NaCl, 20 mM imidazole, 5 mM 2-mercaptoethanol, 5 % 
glycerol, pH 8.0.  Cells were sonicated on ice, and after centrifugation the supernatant 
was decanted and filtered through 0.45 micron Millipore syringe filter.  Ni-fast flow High 
Affinity Resin (GE Healthcare) was washed 3 times with Ni loading buffer and incubated 
with supernatant for 30 min at 4
o
 C with gentle shaking. The resin slurry was transferred 
to a 15 mL glass chromatography column. The column was extensively washed with Ni 
loading buffer to reach baseline aabsorbance and protein was eluted with a 120 mL linear 
gradient with buffer containing 50 mM Tris, 500 mM NaCl, 20 mM imidazole, 2-
mercaptoethanol, 5 % glycerol, pH 8.0 at 2 mL/min.  The fusion VHR protein obtained 
was dialyzed stepwise in TEV-cleavage buffers containing 50 mM Tris-Base, 0.5 mM 
EDTA, 3 mM DTT, 5% glycerol and reducing concentration of NaCl (300 mM, 150 mM, 
0 mM), at 1.5 hour per step followed by addition of 2 mg of TEV protease. The cleavage 
of VHR was rapid and complete in two hours at 4 
o 
C. VHR was dialyzed in the original 
Ni-loading buffer to remove DTT and EDTA for two hours, and the solution was passed 
through Ni-Fast flow High Affinity Resin for one hour to remove cleaved polyhistidine 
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tag and TEV-protease. Collected supernatant was concentrated to 3-5 mL using Millipore 
Centrifuge Concentrator tube and loaded on Superdex 75 26/60 gel filtration column 
(GE-Healthcare) pre-equilibrated with buffer containing 50 mM HEPES, 150 mM NaCl, 
50 mM Imidazole, 5 mM DTT, 10 % glycerol. A single peak corresponding to the VHR 
was collected, concentrated to 6 mg/mL, flash-frozen in the liquid nitrogen and stored at -
80 
o
C.  
   
Cloning and purification of SsoPTP. The S.solfataricus. 
 PTP gene sequence from Uniprot was optimized for the E.coli expression system 
and synthesized by GenScript delivered in a shuttle vector. The gene was ordered with a 
KpnI restriction site followed by TEV cleavage site directly upstream of the SsoPTP 
sequence (Uniprot ID Q97VZ7) and a SacI restriction site directly downstream of the 
stop codon. The shuttle vector containing the described gene was amplified in E.coli 
DH5α, isolated , and digested with KpnI –SacI restriction enzymes in the Green Buffer 
(Fermentas).  The digestion products were separated by electrophoresis using  1% 
agarose gel. The band correspondent to the desired gene was extracted using Qiagene Gel 
Extraction Kit and ligated into pet45 (B+) plasmid pre-digested with the same set of 
restriction enzymes. Unfortunately, unlike VHR (and similar to VHZ), the resulting 
fusion protein was resistant to TEV cleavage, so the poly-His tag and TEV-cleavage site 
was removed from the pet45B(+)-SsoPTP vector by one-step overlapping PCR using the 
following primers: Fwd: TATACCATGTACTGGGTCCGTCGCAAAACG; Rev: 
GACCCAGTACATGGTATATCTCCTTCTTAAAGTAAACAAAATTATTCTAG.  
Tagless SsoPTP was expressed in E.coli BL-21 DE-3 (codon+) cells.  The growth and 
expression conditions were analogous to VHZ and VHR. The cells were harvested by 
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centrifugation and re-suspended in the buffer containing 50mM Tris, 1mM EDTA, 10 
mM DTT, 5% glycerol pH 7.4 (4
o
C).  Cells were disrupted by sonication on ice, and the 
pellet was separated by centrifugation. The supernatant was treated with a 10 % w/v 
solution of polyethyleneimine (PEI, Mw 50000, pH 8.0 at 4 
o
C) added dropwise at 4
o
C to 
reach a final PEI concentration of 0.5% (w/v).  After centrifugation the supernatant was 
loaded at 1mL/min on a Q-HiTrap (GE Healthcare) column pre-equilibrated with buffer 
containing 50 mM sodium acetate, 1 mM EDTA, 3 mM DTT, pH 5.5.  After washing the 
protein was eluted with a 120 mL linear gradient (2 mL/min) buffer containing 50 mM 
sodium acetate, 1 mM EDTA, 600 mM NaCl, 3 mM DTT , pH 5.5. A single isolated 
peak eluted at 200-250 mM NaCl corresponding to SsoPTP, concentrated to 3-5 mL and 
loaded on a Superdex 75 26/60 gel filtration column (GE-Healthcare)  pre-equilibrated  
with buffer containing 25 mM Tris, 50 mM imidazole, 150 mM NaCl, 1 mM EDTA, 5 
mM DTT, pH 7.5 (at 4
o
C). A single peak was collected, concentrated to 10 mg/mL 
(EC280 = 2.36 mL/mg) and flash frozen in liquid nitrogen in the same buffer with 25% 
of glycerol added. 
YopH, PTP1B and their mutants were expressed and purified as previously 
described (8, 9).  
All enzymes were purified to 99% + homogeneity based upon SDS PAGE 
analysis (data not shown). Concentration of each enzyme was determined by measuring 
absorbance at 280 nm using calculated extinction coefficients.       
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Preparation of p-nitrophenyl phosphate (pNPP).  
The dicyclohexylammonium salt of pNPP was synthesized as previously 
described (10).  A phosphate free solution of pNPP was prepared in two separate steps. 
The crude product was dissolved in a minimal amount of 0.8 M NaOH.  Neutral 
cyclohexylamine was extracted with five equal portions of chloroform, accompanied by 
reduction of pH to 8.0-8.5.  Inorganic phosphate was precipitated by addition of a 10x 
solution containing 1M MgCl and 5 M NH4Cl (1:5 ratio of Mg
2+
/NH4
+
) to reach 0.1 M 
final magnesium concentration.  The pH was adjusted to 9.0-9.3 with ammonium 
hydroxide and stirred for 10 minutes until the solution turned cloudy due to the 
precipitation of MgNH4PO4.  The concentration of pNPP in solution remains essentially 
unchanged, in contrast to calcium or magnesium chloride precipitation alone, which 
mostly precipitates pNPP. The precipitate was removed by filtration using a fritted glass 
funnel, and 10 g of pre-activated Chelex100  resin suspension in water (pH 9.0) was 
added to scavenge the remaining magnesium. The resin was removed by filtration, and 
cyclohexylammonium hydrochloride (Fisher) solution (pH 8-9) was added.  The 
dicyclohexylammonium salt of pNPP precipitated, collected by filtration, washed with 
cold absolute ethanol, and dried overnight under vacuum to yield phosphate-free 
dicyclohexylammonium salt of pNPP as a white solid, which was stored at -20 
o
C under 
nitrogen.  
The sodium salt of pNPP allows preparation of stock solutions of higher 
concentrations, and was produced by dissolving the dicyclohexylammonium salt, 
obtained above, in 0.8 M NaOH solution followed by removal of cyclohexylamine by 
chloroform extractions.  The pH of the aqueous layer was adjusted to pH 12 with 0.1M 
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NaOH, as necessary in order to completely remove any traces of  cyclohexylamine.  A 
small amount (0.5-1 g) of Amberlite IR120 H resin, extensively pre-washed with 
deionized water, was added to the solution and stirred for 1 minute.  When pH reached 
6.0-6.5 the resin beads were removed by filtration.  The solution was adjusted to pH 8.5 
with dilute sodium hydroxide, and stirred on ice under reduced pressure overnight to 
remove any traces of organic solvent.  The concentration of the stock solution was 
assayed by adding 10 uL of the pNPP solution to 1 mL of 100mM Tris buffer (pH 10) 
followed by complete hydrolysis with alkaline phosphatase.  The final concentration of 
liberated p-nitrophenol was found using the value of λ400= 18300 M
-1
cm
-1
.  
 
Quantification of inorganic phosphate. 
  A malachite green assay was used to determine the concentration of inorganic 
phosphate in the pNPP substrate, and the concentration of inorganic phosphate in 
inhibition studies. Briefly, 1.5 g of ammonium hexamolibdate were dissolved in 85 mL of 
deionized water. The volume was adjusted to 100 mL with 15 mL of concentrated 
(60.5%) perchloric acid yielding Solution A. The use of perchloric acid was found to 
improve sensitivity and rate of the color development. Malachite green hydrochloride 
(0.2 g) were added to 50 mL of solution A with stirring. After 30 min the dark orange 
solution was centrifuged to separate any undissolved particles yielding Solution B. 
Solution A was used to adjust Solution B to a final A450 = 15 a.u. (measured by assaying 
diluted aliquots and calculating back to the original concentrate). In a separate 250 ml 
Erlenmeyer flask 2.5 g of hydrolyzed PVA (Acros) were stirred in 100 mL of deionized 
water under gentle heating avoiding boiling for several hours to yield clear colorless 
Solution C (2.5% w/v).  Prior to use 2 ml of solution C were added to 10 mL of adjusted 
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Solution B and mixed to yield a dark brown working solution. In a 96 well plate 280 µL 
of working solution were mixed with 30 µL of diluted phosphate standards in the 0-200 
μM range. The color was fully developed in 3-5 minutes and absorbance measured at 625 
nM was plotted versus inorganic phosphate concentration to obtain a calibration curve.  
 
Determination of inhibition constants.   
The effect of buffers and other inhibitors on the activity of VHZ was tested with 
pNPP (sodium salt) in 50 mM sodium acetate buffer (pH 5.5), which showed no 
inhibitory effect, with inhibitor concentrations in the range 25-200 mM.   The data was 
fitted to several inhibition models using non-linear least squares fit (Origin 8.5.1) with 
the competitive model yielding the best results in all cases.   
 
Steady-state kinetic analysis.  
 All reactions were performed in non-inhibitory buffers in the presence of 1mM 
DTT and constant ionic strength adjusted to 150 mM with NaCl at 25 
o
C. The following 
buffers, which showed no inhibition against VHZ, were used: pH 4.75-5.5, sodium 
acetate; 5.75-6.5, sodium succinate; 6.75-7.25, 3,3-dimethylglutarate.  All buffers were 
50 mM.  At least eight substrate concentrations ranging from 0.5-4 x KM were used for 
each enzyme to obtain Michaelis-Menten curves.  Reaction progress was followed 
continuously by the change in absorbance at 400 nm at each pH using a VersaMax plate 
reader (Molecular Devices). Partial extinction coefficients obtained as described in the SI 
were used to convert the measured absorbance values into amount of p-nitrophenol 
released.  The reaction was found to be susceptible to product inhibition, so linear initial 
velocities were used at each substrate concentration.  Control reactions in the absence of 
enzyme verified that non-enzymatic hydrolysis could not be detected. The initial rates 
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were plotted vs. substrate concentrations and fitted to the Michaelis-Menten equation 
using Origin 8.5.1 to obtain kinetic parameters kcat and KM. The values of kcat and kcat/KM 
were plotted versus pH and fitted to the equations shown in the SI to obtain the pKa 
values of catalytically important ionizable residues, presented in the Table S1.  
 
Isotope effect measurements.  
Kinetic isotope effects (KIEs) on the VHZ-catalyzed reaction with pNPP were 
measured using the competitive method, and thus are isotope effects on V/K.   Figure 3-2 
shows the positions where KIEs were measured in the substrate and the designations 
used.   
 
Figure 3-2.  Positions of KIE measurement in the substrate pNPP.  Oxygen-18 KIEs were 
measured at the nonbridging oxygen atoms of the phosphoryl group (a) and the bridging 
ester oxygen atom (b).  The Nitrogen-15 KIE was measured in the nitro group (c).  
 
Natural abundance pNPP was used for measurements of 
15
(V/K). The 
18
O KIEs 
18
(V/K)bridge and 
18
(V/K)nonbridge were measured by the remote label method, using the 
nitrogen atom in p-nitrophenol as a reporter for isotopic fractionation in the labeled 
oxygen positions (5). The isotopic isomers used are shown in the Appendix B, and their 
synthesis was as previously described (11).  KIEs were measured at pH 5.5 using the 
buffer 100 mM acetate, 1 mM DTT, 0.5 mM EDTA. The reactions were conducted at 
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25
o
C and [pNPP] = 25 mM.  All reactions for bridged, non-bridged and natural 
abundance isotope effects were performed in triplicate and the progress was monitored 
continuously by measuring absorbance at 400 nM. Reactions were stopped at 40, 50 and 
60 % completion by acidification to pH 3.0 with HCl, which caused some precipitation of 
protein, which was separated by centrifugation.  To remove remaining enzyme, the 
reaction solution was centrifuged in a Millipore Amicon-Ultra 3kDa protein concentrator.  
The resulting solution was extracted with three 50 mL portions of diethyl ether. Ether 
fractions were collected, dried with anhydrous magnesium sulfate, filtered, and ether was 
removed by rotary evaporation.  The unhydrolyzed pNPP remaining in the aqueous layer 
was hydrolyzed using alkaline phosphatase after the pH was adjusted to 10 by addition of 
1 M Tris to pH 11.  After 8 hours the pNP product was extracted and collected as 
previously described.  After sublimation the p-nitrophenol samples were analyzed by 
isotope ratio mass spectrometry. The isotope effect was calculated from the nitrogen 
isotopic ratios in the p-nitrophenol product at partial reaction, in the residual substrate, 
and the starting material, as described in Appendix B.  The 
18
(V/K)nonbridge values were 
corrected for the dianionic fraction of pNPP at pH 5.5.  
 
Detection of phosphotransferase activity in the presence of ethylene glycol.  
The hydrolysis of pNPP by VHZ and VHZ/P68V was monitored using a JEOL 
300 MHz NMR spectrometer at the 121.5 MHz 
31
P resonance frequency.  Reaction was 
started by addition of VHZ to a solution containing 20 mM pNPP in 50 mM sodium 
acetate (pH5.5), 0.5 mM EDTA, 3mM DTT and 1M ethylene glycol. The instrument was 
locked using D2O in a coaxial tube. The instrument was set to collect 64 scans, relaxation 
delay 4 sec, sweep 50 ppm. 
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The dependence of kcat was measured as a function of ethylene glycol 
concentration for VHR, VHZ, VHZ/E134Q, VHZ/E134A, VHZ/D65A, VHZ/P68V, 
SsoPTP, and SsoPTP/V72P by monitoring release of p-nitrophenol.  Reactions were 
performed in 50 mM sodium acetate buffer (pH 5.5) and concentration of ethylene glycol 
varied in the range of 0-3 M. 
 
Pre-steady-state kinetics.   
Measurement of pNPP hydrolysis catalyzed by VHZ, VHR, as and VHZ/D65A 
mutant were performed at 25 
o
C using a stopped-flow spectrophotometer (KinTek).  
Release of p-nitrophenol was monitored by increase in absorbance at 400 nM in 100mM 
succinate buffer (pH 5.85), using an extinction coefficient corrected for this pH (see SI). 
Enzyme concentration varied in the range 20-65 μM.  The pNPP concentration was 20 
mM for VHZ/D65A, and varied from 0.5 KM to 100 mM for VHR/WT and VHZ. 
Absorbance traces of at least five separate experiments at each substrate and enzyme 
concentration were averaged. The data was fitted to the equation [p-nitrophenol] = At + B 
(1-e
-kt
).  At saturating concentrations of substrate, k = k3 + k5.  The linear steady-state 
phase A = k3k5 / (k3 + k5).  The magnitude of the burst B = Eo [k3 / (k3 + k5)]
2
 / (1 + KM / 
So)
2
. 
 
Computational analysis of pNPP binding to VHZ:   
The computational packages AutoDock (12) and FlexX (13) were used to model 
the docking of pNPP in the active site of VHZ.  The 1.15 Å resolution crystal structure of 
the VHZ-metavanadate complex (PDBID:  4ERC) was used as the starting model.  The 
VO3 ligand at the active site was removed, and the following charges/protonation states 
were assigned to the residues: C95 (-1) ; H94 and R101,(+1) ; D65 and E134, neutral. 
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The side chains of D65, F66, L97, and E134 residues were treated as flexible, the rest of 
the protein was rigid.  The pNPP ligand coordinates were extracted from the crystal 
structure of SsoPTP (PDBID: 2I6P) and the di-anionic form of the phosphate ester was 
used for docking.  Free rotation was allowed around the phosphate monoester bond, 
while the p-nitrophenol ring was treated as planar. The Lamarckian Genetic algorithm 
was selected for its reliability and ability to calculate “deeper minima” (14) and the 
search was conducted within a 15 Å grid region centered at the active site. 
 
Results 
Buffer and oxyanion inhibition.   
The effects of buffers and oxyanions on the catalytic activity of VHZ are summarized in 
Table 3-1.  No inhibitory effects were observed for acetate, succinate, 3,3-
dimethylglutarate, or diglycine.  VHZ is weakly inhibited by triethanolamine 
hydrochloride and cyclohexylamonium hydrochloride, while N-ethyl morpholine (NEM) 
hydrochloride displayed no inhibitory effect.  As expected, the sulfonate containing 
buffer HEPES showed relatively strong inhibition.  Cyclohexylammonium is a common 
counterion for the commercially available substrate pNPP, and although its effect was 
relatively weak, the sodium salt was used in all experiments.  
 
Kinetic isotope effects.   
The KIEs in the positions shown in Figure 3-2 for the VHZ-catalyzed hydrolysis 
of pNPP are presented in Table 3-2, together with previously reported KIEs for PTP1B 
and VHR.  The 
18
(V/K)nonbridge KIEs for VHZ are very similar to these precedents, 
suggesting that, like these related enzymes, the VHZ-catalyzed reaction proceeds via a  
loose transition state.  The 
18
(V/K)bridge KIE is higher in VHZ and a significant magnitude 
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Table 3-1. Inhibition by buffers and oxyanions.  Experiments were carried out at pH 5.5 
in the 100 mM sodium acetate buffer where ionized form of tested buffering agents 
dominates in solution.   
 
Compound Inhibition Type Ki , mM 
Cyclohexylamine  Competitive 140 ± 10 
EDTA Competitive 22 ± 2 
Inorganic phosphate 
VHZ/WT Competitive 0.67 ± 0.05 
VHZ/D65A Competitive 0.43 ± 0.12 
VHZ/D65N Competitive 0.68 ± 0.11 
Sso/WT Competitive 0.54 ± 0.42 
VHR/WT Competitive 0.7 ± 0.3 
YopH/WT Competitive 4.4 ± 0.2 
PTP1B/WT Competitive 3.7 ± 0.1 
Other oxyanions 
Sulfate Competitive 4.6 ± 0.3 
Arsenate Competitive 0.13 ± 0.04 
Vanadate Competitive 0.0027 ± 0.0003 
Buffers 
Tris Competitive 88 ± 9 
N-ethyl morpholine NEM No No 
Bis-Tris Competitive 122±12 
Triethanolamine  Competitive 52 ± 5 
HEPES Competitive 26 ± 3 
Glycylglycine Competitive 118 ± 12 
Sodium acetate No No 
Sodium succinate No No 
3,3-demethylglutarate No No 
 
 
Table 3-2.  Kinetic isotope effects of native VHZ, PTP1B and VHR. 
 
 
 
 
PTP name 
15
(V/K) 
 18
(V/K)bridge     
18
(V/K)non-bridge 
VHZ 
 
 
1.0013±0.0004 
 
1.0164±0.0017 
 
0.9986±0.0008 
PTP1B (8) 1.0001±0.0002 1.0142 ± 0.0004 0.9981±0.0015 
VHR (4) 0.9999±0.0004 1.0118±0.0020 1.0003±0.0003 
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for the 
15
(V/K) isotope effect contrasts with the absence of a measureable KIE in this 
position in the other two phosphatases.  Both observations are consistent with incomplete 
neutralization of the leaving group by the general acid in the transition state. 
   
Steady-state kinetics analysis.   
Table 3-3 shows the kinetic parameters, kcat, KM, and kcat/KM for VHZ, VHR, 
YopH, PTP1B, SsoPTP, and several VHZ mutants, measured at pH 5.5 at 23 °C.  This 
corresponds to the pH optimum of many PTPs, including VHZ.  The kinetic parameters 
for VHR, YopH, and PTP1B measured by continuous assay at 400 nm are in good 
agreement with the literature values.  We obtain values of kcat = 3.9 s
-1
 and KM = 8.3 mM 
for pNPP hydrolysis by VHZ at the pH optimum of 5.5, compared with previously 
reported kcat = 0.009 s
-1
 and KM = 1.5 mM (15, 16).  The revised kcat  is comparable to 
those of native VHR and SsoPTP.  The KM is significantly higher than previously 
reported, resulting in lower overall enzymatic efficiency (kcat/KM).  
 
pH dependency for the hydrolysis of pNPP by VHZ:  
The pH-rate profiles for native VHZ and the mutants D65A and E134Q are shown 
in Figure 3-3. The pKa values of ionizable residues were determined by non-linear least 
squares fitting of experimental data to the appropriate equations (see SI), for kcat and 
kcat/KM, and shown in Table S-1. The second ionization constant for pNPP was set to the 
literature value of 4.96 (17).  The pKa values obtained are in good agreement with those 
previously obtained for other PTPs, and the bell-shaped profiles are typical of the PTP  
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Table 3-3.  Kinetic data for native VHZ, YopH, VHR, PTP1B, and SsoPTP and selected 
mutants. Values are the results from at least six independent experiments.    
Kinetic parameters with pNPP at pH 5.5 (optimum), 25°C 
  kcat,(s
-1
) KM, mM (18) kcat/KM, mM
-1
s
-1 
Native PTPs 
VHZ 3.92 ± 0.03 8.31 ± 0.71 0.47 
VHR 3.1 ± 0.1 1.96 ± 0.11 1.59 
SsoPTP 3.15 ± 0.05 4.31 ± 0.19 0.73 
YopH 720 ± 25 0.98 ± 0.11 735 
PTP1B 51.7 ± 0.9 0.12 ± 0.01 430 
IPD- loop mutations 
Sso PTP/V72P 2.61 ± 0.1 4.62 ± 0.43 0.56 
VHZ/D65A 0.84 ± 0.12 0.22 ± 0.01 4.19 
VHZ/D65N 3.42 ± 0.12 8.73 ± 0.68 0.39 
VHZ/D65N/E134Q 0.027 ± 0.002 2.57 ± 1.15 0.001 
VHZ/P64A 0.07 ± 0.04 32.92 ± 2.98 0.002 
VHZ/P69A 0.09 ± 0.05 31.00 ± 3.80 0.003 
VHZ/P68V 3.34 ± 0.06 5.88 ± 0.27 0.57 
Q-loop 
VHZ/E134Q 0.42 ± 0.07 7.66 ± 0.25 0.07 
VHZ/E134A 0.29 ± 0.02 10.15 ± 1.32 0.03 
VHZ/Q138A 0.13 ± 0.01 13.1 ± 1.7 0.01 
 
family.  The acid limb is ascribed to the deprotonated C95 nucleophile, which has an 
unusually low pKa due to stabilizing influences of the neighboring H94 in VHZ.  The 
basic limb is ascribed to general acid catalysis in the first step consistent with the PTP 
mechanism (Scheme 3-1).   The IPD-loop in VHZ bears the putative D65 general acid.   
This loop and the position of the acid correspond to the conserved WPD-loop in classical 
PTPs (Figure 3-4).  D65 was proposed to be the general acid catalyst by structural 
analogy, and based on the observation of lost hydrolysis of pNPP by the D65A mutant 
(16, 19).  In our hands, the D65A mutation resulted in a 5-fold reduction of kcat and a 40-
fold reduction of KM.  The pH-rate profile remains bell-shaped (Figure 3-3).  In contrast, 
the analogous mutation of the general acid in other PTPs to alanine or to asparagine 
results in a 100 to 1000-fold reduction in kcat, and the loss of the basic limb in the kinetic  
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Figure 3-3.  pH rate profiles.  A) kcat  for the native VHZ (black), D65A (red), and E143Q 
(blue) , D65N/E134Q (green) mutants.  B) kcat/KM for native VHZ, D65A ,E134Q, 
D65N/E134Q  mutants.  The D65A mutant is more efficient than the native VHZ due to 
simultaneous reduction of kcat and KM.  Both D65A and E134Q mutants retain the basic 
limb diagnostic of general acid catalysis. The basic limb completely disappears in 
VHZ/D65N/E134Q double mutant. 
 
Figure 3-4. Structural comparison of the active sites of: A) the PTP YopH; B) the DSP 
VHR; and C) VHZ. The structural arrangement of the VHR active site differs from YopH 
and VHZ in the replacement of the highly conserved Q-loop with the N-loop, and a 
different position of the general acid. 
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Figure 3-5. Pre-steady state kinetics of:  A) 48 μM native VHZ, with 50 mM  pNPP; B) 
26μM native VHR, with 50 mM pNPP; C) 58 μM VHZ/E134Q with 50 mM pNPP;  D) 
28 μM VHZ/D65A and 10 mM pNPP.  All experiments were performed at 25 oC. 2000 
data points were collected after 1ms mixing delay and are omitted for the clarity of the 
fit. 
 
pH-rate profile, indicating loss of general acid catalysis (20, 21).  In contrast, the kinetic 
constants for the D65N mutant are similar to those of native VHZ (Table 3-3). 
pH-rate profile, indicating loss of general acid catalysis (20, 21).  In contrast, the 
kinetic constants for the D65N mutant are similar to those of native VHZ (Table 3-3). 
The active site of VHZ possesses another acid (E134 from the Q-loop) in position to 
potentially protonate the leaving group (Figure 3-4).  The E134Q and E134A mutations  
both reduce kcat by about an order of magnitude (Table 3-3) with no significant effect on 
KM.  The pH profile of the E134Q mutant remains bell-shaped.  Only the simultaneous 
removal of both general acids (D65N/E134Q) leads to a significant reduction of kcat and 
loss of the basic limb of the pH-rate profile (Figure 3-3).  The double mutants  
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Table 3-4. Elementary rate constants for pNPP hydrolysis and substrate dissociation 
constant for native VHR, VHZ/D65A, and native VHZ.   The values for k3, k5 and KS 
were obtained from burst kinetics as described in the SI.  The kinetic constants for native 
VHZ were calculated based on the assumption that k3 is not affected by the VHZ/D65A 
substitution, as described in the text. Under such circumstances, the system consisting of 
the two equations 5 3
3 5
cat
k k
k
k k



and 5
3 5
M S
k
K K
k k
 

 can be solved to obtain values of 
k5 and Ks. 
 
 
k3,(s
-1
) 
 
 
k5,(s
-1
) 
 
 
KS, mM 
VHZ/D65A 17.44 ± 0.13 1.71 ± 0.37 2.5 
VHR 48.30 ± 0.34 9.70 ± 0.21 11.8 
VHZ/WT 17.44 ± 0.13 5.19 35 
 
precipitated below pH 5.25 precluding measurement of kinetic data at more acidic 
conditions. 
 
Pre-steady-state kinetics.   
Many PTPs, including YopH, PTP1, and VHR, exhibit burst kinetics, indicating 
that the second step is rate-limiting (6, 10).  When native VHR was rapidly mixed with 
pNPP a pre-steady state burst of p-nitrophenol release was observed (Figure 3-5).   
The values of k3 and k5 obtained for VHR are close to those previously reported 
(6). Under the same conditions native VHZ and its E134Q mutant revealed no pre-steady  
state burst.  In contrast, the VHZ/D65A mutant displayed a pre-steady state burst 
stoichiometric with the amount of enzyme. Values of k3, k5 and KS (the true substrate 
binding constant) were calculated for native VHR and VHZ/D65A and are presented in 
Table 3-4.  Although the decrease in the ratio (k5/k3) in VHZ/D65A reduces KM (see SI), 
it does not fully explain the magnitude of the reduction, indicating that KS is reduced as 
well.  Despite the absence of a burst, the value of KS for native VHZ may be calculated if 
we assume that the D65 residue is primarily important for orienting the nucleophilic 
water in the second catalytic step.  This assumption is supported by the negligible effect 
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on kcat of the VHZ/D65N substitution. By setting k3 for native VHZ equal to that of 
VHZ/D65A, the other elementary rate constants for the reaction of the native enzyme 
were calculated as shown in Table 3-4.  The VHZ/D65A substitution decreases the 
magnitude of KS 14-fold.  Because substitution of D65 with A (but not N) increases 
enzyme substrate affinity, we conclude the existence of an unfavorable steric, rather than 
electrostatic, interaction between D65 and the aromatic ring of the substrate.   The Ki for 
inorganic phosphate is lower than KS for pNPP in both native VHZ and the VHZ/D65A. 
However, whereas KS for pNPP is reduced 14-fold by the removal of D65 side chain 
(Table 3-4), the Ki for inorganic phosphate is reduced only ~ 1.5-fold (Table 3-1). 
 
Table 3-5.   Second order rate constants for alcoholysis and hydrolysis of pNPP by 
several members of PTP family. The kcat values obtained in the absence of alcohol 
(intercept with Y axis) were divided by the molarity of water (55.5 M) to yield the second 
order hydrolysis rate constant kcat’.  Nucleophilic specificity is defined by the relative 
preference for alcoholysis over hydrolysis. kt corresponds to k7 only when k5>>k3, 
otherwise 3 7t
5 3
k k
k
k k



 (see SI for more detailed description). The values of kt depend on 
the rate limiting step and on the overall activity, and should not be used to judge the 
preference for alcoholysis.   
 
Name kt ,  M
-1
*sec
-1
 kcat'=(kcat/55.5), M
-1
*sec
-1
 S=kt/kcat' 
Ltp1/WT(3) 5.5 0.026 211.5 
YopH/WT(2) 0.0 11.3 0.0 
SsoPTP/WT 0.0 0.07 0.0 
VHR/WT(2) 0.48 0.07 6.85 
VHZ/WT 1.3 0.09 14.4 
VHZ/E134Q 0.06 0.005 12.1 
VHZ/E134A 0.13 0.0036 36.1 
YopH/Q446A(2) 21.6 1.11 19.4 
VHZ/D65A 1.55 0.015 103.3 
VHZ/P68V 0.0 0.060 0.0 
SsoPTP/V72P 0.49 0.041 11.95 
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Reaction in the presence of ethylene glycol.  
The dependence of kcat on ethylene glycol concentration was measured for native 
VHZ and several mutants.  It should be noted (discussed in the SI) that the slope of such 
a plot where cat 5 7 [ROH]k k k    yields the second order rate constant for ethylene 
glycol phosphorylation (k7, Scheme 3-2) only when k3>>k5.  In the more general case, 
when  
no distinct rate-limiting step exists and no pre-steady state burst is present, the expression   
3 5 3 7
cat
5 3 5 3
[ROH]
k k k k
k
k k k k
 
  
 
 holds and interpretation of the calculated slope is more 
complex.  However, the nucleophilic selectivity 
3 7
5 3 7
3 5 5
5 3
k k
k k kSlope
S
k kIntercept k
k k


  


 (Table 3-5, 
column 3) is independent of k3 and reflects the relative preference for alcoholysis over 
hydrolysis.  
The E134Q mutation results in no significant change in phosphotransferase 
ability.  The E134A mutation significantly increases the alcoholysis to hydrolysis ratio, 
indicating that E134 participates in the second step of the reaction, like Q446 in YopH.  
Although Q-loop residues in PTPs are generally thought to control access to the 
phosphoenzyme intermediate, the D65A mutation on the IPD-loop has a more 
pronounced effect than E134A.  Because the closely related SsoPTP lacks 
phosphotransferase activity, we compared the effects of mutations on the IPD-loops in 
VHZ and SsoPTP.  The SsoPTP contains only two proline residues on its IPD-loop, P68 
and P73, corresponding to P64 and P69 in VHZ.   These residues are highly conserved in 
classical PTPs (see the sequence alignment in Figure 3-8) and mutations result in similar, 
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adverse catalytic effects in VHZ (Table 3-3).  VHZ possesses another proline, P68, which 
is occupied by V72 in SsoPTP.  The VHZ/P68V mutation abolished phosphotransferase 
activity (Figure 3-6).  This effect was further supported by 
31
P NMR spectroscopy shown 
in Figure 3-7.  The orthogonal SsoPTP/V72P mutation conferred phosphotransferase 
ability comparable to that of native VHZ.    
 
Discussion. 
Although VHZ is related to classical PTPs and utilizes the same mechanism (1) it 
differs in several important ways from most PTP family members.    
 
 
VHZ is inhibited by commonly used buffers, and by inorganic phosphate more 
strongly, than typical PTPs.   
Previous kinetic investigations of VHZ utilized single time point assays after 20 
or 30 minutes, and buffers containing Tris (16) or Bis-Tris, which are weak competitive 
inhibitors (Table 3-1).  Although the inhibition constants are in the high millimolar range, 
buffers are typically used at such concentrations.  While buffers containing the sulfonate 
functional group, such as HEPES, are recognized as inhibitors of PTPs, and have been 
observed in some PTP crystal structures, the inhibition of VHZ by buffers such as Tris 
and triethanolamine was unexpected.  This behavior may result from the combined effect 
of several anionic residues near the VHZ active site (D65, E44, E134 and E137) but the 
molecular origin of buffer inhibition was not tested.  The inhibition constant for inorganic 
phosphate is lower than in classical PTPs, and is significantly lower than the KS for pNPP 
(Table 3-4).  Probable structural origins for this difference are discussed below.  The net 
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effect of these properties led to a significant underestimation of VHZ activity in previous 
reports.  
In addition to avoiding inhibitory buffers, we validated a method for the 
continuous collection of rate data using the substrate pNPP monitoring reaction progress 
at 400 nm using extinction coefficients measured at the experimental conditions (see SI).  
Continuous monitoring of the reaction showed that VHZ becomes inhibited by product 
after several minutes.  Finally, commercial pNPP, which often contains small but 
experimentally significant amounts of inorganic phosphate, was used in previous studies.  
We developed a purification strategy to minimize contamination by inorganic phosphate, 
that also offers a simple means to convert the di-cyclohexylammonium salt to the more 
soluble disodium salt. Using non-inhibitory buffers, a continuous assay, and phosphate-
free substrate, VHZ proved to be significantly more active than previously thought (kcat = 
3.9 s
-1
 versus 0.009 s
-1
).  We also developed a process for the expression and purification 
of the native enzyme with no tags.  Although previous reports used tagged versions of 
VHZ, the difference in activity is too significant to be explained by the absence of tags.  
Furthermore, discontinuous assays with the tagless enzyme using fixed time point 
methods like those previously reported yielded results similar to the previous reports 
(16).  
 
The leaving group is not fully neutralized in the first step of the VHZ reaction.   
The KIEs for the hydrolysis of pNPP have been reported for a number of PTPs 
including YopH (22), PTP1B (23), VHR (24), and the LMW PTP Stp1 (4).  Because 
these are measured by the competitive method, the KIEs reflect the portion of the kinetic 
mechanism up to the first irreversible step, cleavage of pNPP.  The mechanistic origins of 
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the KIEs for pNPP hydrolysis have been described elsewhere (5).  In brief, a normal 
15
(V/K) up to a maximum of 1.003 arises from negative charge development on the 
leaving group.  Efficient general acid catalysis by PTPs abolishes this effect, resulting in 
a 
15
(V/K) of unity.  Fission of the P-O bond produces a normal 
18
(V/K)bridge effect. 
Simultaneous leaving group protonation produces an inverse effect that partially reduces 
the normal effect from P-O cleavage.  Thus, in general acid mutants, 
18
(V/K)bridge is 
typically ~ 1.03, compared to ~1.015 in native PTPs.  The 
18
(V/K)nonbridge KIE responds to 
change of hybridization state of the phosphoryl group.  This KIE is slightly inverse to 
near unity in PTPs, reflecting the loose metaphosphate-like transition state; associative 
transition states result in normal values. Both of the oxygen isotope effects for the VHZ  
 
Figure 3-6 - Dependence of pNPP turnover on ethylene glycol concentration.  A: VHZ 
/WT and VHZ/P68V mutant.  B: SsoPTP/WT and Sso/V72P.  The kcat for pNPP release 
was plotted versus ethylene glycol concentration.  All experiments were performed at 
25
o
C. 
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Figure 3-7 – Reaction of pNPP catalyzed by VHZ/P68V and VHZ monitored by 31P 
NMR spectroscopy. Panel A shows the reaction of the VHZ/P68V mutant after 30 
minutes in the presence of 1M Ethylene Glycol. Panel B shows the reaction catalyzed by 
VHZ after 30 minutes.  All reactions were performed at pH 5.5 in 100 mM sodium 
acetate buffer in the presence of 20 mM pNPP. The chemical shift of pNPP was -1.6 
ppm, inorganic phosphate was set to 0 ppm, and the shift of phosphorylated ethylene 
glycol is 1.7 ppm. 
reaction are within experimental error of previous data with PTP1B and VHR (Table 3-
4).  In contrast, the 
15
(V/K) differs from the other PTPs and is slightly normal, indicating 
that the leaving group is not completely neutralized in the transition state.  The magnitude 
suggests approximately 1/3 of a negative charge, from protonation that is not fully 
synchronous with P-O bond fission.  This has been observed in one previous PTP family 
member, the LMW PTP Stp1 (25).  Incomplete protonation of the leaving group in the 
first step may contribute to a reduction of k3 and explain the absence of a burst in the 
VHZ catalyzed reaction of pNPP.    
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Figure 3-8 – Sequence alignment of residues 65-138 of VHZ with several classical PTPs 
(top) and atypical DSPs (bottom). The alignment is confined to the three catalytically 
important PTP regions, as they contain the highest sequence similarity in the PTP family. 
VHZ is more similar to classical PTPs than to the DSP family, with two important 
distinctions in the aligned regions: substitution of highly conserved W by I in the WPD-
loop region; and; substitution of Q by E the Q-loop region. 
 
Two potential and functional general acids in the active site of VHZ.   
The D65 residue resides on the IPD-loop, a structure analogous to the WPD-loop 
in classical PTPs that bears the conserved general acid (Figure 3-8).  The E134 residue in 
VHZ is superimposable with a conserved Q residue located on the Q-loop in classical 
PTPs that orients the nucleophilic water in the second step (26).  The pH rate profiles of 
the D65 and E134 mutants both retain their basic limbs.  The D65N mutation has no 
significant effect on catalysis, and the D65A and E134Q mutations have kcat values that 
are reduced by only an order of magnitude.  Only in the double mutant is catalysis 
reduced to the extent seen in general acid mutants of other PTPs, consistent with 
complete elimination of general acid catalysis.  We conclude the D65 and E134 single 
mutants both retain general acid function. We conclude that native VHZ utilizes E134 as 
the primary general acid, with a minor contribution from D65, which becomes the major 
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general acid when E134 is mutated.  The data suggest that, unlike any other known PTP 
or DSP, VHZ contains two acidic residues in the active site and either one can protonate 
the leaving group in the absence of the other. 
 
D65 has a role primarily in the second step, and affects substrate binding. 
The fact that the D65N mutation does not significantly affect activity, while the 
D65A mutation does, suggests that the reduced catalysis in the D65A mutant arises due 
to inability of the alanine side chain to participate in phosphoenzyme hydrolysis by 
orientation of the nucleophilic water.  In this sense, the roles of D65 and E134 are 
reversed from classical PTPs, in which the conserved glutamine corresponding to E134 
positions the nucleophilic water, and the acid corresponding to D65 is the general acid in 
the first step and a general base in the second step. 
The D65A mutation significantly reduces KM and KS.  This effect is less 
pronounced for mutations of the corresponding residue in other PTPs.  This may be 
explained by fact that in classical PTPs this residue resides on the mobile WPD-loop, 
which is primarily in an open conformation in the free enzyme.  Because the IPD-loop in 
VHZ is permanently closed (1), the D65 side chain is fixed in a position that restricts 
access to the deep and narrow VHZ active site.  DSPs, such as VHR, also have a non-
movable general acid loop; however, in these enzymes the general acid is positioned on 
another side of the active site (Figure 3-4), and presents less steric hindrance to incoming 
ligands.  This explains the higher KM for pNPP in VHZ compared to other PTPs.  The 
structurally analogous SsoPTP, which also contains a rigid IPD-loop, has a KM value 
approximately 3-fold lower than VHZ and comparable to that of VHR.  However, unlike 
VHZ, which has a narrow and deep active site pocket (1) the active site of SsoPTP is 
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broad and shallow due to the presence of multiple surrounding glycine residues in the P-
loop and IPD-loop.  
Neither D65A nor D65N substitution significantly affects the Ki for inorganic 
phosphate (Table 3-1). It also confirms that the mutation of D65 side chain side chain 
does not disrupt the P-loop, which serves as the dominant binding element to the anionic 
phosphoryl group.  In contrast, the D65A mutation lowers the Ks for pNPP 14-fold.  This 
suggests the effect of D65 substitutions on binding is primarily steric rather than 
electrostatic, involving the ester group of the substrate more than the phosphoryl group.  
This would permit the biological activity of VHZ to be more regulated by levels of 
intracellular phosphate than most PTPs.  The intracellular regulation of phosphatases by 
phosphate has been recently discussed (13).  Unlike classical PTPs with much higher Ki 
values, VHZ, SsoPTP, and VHR have inhibition constants similar to the average 
physiological concentration of inorganic phosphate (1-1.3 mM) (27). 
 
VHZ has a low catalytic efficiency and different rate-limiting step compared to most 
PTPs.   
Despite the fact that VHZ is more active than previously thought, it remains one 
of the least active PTPs.  A significant part of its reduced catalytic efficiency arises from 
its high KS. Indeed, for the PTP catalyzed reaction (Scheme 3-1) 
cat 3
M SK K
k k
  (see SI for 
derivation), which means that VHZ requires a 5-8 fold higher substrate concentration to 
achieve its limiting velocity.  In addition to high Ks values, the kcat for VHZ is lower than 
classical PTPs.  Our data suggest that both steps of the VHZ catalyzed reaction are slower 
than in classical PTPs, and both contribute to the overall rate ( 5 3cat
3 5
k k
k
k k



 ) under 
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steady state conditions.  According to the KIE results the neutralization of the leaving 
group in the first step is incomplete, which reduces k3, but cannot explain the reduction of 
k5.  It was previously shown that mutations of Q-loop residues in classical PTPs reduces 
k5 by 2 orders of magnitude, an effect that was used to trap the phosphoenzyme 
intermediate of PTP1B (26, 28).  The E134Q mutation makes VHZ structurally more 
similar to classical PTPs and affects only the first step, resulting in the 8-fold reduction of 
activity.  The kcat value of the E134A mutant is 70% that of the E134Q mutant.  Such an 
insignificant reduction from complete removal of the functional group indicates that the 
residue does not function in the second step like the Q in this position in classical PTPs, 
explaining the lower k5 in VHZ compared to other PTPs.  The k5 value of native VHZ is 
more similar that of VHR (Table 3-4) which, in place of the Q-loop,  (Figure 3-4) has an 
N-loop region (Figure 3-8) that is highly conserved among atypical DSPs.  
 
VHZ has two substrate binding modes for pNPP. 
The expressions for kcat and KM for the PTP-catalyzed reaction (Scheme 3-1), 
5 3
cat
3 5
k k
k
k k



 and 5
3 5
M S
k
K K
k k
 

 contain the same elementary constants, and thus, 
any change in kcat is reflected in KM and vice versa.  A reduction in k3 results in increased 
KM as is seen in the VHZ/E134Q/D65N double mutant, in which both general acids 
important in k3 are mutated, but k5 remains unaffected. As k3 becomes smaller with 
respect to k5, KM approaches KS.  Because of this, the KM for the VHZ/D65N/E134Q 
double mutant (Table 3-3) is close to the KS for native VHZ determined from pre-steady 
state kinetics (Table 3-4). The same effect has been previously observed in the general 
acid D92N mutant of VHR (15).  In contrast, mutations of Q loop residues that do not 
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affect k3 but decrease k5, have the opposite effect on KM.  The same trend was previously 
observed in the Q556M Q446A mutants of YopH (2).  The reduction of k5 reduces the 
rate of formation of the free enzyme form E from the enzyme-phosphate intermediate E-P 
(Scheme 3-1), which lowers observed values of KM parameter in the steady-state 
experiment. This mutual dependence of kcat and KM becomes less obvious when k3 >>k5 
but, because in native VHZ the two constants are relatively similar, (consistent with the 
absence of a burst) even small changes should be easily detected.  The E134Q mutation 
in VHZ eliminates the major general acid but results in only a 10-fold reduction of kcat 
and has no effect on KM.  The D65N substitution results in a modest rate reduction, 
consistent with its role as the minor general acid, but also has no significant effect on KM. 
The pH rate profiles of both mutants remain bell-shaped, indicating that when one 
general acid is eliminated, the other one takes over, maintaining general acid catalysis.  
The kinetic behavior of the mutants suggests the presence of two catalytically equivalent, 
but differently populated, forms of the Michaelis complex.  Similar to the mode of action 
one would expect from a pure noncompetitive inhibitor on the native enzyme, the E134Q 
or D65N mutation renders one of the two conformations catalytically unproductive, 
which reduces the rate but has no effect on KM.  
In order to obtain insights into substrate binding modes in VHZ that might explain 
how either D65 or E134 can act as a general acid, the programs AutoDock (12, 29-31) 
and FlexX (32, 33) were used to predict the orientation of pNPP in the active site.  Both 
programs predicted two possible conformations, presented in Figure 3-9.  In each, the 
phosphate moiety of the substrate is coordinated by the P- loop and the side chain of 
R101, and is properly positioned for nucleophilic attack by the negatively charged  
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A B WT WT WT WT WT
max max max A max B max A B max maxV +V =V ×α +V ×α =V ×(α +α )=V ×1=V  
Figure 3-9 – Two pNPP docking modes in the active site of VHZ predicted by docking 
studies.  In mode A the scissile ester oxygen of the pNPP substrate is oriented towards 
the E134 side chain.  Acid catalysis by D65 is unavailable, as its side chain is displaced 
to relieve a steric clash with the substrate.  The D65A mutation removes this clash, 
explaining its lower KM.   When E134 is mutated, general acid catalysis by D65 can occur 
from the binding mode shown in B.  Conformation B is analogous to that observed in the 
crystal structure of substrate bound to an inactive mutant of SsoPTP, and is consistent 
with the pH rate profile of E134Q. 
 
cysteine at the bottom of the active site.  In conformation A the scissile oxygen is 
oriented towards E134, consistent with its assignment as the primary general acid.  The 
D65 side chain turns away to avoid a steric clash with the p-nitrophenyl ring.  We 
conclude that this substrate conformation is the predominant one, consistent with the 
kinetic effects of the E134Q mutation and steric relief observed in the D65A mutant. The 
substrate conformation in panel 9B is the one commonly observed in classical PTPs, 
except for the position of the glutamine residue analogous to E134, which occupies a 
different conformation to avoid a steric clash with the substrate phenyl ring (26).  
However, it resembles the position of the corresponding Q135 residue in several 
structures of SsoPTP in complex with peptide substrates (7).   In this conformation the 
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phenolate ring is in close proximity to the L97 side chain, and D65 is oriented in position 
to donate its proton to the scissile oxygen of the leaving group. This substrate orientation 
is consistent with the kinetic behavior of the E134Q mutant, which utilizes D65 as its 
general acid.   
The presence of two binding conformations explains why the E134Q and D65N 
mutants have a reduced kcat with no significant effect on KM.  If conformation B, in which 
the E134Q mutant can utilize the D65 general acid, presents a minor fraction of the 
overall enzyme-substrate complex, then it would kinetically appear as a reduction of kcat 
because the predominant conformation A would be catalytically unproductive in this 
mutant.  The different effects of the D65N and E134Q mutations on kcat with no 
significant effect on KM suggest that both conformations A and B coexist, and 
conformation A dominates.  The E134Q or D65N substitution, which results in 
conformation A or B becoming non-productive, respectively, is similar to the effect from 
noncompetitive inhibition.  Noncompetitive inhibition results from the formation of a 
non-productive enzyme-substrate-inhibitor complex that reduces Vmax but has no effect 
on KM.  The reaction catalyzed by the E134Q mutant where conformation A is 
unproductive and conformation B leads to product formation according to the equation
max
max
1
1
WT
A
AB
V
V
K

 
 
 
, where 
WT
maxV  is the maximal rate of the reaction by the native VHZ 
containing both acids, and 
A
maxV  is the maximal velocity for the E134Q mutant.  The 
calculated value of AB
[B]
K = =0.12
[A]
 indicates that about 89% of the VHZ [ES] complex 
exists in conformation A, and 11% in form B.  This ratio is consistent with the modest 
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reduction of kcat in the D65N mutant.  The equilibrium constant of 0.12 implies a modest 
energetic difference of slightly more than 1 kcal/mol, consistent with the nearly equal 
scoring function obtained from the docking programs for the two conformations.   
The predominance of conformation A in which the phenolate ring interacts with 
the D65 side chain explains the steric relief produced by the D65A mutation.  The 
presence of the E134 general acid and its use in conformation A appears to be a 
reasonable evolutionary solution which to permit a bulky substrate from entering the 
narrow and sterically demanding active site pocket. Conformation B is the one the most 
commonly observed in classical PTPs, which possess a movable WPD-loop.  This 
conformation allows VHZ to utilize its D65 general acid.  However, under the condition 
of a non-movable general acid-bearing IPD-loop, conformation B is sterically disfavored, 
making it significantly less populated than conformation A.  The presence of the two 
coexisting but unequally populated A and B conformations explains why both 
VHZ/E134Q and VHZ/D65N mutants retained their basic limbs but produced 
proportionally different effect on kcat without affecting KM. 
   A similar phenomenon may explain anomalous behavior reported in the Tk-
PTP, a protein tyrosine phosphatase isolated from the Thermococcus kodakaraensis 
KOD1.  On the basis of structural comparisons with known PTPs, D63 was assigned as 
the putative general acid.  Unexpectedly, the D63A mutant was found to be more active, 
not less, than the native enzyme (34).  No explanation was suggested, and no structure of 
Tk-PTP has been published; however, the protein sequence (Figure S-2) suggests the 
presence of a glutamic acid residue in a position corresponding to that of E134 in VHZ.  
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Like VHZ, Tk-PTP may utilize a different general acid than the one implicated by 
structural comparisons with the PTP family. 
The possibility that the results arise from the presence of a good leaving group in 
pNPP that does not need an enzymatic general acid to protonate it at pH 5.5 is unlikely.  
Across the PTP family, KIE results at this pH show that the leaving group leaves as the 
nitrophenolate anion when the enzymatic general acid is mutated, rates are significantly 
reduced, and pH-rate profiles lose their basic limbs (5).  Recently the existence of two 
alternate binding modes depending on peptide sequence has been reported for VHR (35).  
The results here do not address the question of whether the finding of two alternate 
binding modes and two general acids pertains to peptide substrates of VHZ.  Specific 
substrates for VHZ have not been identified.  Tests with pY-containing peptide substrates 
(11-mers) of varying sequence yielded kcat values that were the same within experimental 
error (0.5 s
-1
) and KM values from 2 to 4 mM (1).   
 
VHZ exhibits phosphotransferase activity controlled by a single residue in an 
unexpected location.  
In classical PTPs, Q-loop residues such as Q446 and Q450 in YopH (Figure 3-4), 
in locations analogous to E134 and Q138 in VHZ, position the nucleophilic water for the 
second step and shield the phosphoenzyme from larger nucleophiles (2).  In classical 
PTPs catalysis is unaffected by added ethylene glycol.  In contrast, YopH mutants in 
which these glutamines are mutated show significant phosphoryl transfer to ethylene 
glycol (2).  This has provided a rationalization for why the native VHR and LMW-Ltp1, 
which lack an analogous Q-loop, display phosphotransferase activity (3).  Thus, the 
observation of phosphotransferase activity by VHZ was unexpected, since its E134 and 
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Q138 residues are superimposable with Q446 and Q450 in YopH.  The ratio S of the 
second-order rate constant for alcoholysis by ethylene glycol (kt) to the hydrolysis of the 
phosphoenzyme intermediate (kcat’) is 14.4 (Table 3-5).  This ratio was not significantly 
affected by the E134Q mutation, indicating that the E and Q residues, as was previously 
shown with YopH, are interchangeable (2).  The higher transphosphorylation by the 
E134A mutant indicates that that E134 provides some shielding of the phosphoenzyme. 
However, the analogous YopH/Q446A mutation results in a greater increase, from which 
we conclude that E134 in VHZ does not function as effectively in the second step as 
Q446 in YopH.   The VHZ/D65A substitution results in the most pronounced increase in 
the S ratio, which, together with the reduced kcat indicates that D65 is important in the 
second catalytic step.  
Interestingly, unlike VHZ, there is no effect of ethylene glycol concentration on 
catalysis by SsoPTP.  A sequence alignment of the IPD-loops of VHZ and SsoPTP 
revealed that while SsoPTP contains two proline residues in this region, a pattern that is 
highly conserved in the PTP family, VHZ has an extra proline, P68.  Other PTPs do not 
have a proline in this position.  In SsoPTP, V72 is found in the corresponding position.  
The VHZ/P68V mutation results in no significant change in kcat; however, 
phosphotransferase activity is lost and there is no dependence of rate on ethylene glycol 
concentration.  The orthogonal SsoPTP/V72P mutation confers phosphotransferase 
ability similar to that of native VHZ.  We thus conclude that the single point mutation of 
proline at the P68 position in VHZ, and the analogous V72 position in SsoPTP, controls 
the ability of these enzymes to phosphorylate alcohols.  Because the IPD-loop in VHZ 
and SsoPTP is a rigid structural element, this mutation has no effect on kcat.  Further 
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studies, including structural comparisons, are underway to seek an explanation of how 
this residue controls phosphotransferase activity. 
 
Conclusions:  
Although VHZ is most closely related to classical PTPs, it is unique and has a 
number of unusual and interesting properties.  VHZ has two functional general acids, 
and, for the small molecule substrate pNPP, two substrate binding modes.  Both binding 
modes are catalytically equivalent but not equally populated.  Each binding mode utilizes 
a different general acid.  
Despite the fact that VHZ shares a common active site with classical PTPs, it is a 
significantly less efficient catalyst. Both catalytic steps k3 and k5 are slower compared to 
other PTPs. The reduced k3 is consistent with incomplete neutralization of the leaving 
group, as revealed by KIEs.  Reduction of k5 is due to the incomplete involvement of the 
E134 residue in the second step, as revealed by the E134Q and E134A mutations. 
The results also provide a rationale for the advantage of mobility of the general 
acid-bearing WPD-loop in classical PTPs.  The availability of an uncatalytic, open 
conformation allows the general acid to avoid sterically unfavorable interactions with 
substrate binding, and to alleviate product release and avoid product inhibition.  
The discovery of phosphotransferase activity by VHZ also leads to several 
conclusions: 
1. The fact that the reaction rate increases linearly with ethylene glycol 
concentration indicates the second step is at least partially rate limiting. Together with the 
absence of a burst in the pre-steady state analysis of VHZ, we conclude that both steps 
contribute to the overall rate.  
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2. The Q-loop does not fully participate in protecting the active site from 
incoming alcohol nucleophiles.  In VHZ mutations on the IPD-loop have more control 
over phosphotransferase ability.  It is logical to conclude that the phosphotransferase 
activity observed in VH1-related DSPs and Low molecular weight PTPs can no longer be 
explained solely by the absence of the Q-loop.  Significant difference in position of the 
general acid loop between classical PTPs, LMW-PTPs and VH1-related DSPs 
undoubtedly contributes as well.  
3. The presence of phosphotransferase activity in some phosphatases, but not 
others, may have significant biological consequences.  It may not be coincidental that 
some proteins known to be associated with cancer, such as VH1-related DSPs and LMW-
PTPs, and, recently, VHZ, reveal a high level of phosphotransferase ability (20, 21). 
Whether this process is random and nonspecific, or transphosphorylation is selective for 
some protein target, remains to be discovered. However, because VHZ has a stringent 
phosphotyrosine specificity because of its deep and narrow active site, we can conclude 
that its transphosphorylation target would likely be limited to tyrosine protein sites, or to 
small molecule nucleophile acceptors capable of entering the active site.  
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METAVANADATE AT THE ACTIVE SITE 
OF THE PHOSPHATASE VHZ
3
 
Abstract  
Vanadate is a potent modulator of a number of biological processes and has been 
shown by crystal structures and NMR to interact with numerous enzymes.  Although 
these effects often occur under conditions where oligomeric forms dominate, crystal 
structures and NMR data suggest the inhibitory form is usually monomeric 
orthovanadate, a particularly good inhibitor of phosphatases due to its ability to form 
stable trigonal-bipyramidal complexes.  We performed a computational analysis of a 1.14 
Å structure of the phosphatase VHZ in complex with an unusual metavanadate species, 
and compared it with two classical trigonal-bipyramidal vanadate-phosphatase 
complexes. The results support extensive delocalized bonding to the apical ligands in the 
classical structures.  In contrast, in the VHZ metavanadate complex the central, planar 
VO3 moiety has only one apical ligand, the nucleophilic cysteine-95, and a gap in 
electron density between vanadium and sulfur.  A computational analysis shows the V-S 
interaction is primarily ionic.   A mechanism is proposed to explain the formation of 
metavanadate in the active site from a dimeric vanadate species that previous 
crystallographic evidence shows can bind to the active sites of phosphatases related to 
VHZ.  Together, the results show that the interaction of vanadate with biological systems 
is not solely reliant upon the prior formation of a particular inhibitory form in solution.  
The catalytic properties of an enzyme may act upon the oligomeric forms primarily 
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present in solution to generate species such as the metavanadate ion observed in the VHZ 
structure.  
Introduction 
Because of vanadate’s ability to modulate a number of biological processes there 
is considerable interest in the origin of the interactions of this simple inorganic species 
with proteins(1-8). Over 173 structures in the Protein Data Bank (PDB) display the 
interactions of different vanadate forms with a broad number of enzymes from multiple 
organisms(9-13).  Vanadate is a potent inhibitor of many phosphatases, enzymes with key 
roles in biological signaling throughout the living world. In particular, the insulin 
mimetic effect of vanadate is associated with its inhibition of protein tyrosine 
phosphatases (PTPs) (14, 15). Compared to orthophosphate ion (PO4
3
), orthovanadate ion 
(VO4
3-
) is a more potent inhibitor of phosphatases with a Ki that is often several orders of 
magnitude lower.  This difference is attributed to the ability of vanadate to form a 
trigonal bi-pyramidal complex at the active site, resembling the transition state for 
phosphoryl transfer (13, 16-20). Experimental data with PTPs indicate that both 
formation and hydrolysis of the phosphoenzyme intermediate proceed via a loose 
transition state with low bond orders to the nucleophile and the departing leaving group, 
(21-24) whereas crystal structures of trigonal bi-pyramidal vanadate complexes in 
enzymes are commonly modeled with full bonds to the apical ligands. Previous 
experimental and computational results suggest that such complexes resemble the 
transition state only in overall geometry and charge, whereas the bond orders between 
vanadium and the apical ligands are higher than those of the corresponding bonds in the 
transition state (25, 26). 
 
 
 
100 
 
An understanding of the inhibitory effect of vanadate on phosphatases, and of its 
biological effects, is complicated by the tendency of vanadate to oligomerize in solution 
(27). These effects are frequently observed under conditions where vanadate is primarily 
oligomerized and the monomer is a minor form (3, 27).  Interestingly, even though 
crystallization conditions often require vanadate concentrations that would primarily 
result in oligomeric species, crystal structures almost exclusively show monomeric 
vanadate at the active site.  This has been attributed to the facile interconvertability of 
different vanadate species in solution and the ability of the active site of phosphatases to 
selectively stabilize the monomeric form (28). Here, we report results indicating that the 
classical trigonal bi-pyramidal vanadate species is not the only form capable of binding to 
PTPs, and that other forms contribute to the inhibition of PTPs and potentially to other 
biological effects of vanadate.   
 
Results and discussion 
VHZ is a recently described member of the PTP family of phosphatases (29).  A 
recently obtained high-resolution structure of VHZ in complex with vanadate revealed 
what appeared to be an unusual “metavanadate” in the active site (Figure 4-1; PDB ID 
4ERC). The VO3 moiety is coordinated to the sulfur atom of cysteine 95 as one apical 
ligand, with a 2.4 Å V-S distance.  The opposite apical position is occupied by a nitrogen 
atom of the arginine 60 (R
S
60) side chain trapped in the active site from a symmetry-
related VHZ molecule in the crystal (Figure 4-2, A).  The V-N distance of 3.2Å argues 
against a significant bonding interaction, nor would a significant interaction be expected 
with the positively charged guanidinium group.  Although the V-S distance is typical of 
those commonly observed in trigonal bi-pyramidal vanadate-PTP complexes, (17) a 
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distinct electron density gap between the atoms is evident in the high resolution unbiased 
composite omit map (Figure 4-1).  Furthermore, the VO3 moiety is nearly planar, while a 
tetrahedral geometry would be expected from a covalent V-S bond and the absence of an 
apical V-N bond (20, 30).  These observations suggest that the VO3 moiety is better 
described as an electrostatically stabilized metavanadate (VO3
-
) rather than a covalent 
thiovanadate adduct. A computational analysis of this structure was carried out to analyze 
the unusual bonding in this complex, compared with more typical, previously reported 
vanadate-PTP structures (Figure 4-2). The two more conventional structures chosen for 
comparison were the complex of PTP1B with a vanadate ester of the peptide DADEYL 
(Figure 4-2 B, PDB ID 3I7Z), and PTP1B with orthovanadate (Figure 4-2 C, PDB ID 
3I80).  Both of the latter structures are typical of the trigonal bi-pyramidal vanadate-PTP 
complexes well represented in the literature. The nature of the chemical bonding between 
the VO3 ion and the protein was assessed using quantum mechanical calculations. For 
this purpose portions of the proteins shown in Figure 4-2 were extracted directly from the 
crystal structures.  
 
Figure 4-1. The electron density at the VHZ active site. It suggests a non-covalently 
bound VO3
-
 ion. Shown is an unbiased composite omit map contoured at 1.5 σ in the 
refined model. 
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Truncation was done to include all residues interacting with vanadate; all residues 
with hydrogen bonds or pi-stacking to residues that interact with vanadate; and all groups 
that are polar or charged, and located in proximity to the vanadate ion even if they do not 
directly interact.  Hydrogen atoms were added to satisfy all dangling valencies using the 
Chimera program(31). The standard protonation states of amino acids were assumed 
(deprotonated Asp, Glu, protonated Lys and Arg), except for the Tyr coordinating 
vanadium in Figure 4-2 B, which was deprotonated.  The nucleophilic cysteine was 
assumed to be deprotonated; this residue has a pKa in the range of 5.5 to 6 in this enzyme 
family(32). The truncated complexes effectively contained the first and the second 
coordination spheres of the vanadate ion, and consisted of 140-170 atoms (including 
hydrogens), depending on the complex. The spin states of the complexes were zero, 
assuming the empty d-shell in vanadium. The Natural Bond Orbital (NBO) analysis(33-
36), at the B3LYP (37-39)/6-31G* (40, 41) level of theory, was used to elucidate the 
chemical bonds present in the complexes. This level of approximation, including the 
fairly modest size of the basis set, were considered adequate for the problem at hand, 
because NBO results in general are quite insensitive to the basis set used, and because 
only the qualitative assessment was required to differentiate the state of V in the 
complexes. Calculations were performed using the Gaussian 09 suite of programs (42). 
Table 4-1 contains the key electronic structure parameters characterizing the 
vanadium atom and its bonding environment in the three complexes. There is an apparent 
difference between the bonding exhibited by VHZ complex containing VO3 (Figure 4-2 
A) and the other two complexes. As expected from its distance of 3.2 Å, there is no 
significant interaction between the V and the apical N of R
s
60. The partially populated 
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lone pair (LP) on N of the distant apical Arg (1.66 |e|) donates electron density to the 
guanidinium group, participating in π-resonance, and is only weakly coordinated to V 
through  van der Waals interactions. One of the O atoms of the VO3 ion exhibits a pi 
bond with V, representing one of the resonance structures (the lowest energy one) 
possible in this π-delocalized VO3 ion.  There is a clear 2 center – 2 electron (2c-2|e|) 
bond between V and SCys95. This bond is primarily ionic, with 79% of electron density 
residing on S and 21% on V.  This is consistent with the electron density gap observed in 
the unbiased composite omit map between the C95 sulfur and V, which is indicative of 
ionic rather than covalent ligand stabilization. The bonding within the vanadate moiety 
and its interaction with VHZ differ in several ways from the more conventional PTP1B 
complexes.  In contrast to the VHZ-VO3 complex 2A, in the PTP1B complexes 2B and 
2C there is no π-bonding within the central VO3 part of the ion.  This is reflected in 
different averaged V-O bond lengths in the x-ray structures, which are 1.70 Å for 2A, 
1.89 Å for 2B, and 1.91 Å for 2C. One lone pair on SCys215 (LP3) and one on OTyr (LP3) 
are populated only by ca. 1.7 |e|, within the NBO localized picture. The low-populated 
lone pair on S (LP3) partially donates electron density to the d-atomic orbitals (AOs) of 
vanadium. The low-populated lone pair on O of Tyr (LP3) primarily donates electrons 
into π-resonance within the Tyr phenyl ring. However, both LP2 and LP3 on OTyr also 
donate to the d-AOs on vanadium.  
To summarize, in complexes 2B and 2C neither the V-SCys, nor the V-OTyr apical 
interactions are classic 2c-2|e| bonds.  Bonding between vanadium and these apical 
ligands is significant and highly delocalized between SCys, V, and OTyr.  The equatorial V- 
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Figure 4-2. The regions of the three vanadate complexes used in quantum mechanical 
calculations. (A) VHZ-VO3 (PDB 4ERC) (B) PTP1B-Tyr-VO4 (PDB 3I7Z), (C) PTP1B-
VO4 (PDB 3I80). Hydrogens have been omitted from the picture for the sake of clarity.  
In the VHZ complex, the R
s
60 residue in the active site comes from a symmetry-related 
VHZ molecule. DADEYL peptide was omitted with exception of Y side chain. 
Coordinates are available in Appendix C.  
 
O interactions are single bonds.  In contrast, the complex 2A can be described as a 
π-delocalized VO3 ion with only one apical interaction, an ionic bond between V and 
SCys. 
The complex solution chemistry of vanadate must be considered together with the 
chemical properties of the enzymes it can associate with.  Monomeric vanadate 
dominates at low concentrations, with dimeric forms becoming significant at 
concentrations above 0.2 mM, followed by higher oligomers(28). Interconversion is 
rapid, and it is logical that the various forms of vanadate should be similarly labile in an 
enzymatic active site. There is no reason, a priori, that an inhibiting form of vanadate 
must pre-form in solution before binding to the enzyme.  While numerous oligomeric 
forms of vanadate have been documented, metavanadate has not been reported in 
solution, and presumably was generated by the enzyme from some other vanadate species 
present in solution, and subsequently stabilized by the active site environment. We 
propose a simple mechanism that can explain the formation of this species from 
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Table 4-1. Electronic structure parameters characterizing the vanadium atom and its 
bonding in complexes 2A-C. The parameters calculated with NBO at B3LYP/6-31G*: 
Charges on atoms (Q) , electronic populations of 2 center-2 electron (2c-2|e|) σ and π 
bonds, and electronic populations of lone pairs (LP). Atoms are labeled according to 
Figure 4-2. 
 
  VO3 (2A) VO4 (2B) VO4 
(2C) 
Q(V) 1.09 1.34 1.33 
Q(SCys) -0.31 -0.42 -0.42 
Q(N/Oapical) -0.79
a
 -0.68 -0.9 
2c-2|e| bonds:       
   V-O1 1.99 |e| - σ 1.99 |e| 1.98 |e| 
1.96 |e| - π none none 
   V-O2 1.98 |e| 1.99 |e| 1.99 |e| 
   V-O3 1.98 |e| 1.99 |e| 1.98 |e| 
   V-S 1.95 |e| none none 
Lone pairs:       
   LP1(S) 1.94 |e| 1.94 |e| 1.94 |e| 
   LP2(S) 1.87 |e| 1.88 |e| 1.88 |e| 
   LP3(S) none
b
 1.73 |e| 1.73 |e| 
   V-N or Oapical none none none 
   LP1(N or Oapical) n/a
c
 1.91 |e| 1.94 |e| 
   LP2(Oapical) n/a 1.86 |e| 1.83 |e| 
   LP3(N or Oapical) 1.66 |e| 1.61 |e| 1.65 |e| 
 
a 
-0.79 is the atomic charge on the R
s
60 nitrogen atom in an apical position to vanadium; 
the total charge on the guanidinium group of this arginine is +0.6.
   b
 “none” indicates that 
suitable orbitals are available, but not occupied.  
c
 “n/a” indicates that the lone pair 
orbitals are not present. 
 
 
divanadate, and possibly polyvanadate, forms that are well known to exist, and usually 
dominate, in solution.  In light of the highly conserved nature of the active sites of PTPs, 
this mechanism would apply to this family as whole, and potentially to any similar 
enzyme with a general acid.This proposal (Figure 4-3) incorporates the general acid 
conserved in PTPs, and also explains why the first report of a divanadate
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species at the active site of a PTP was found in a YopH W354F mutant in which the 
flexible loop that bears the general acid is locked in a catalytically unproductive 
position(43). The crystal structure of this divanadate complex showed that dimeric, and 
possibly higher oligomeric species, are capable of binding to PTPs (Figure 4-3 D).  We 
believe it is no coincidence that this complex was identified in a mutant in which general 
acid catalysis is disabled.  Presumably, this or other dimeric forms bind to the native 
enzyme, but are rapidly hydrolyzed to the monomer and not observed 
crystallographically. 
According to the proposed mechanism, divanadate (Figure 4-3 D) binds in the 
active site and the general acid protonates one of its bridge oxygens, triggering 
decomposition and formation of “metavanadate,” stabilized by the P-loop and 
electrostatic interaction with the nucleophilic thiolate.  The resulting complex (Figure 4-3 
E) is the species trapped in the VHZ-VO3 crystal structure.  The classically observed 
trigonal bi-pyramidal orthovanadate species can result from a process analogous to the 
second step of the PTP-catalyzed reaction, in which a nucleophilic water attacks with 
positioning assistance of Q-loop residues, assuming the other apical position. Such a 
process would explain the high affinity and selectivity in crystal structures of PTPs for 
monomeric orthovanadate under conditions where oligomeric polyvanadates dominate in 
solution. Recent work (44) shows that vanadate speciation is sensitive to surfaces such as 
micelles, consistent with the idea that an enzyme active site could preferentially stabilize 
a species such as the dimer in 3D, or metavanadate.  
We note that the reversible interconversion between F and G in Figure 4-3 
provides an alternative pathway for enzyme-catalyzed metavanadate formation without 
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invoking binding of a dimeric form.  However, the VHZ crystals were grown in the 
presence of 10 mM vanadate, far above the 0.2 mM level at which dimeric and higher 
forms begin to dominate. Potent vanadate inhibition of many phosphatases is reported 
across wide ranges of pH and vanadate concentrations, supporting the notion that 
multiple forms are capable of binding, and that the interconvertability in the active site is 
similar to that in solution.  If anything, the active site of an enzyme optimized to catalyze 
hydrolysis should facilitate such processes.  
The metavanadate species observed here is not an anomalous structure only 
relevant to VHZ, or potentially other PTPs.  A geometrically similar VO3 species has 
been previously observed in a crystal structure of phosphoglucomutase, (45) an enzyme 
that has no similarity to PTPs.  That structure also reveals a planar VO3 moiety with a 
single apical ligand (an aspartate carboxyl group) and a similar gap in the 2Fo-Fc electron 
density obtained from the Electron Density Server (EDS) observed at 1.0 σ. 
 
Conclusion 
In summary, this work shows that the interaction of vanadate with the active sites 
of PTPs in solution is more versatile than the simple trigonal bi-pyramidal model that 
dominates the RCSB.  The inhibitory effect of vanadate can involve dimeric, and 
potentially higher oligomers, an important factor since such species often dominate in 
solution. The ability of the active site environment to electrostatically stabilize a 
metavanadate ion adds another facet to the interaction of vanadate with such enzymes. In 
the VHZ-VO3 complex there is only a single significant apical interaction, which is 
primarily ionic.       
 
 
 
109 
 
This complex is a good analogue of the loose metaphosphate-like transition state 
concluded from experimental studies. The average V-Oeq bond distance in the VHZ-VO3 
structure is shorter compared to the commonly observed trigonal bi-pyramidal vanadate 
complexes, but in a good agreement with experimental values determined with Raman 
difference spectroscopy of vanadate at the active site of the related enzyme YopH.  
Hence, it is conceivable that such VO3 species may form more commonly than suspected 
in PTP-vanadate solutions, and the dominance among crystal structures of the trigonal bi-
pyramidal structures (like 3E and 3F) arise from species that subsequently form and are 
more amenable to trapping. The rich speciation of vanadate in solution clearly extends to 
its ability to also adopt multiple species at enzymatic active sites. 
 
References 
1. Bishayee, A., Waghray, A., Patel, M. A., and Chatterjee, M. (2010) Vanadium in the 
detection, prevention and treatment of cancer: The in vivo evidence. Cancer Lett. 294, 
1-12. 
2. Cam, M. C., Brownsey, R. W., and McNeill, J. H. (2000) Mechanisms of vanadium 
action: Insulin-mimetic or insulin-enhancing agent? Can. J.Physio.l Pharmacol. 78, 
829-847. 
3. Crans, D. C., Smee, J. J., Gaidamauskas, E., and Yang, L. (2004) The chemistry and 
biochemistry of vanadium and the biological activities exerted by vanadium 
compounds. Chem. Rev. 104, 849-902. 
4. Evangelou, A. M. (2002) Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 
42, 249-265. 
 
 
 
110 
 
5. Heyliger, C. E., Tahiliani, A. G., and McNeill, J. H. (1985) Effect of vanadate on 
elevated blood glucose and depressed cardiac performance of diabetic rats. Science 
227, 1474-1477. 
6. Rubinson, K. A. (1981) Concerning the form of biochemically active vanadium. Proc. 
R. Soc. B. 212, 65-84. 
7. Tsiani, E., Bogdanovic, E., Sorisky, A., Nagy, L., and Fantus, I. G. (1998) Tyrosine 
phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and 
GLUT translocation in muscle cells by a mechanism independent of 
phosphatidylinositol 3-kinase and protein kinase C. Diabetes 47, 1676-1686. 
8. Tsiani, E., and Fantusa, I. G. (1997) Vanadium compounds biological actions and 
potentialas pharmacological agents. Tr. Endocrin. Met. 8, 51–58. 
9. Crans, D. C., Sudhakar, K., and Zamborelli, T. J. (1992) Interaction of rabbit muscle 
aldolase at high ionic strengths with vanadate and other oxoanions. Biochemistry 31, 
6812-6821. 
10. Crans, D. C., Willging, E. M., and Butler, S. R. (1989) Vanadate tetramer as the 
inhibiting species in enzyme reactions in vitro and in vivo. J.Am.Chem.Soc. 112, 427–
432. 
11. Messmore, J. M., and Raines, R. T. (2000) Pentavalent organo-vanadates as transition 
state analogues for phosphoryl transfer reactions. J.Am.Chem.Soc. 122, 9911-9916. 
12. Messmore, J. M., and Raines, R. T. (2000) Decavanadate inhibits catalysis by 
ribonuclease A. Arch. Biochem. Bioph.381, 25-30. 
13. Stankiewicz, P. J., and Gresser, M. J. (1988) Inhibition of phosphatase and sulfatase 
by transition-state analogues. Biochemistry 27, 206-212. 
14. Shechter, Y. (1990) Insulin-mimetic effects of vanadate. Possible implications for 
future treatment of diabetes. Diabetes 39, 1-5. 
 
 
 
111 
 
15. Bhattacharyya, S., and Tracey, A. S. (2001) Vanadium(V) complexes in enzyme 
systems: aqueous chemistry, inhibition and molecular modeling in inhibitor design. J. 
Inorg. Biochem. 85, 9-13. 
16. Zhang, M., Zhou, M., Van Etten, R. L., and Stauffacher, C. V. (1997) Crystal 
structure of bovine low molecular weight phosphotyrosyl phosphatase complexed 
with the transition state analog vanadate. Biochemistry 36, 15-23. 
17. Brandao, T. A., Hengge, A. C., and Johnson, S. J. (2010) Insights into the Reaction of 
Protein-tyrosine Phosphatase 1B: Crystal Structures for Transition State Analogs of 
Both Catalytic Steps. J. Biol. Chem. 285, 15874-15883. 
18. Davies, D. R., and Hol, W. G. (2004) The power of vanadate in crystallographic 
investigations of phosphoryl transfer enzymes. FEBS Lett. 577, 315-321. 
19. Stankiewicz, P. J., Tracey, A. S., and Crans, D. C. (1995) Inhibition of phosphate-
metabolizing enzymes by oxovanadium(V) complexes. Met. Ions Biol.Syst. 31, 287-
324. 
20. Denu, J. M., Lohse, D. L., Vijayalakshmi, J., Saper, M. A., and Dixon, J. E. (1996) 
Visualization of intermediate and transition-state structures in protein-tyrosine 
phosphatase catalysis. Proc. Natl. Acad. Sci. 93, 2493-2498  
21. Lassila, J. K., Zalatan, J. G., and Herschlag, D. (2011) Biological phosphoryl-transfer 
reactions: understanding mechanism and catalysis. Annu. Rev. Biochem. 80, 669-702. 
22. Hengge, A. C. (2005) Mechanistic studies on enzyme-catalyzed phosphoryl transfer. 
Adv. in Phys. Org. Chem. 40, 49–108. 
23. Hengge, A. C., Zhao, Y., Wu, L., and Zhang, Z. Y. (1997) Examination of the 
transition state of the low-molecular mass small tyrosine phosphatase 1. Comparisons 
with other protein phosphatases. Biochemistry 36, 7928-7936. 
24. Hengge, A. C., Sowa, G. A., Wu, L., and Zhang, Z. Y. (1995) Nature of the transition 
state of the protein-tyrosine phosphatase-catalyzed reaction. Biochemistry 34, 13982-
13987. 
 
 
 
112 
 
25. Krauss, M., and H. Basch. (1992) Is the vanadate anion an analogue of the transition 
state of RNase A? J. Am. Chem. Soc. 114, 3630-3634. 
26. Deng, H. C. R., Huang, Z, Zhang, Z.Y. ( 2002) Is the PTPase-vanadate complex a 
true transition state analogue? Biochemistry 41, 5865-5872. 
27. Crans, D. C., Bunch, R. L., and Theisen, L. A. (1989) Interaction of trace levels of 
vanadium(IV) and (V) in biological systems. J. Am. Chem. Soc. 111, 7597-7607. 
28. Crans, D. C., Rithner, C. D., and Theisen, L. A. (1990) Application of time-resolved 
V-51 2d Nmr for quantitation of kinetic exchange pathways between vanadate 
monomer, dimer, tetramer, and pentamer. J. Am. Chem.Soc. 112, 2901-2908. 
29. Alonso, A., Burkhalter, S., Sasin, J., Tautz, L., Bogetz, J., Huynh, H., Bremer, M. C., 
Holsinger, L. J., Godzik, A., and Mustelin, T. (2004) The minimal essential core of a 
cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like 
phosphatase, VHZ. J. Biol.Chem. 279, 35768-35774. 
30. Pannifer, A. D., Flint, A. J., Tonks, N. K., and Barford, D. (1998) Visualization of the 
cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by x-ray 
crystallography. J. Biol.Chem. 273, 10454-10462. 
31. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., 
Meng, E. C., and Ferrin, T. E. ( 2004) UCSF Chimera--a visualization system for 
exploratory research and analysis. J. Comput.Chem. 25, 1605-1612. 
32. Denu, J. M., and Dixon, J. E. (1995) A catalytic mechanism for the dual-specific 
phosphatases. Proc. Natl. Acad. Sci. 92, 5910-5914. 
33. Carpenter, J. E., and Weinhold, F. (1988) Analysis of the geometry of the 
hydroxymethyl radical by the “different hybrids for different spins” natural bond 
orbital procedure. J. Mol. Struct. (THEOCHEM) 41-62, 169. 
34. Foster, J. P., and Weinhold, F. (1980) Natural hybrid orbitals. J. Am. Chem. Soc. 102, 
7211–7218. 
 
 
 
113 
 
35. Reed, A. E., and Weinhold, F. (1983) Natural bond orbital analysis of near Hartree–
Fock water dimer. J. Chem. Phys. 78, 4066. 
36. Reed, A. E., Curtiss, L. A., and Weinhold, F. (1988) Intermolecular interactions from 
a natural bond orbital, donor-acceptor viewpoint. Chem. Rev. 88, 899–926. 
37. Parr, R. G., and Yang, W. (1989) Density-functional theory of atoms and molecules. 
Oxford Univ. Press, Oxford. 
38. Becke, A. D. (1993) Density-functional thermochemistry. III. The role of exact 
exchange. J. Chem. Phys. 98, 5648-5652. 
39. Perdew, J. P., Chevary, J. A., Vosko, S. H., Jackson, K. A., Pederson, M. R., Singh, 
D. J., and Fiolhais, C. (1992) Atoms, molecules, solids, and surgaces: applications of 
the generalized gradient approximation for exchange and correlation. Phys. Rev. B 46, 
6671-6687. 
40. Clark, T. C., J.; Spitznagel, C. W.; Schleyer, P. v. R. . (1983, ) Efficient diffuse 
function-augmented basis sets for anion calculations. III. The 3-21+G basis set for 
first-row elements, Li-F. J. Comput. Chem. 4, 294-301. 
41. Frisch, M. J. P., J. A.; Binkley, J. S. (1984) Self-consistent molecular orbital methods 
25. supplementary functions for gaussian basis sets. J. Chem. Phys. 80, 3265-3269. 
42. Gaussian 09, R. A., Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; 
Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, 
G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, 
J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; 
Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; 
Montgomery, Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, 
E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; 
Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, N. 
J.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; 
Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; 
 
 
 
114 
 
Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; 
Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. 
B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. . (2009.)  (Gaussian, I., Wallingford, C.T., 
Ed.). 
43. Brandao, T. A., Robinson, H., Johnson, S. J., and Hengge, A. C. (2009) Impaired acid 
catalysis by mutation of a protein loop hinge residue in a YopH mutant revealed by 
crystal structures. J. Am. Chem. Soc. 131, 778-786. 
44. Crans, D. C., Baruah, B., Ross, A., and Levinger, N. E. (2009) Impact of confinement 
and interfaces on coordination chemistry: Using oxovanadate reactions and proton 
transfer reactions as probes in reverse micelles. Coordin. Chem. Rev. 253, 2178-2185. 
45. Lu, Z., Dunaway-Mariano, D., and Allen, K. N. (2008) The catalytic scaffold of the 
haloalkanoic acid dehalogenase enzyme superfamily acts as a mold for the trigonal 
bipyramidal transition state Proc. Natl. Acad. Sci.105, 5687-5692. 
 
 
CHAPTER 5 
CONCLUSIONS AND PROSPECTIVE DIRECTIONS 
Summary of the research 
Our work with VHZ has revealed new aspects of this unique enzyme and 
corrected in many ways the original misinterpretation primarily affecting its 
classification, kinetic behavior, substrate specificity and structural properties. We have 
shown that VHZ is the simplest classical PTP with strict phosphotyrosine substrate 
specificity. Its sequence and structural analysis revealed that it bears several important 
distinctions from the atypical DSP subfamily where it was originally believed to belong 
to. Its general acid IPD-loop is highly superimposable with the analogous WPD-loop 
region in classical PTPs. However, unlike the WPD-loop in classical PTPs, which is 
highly flexible and has been repeatedly observed in open and closed conformational 
states, the IPD-loop in VHZ is a rigid and permanently closed element. Our kinetic 
analysis of VHZ has shown it has an unusual ability to utilize two alternative general acid 
residues which is made possible by two different, unequally populated substrate binding 
modes.   
Although we showed that VHZ is significantly more active than was previously 
believed, its catalytic efficiency remains significantly lower compared to the classical 
PTPs. Using kinetic isotope effects we revealed that the leaving group remains only 
partially protonated in the first step of the reaction, despite the fact VHZ contains two 
general acids. The pre-steady state kinetic analysis revealed that the first step of the 
reaction contributes to the rate limiting step of the overall process, whereas in classical 
PTPs the second step is predominantly rate limiting. Additionally, we revealed that VHZ 
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displays a high level of phosphotransferase ability despite the fact it contains a conserved 
Q-loop which is highly superimposable with the analogous region in classical PTPs. This 
protein element is believed to protect the phosphoenzyme intermediate from alcohol 
nucleophiles. Although, similar to classical PTPs, the Q-loop in VHZ plays an important 
role in controlling phosphotransferase ability, the general acid IPD-loop appears to be 
more important and critical as shown by the fact that the VHZ/P68A mutation in this 
region completely abolishes transphosphorylation. Finally, we identified SsoPTP as the 
closest relative to VHZ in terms of structure and kinetic properties. Both VHZ and 
SsoPTP are similar in size, and reveal the highest sequence and structural similarity as 
well as similar kinetic parameters. Both enzymes, unlike classical PTPs, contain a rigid 
IPD-loop and lack a substrate binding loop. SsoPTP, however, like many other PTPs and 
unlike VHZ, utilizes a single general acid but appears to have a shallow and broad active 
site crevice like many DSPs.  Thus, SsoPTP represents a hybrid containing features of 
VHZ, classical PTPs, and DSPs in one enzyme.  
 
Prospective research direction 
Although VHZ was the major focus of this study, it raised several important 
questions pertinent to the PTP family in general.  The answers to these questions will lead 
to better understanding of the PTP-catalyzed reaction and contribute to the field of 
enzymology.  
Despite the fact that VHZ is structurally identical to classical PTPs, utilizes the 
same mechanism, and all the catalytic residues are highly superimposable, it remains 
significantly less active when compared to classical PTPs. Incomplete protonation of the 
leaving group in the first step cannot explain the difference in activity, because the 
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second step, which involves water attack on the phosphoenzyme intermediate, is 
significantly slower as well. The answer to the question of why VHZ and SsoPTP are less 
active will allow a deeper understanding of catalytic mechanism of PTP catalyzed 
phosphate monoester hydrolysis. Explanations remain to be discovered to several 
questions: 
 In what way does the mobility of the WPD-loop affect catalytic 
activity? Can we make the IPD-loop movable, and what effect will it have on 
catalytic activity?  
 Does the substrate binding loop in classical PTPs contribute to 
their catalytic activity, and if so, then in what way? Can we increase the catalytic 
activity of VHZ and SsoPTP by introducing a substrate binding loop to these 
enzymes?  
Importance of the substrate binding loop 
This N-terminal region in PTPs is called the substrate binding loop because it 
makes a π-π stacking interaction with PTP substrates (1). It is absent in SsoPTP and VHZ 
which are shorter versions of classical PTPs. This region has not been considered as 
catalytically significant and is primarily responsible for substrate recognition and 
interaction. However, a single mutation of highly conserved Y residue in PTP1B 
substrate binding loop to yield the PTP1B/Y46E mutation resulted in a 100-fold 
reduction of kcat and a 40-fold increase in KM. Although such effect remains primarily 
unexplained, more work has to be done to study this phenomenon. In particular, the entire 
substrate binding loop can be removed by a simple one-step PCR experiment and the 
truncated version of PTP1B should be tested and evaluated crystallographically. 
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Alternatively, the substrate binding loop can be genetically introduced to VHZ and/or 
SsoPTP and such chimeric proteins can be studied to see if the presence of such  loop 
changes the activity of these enzymes. 
 
Factors affecting general acid IPD-loop stability in VHZ 
In order to selectively target the mobility of IPD-loop region in either VHZ or 
SsoPTP we need to understand the underlying factors that stipulate its permanently stable 
conformation. We have tested several VHZ and SsoPTP mutants to identify the factors 
that stipulate IPD-loop rigidity. The kinetic parameters of the mutants are presented in the 
Table 5-1 whereas VHZ/WT substituted positions are presented in Figure 5-1.  
 
IPD-loop vs WPD-loop - the substitution effect 
There is very little information available in the literature that describes the factors 
affecting WPD-loop mobility.  Several studies clearly revealed that the highly conserved 
W residue in the structure of WPD-loop is crucial for its proper oscillation and 
substitution of this residue to aliphatic alanine results in the reduction of kinetic 
parameters as a result of loop being locked in a semi-open conformational state (2, 3). 
Another study suggested that the residues surrounding the conserved WPD-loop region 
also play important role in its flexibility (4).  The sequences of VHZ and classical PTPs 
bear one significant difference in this region, and whereas classical enzymes contain a 
WPD-loop, VHZ and SsoPTP have an IPD-loop instead. Structurally these regions are 
highly superimposable, but the I63 residue in VHZ and I67 in SsoPTP correspond to the  
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Figure 5-1. Active site of VHZ and residues analyzed by site directed mutagenesis. 
Dashed line connects atoms within hydrogen bond distance (≤ 3Å).  We have tested 
several positions in VHZ which, based on the structural evidence, or previously 
knowledge about analogous WPD-loop motion in classical PTPs, could affect its 
mobility. For example, Q73 stabilizes the IPD-loop by making two hydrogen bonds to the 
backbone.  Analogous stabilization to the IPD-loop is provided by Q77 in SsoPTP.  
 
W residue highly conserved in all classical PTPs. The VHZ/I63W mutant was made to 
study the importance of this position on catalytic parameters of VHZ.Substitution of I63 
for a bulky W makes it closer to the classical PTPs, yet resulted in the 50-fold reduction 
of kcat which makes it very similar to the effect produced by P64A and P69A 
substitutions (Table 5-1). VHZ/I63W mutation resulted in no change of KM and Ki for 
the inorganic phosphate (Table 5-1 and Table 5-2) indicating it affects the general acid 
loop region but not active site geometry. These results suggest that the substitution of W 
for I in VHZ is catalytically important and cannot be a mere consequence of IPD-loop 
staying in the permanently closed conformation.  
 
Residues surrounding the IPD-loop region 
Considering that residues surrounding this loop may affect its flexibility as well, 
we observed that unlike any other PTP, VHZ/WT contains three proline residues in its 
IPD-loop structure (Figure 5-1). Proline residues are known to affect flexibility of loop 
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regions and in classical PTPs the WPD-loop most commonly contains two or even one 
proline residue in its structure. VHZ, however, in addition to the P64 and P69 proline 
residues (VHZ numbering) common for classical PTPs, also contains P68. 
Table 5-1.  Kinetic parameters of native and mutated PTPs. The mutants were made to 
probe the factors affecting the IPD-loop rigidity. 
 
Native enzymes kinetic parameters 
 kcat, s
-1
 KM, mM kcat/KM, (=mM/s)= 
VHZ/WT 3.900 ± 0.028 8.30 ± 0.67 0.47 
VHR/WT 3.116 ± 0.102 1.96 ± 0.11 1.59 
S.soPTP/WT 3.152 ± 0.048 4.31 ± 0.19 0.73 
YopH/WT 720.000 ± 24.600 0.98 ± 0.11 734.69 
PTP1B/WT 51.667 ± 0.860 0.12 ± 0.01 430.56 
Mutational analysis of  WPD/IPD-loop rigidity 
 kcat,(s
-1
) KM, mM kcat/KM, (mM/s) 
Sso PTP/V72P 2.61 ± 0.1 4.62 ± 0.43 0.56 
PTP1B/V184P 0.610 ± 0.130 1.20 ± 0.23 0.51 
VHZ/P68A 3.34 ± 0.06 5.88 ± 0.27 0.57 
VHZ/Q73L 0.93 ± 0.03 13.00 ± 0.99 0.07 
YopH/S287A 210.5 ± 8.5 1.1 ± 0.1 196.7 
VHZ/E44R 4.26 ± 0.06 6.53 ± 0.26 0.65 
VHZ/E44Q 4.75 ± 0.02 8.20 ± 0.67 0.58 
VHZ/E44S 3.78 ± 0.03 8.80 ± 1.21 0.43 
Additional Mutations 
 kcat,(s
-1
) KM, mM kcat/KM, (mM/s) 
VHZ/I63W 0.065 ± 0.001 8.50 ± 0.42 0.007 
VHZ/P64A 0.068 ± 0.034 32.92 ± 2.98 0.002 
VHZ/P69A 0.096 ± 0.005 31.00 ± 2.80 0.003 
 
Mutations of VHZ/P64A and VHZ/P69A, as can be seen from Table 5-1, 
significantly alter its kinetic parameters, indicating that similarly to classical PTPs these 
proline residues are highly important for catalysis (Table 5-1). The VHZ/P68V mutation 
resulted in no kinetic effect. Additionally, the inverse SsoPTP/V72P mutation in SsoPTP 
did not yield any significant kinetic effect. Unlike any other amino acids, proline imposes 
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significant constraints on the protein backbone which is believed to be one of the 
important factors affecting its proper folding. The transformation of the WPD-loop is 
accompanied by significant changes of the φ and ψ angles in the movable segment of the 
loop. For WPD-FGVP sequence in PTP1B the Δφ and Δψ changes for the closed-to-open 
transition were found to be: Δφ=195,Δψ=120; Δφ= 200, Δψ=20; Δφ=6 Δψ=0; Δφ=4 
Δψ=30; for F,G,V,P respectively (Figure 5-2). In VHZ the analogous IPD-FCPP segment 
contains two proline residues (di-proline segment, P68-P69). The presence of proline and 
especially di-proline segments in protein structures presents structural constraints 
resulting in a protein element with significantly reduced conformational choices. As was 
shown by Schimmel and Flory and later by MacArthur and Thornton (5, 6) the residues 
that precede proline are sterically constrained as well, and have a marked preference to be 
in the β-region of the Ramachandran plot. For a pre-proline amino acid the preference for 
the β-region over the α-region was estimated to be 9:1 respectively, whereas for residues 
in general (followed by any other amino acid) the distribution is almost equal. This effect 
is due to the steric clashes of the proline five-membered ring with the Cβ carbon and 
amide nitrogen of the preceding residue (7). Even glycine which has no Cβ carbon 
appeared to be sterically constrained at this position and out of  62 Gly-Pro segments in 
the protein databank only 5 were found in an unfavorable α region in the range of ψ -30o -
70
o
 whereas the major clustering occurs in a narrow ψ region of 180 (±30o) (5). In the 
native PTP1B the G183 residue is located in the β-region (φ=-118, ψ= 180) when WPD-
loop is closed and in the open conformation it occupies αL (φ=82, ψ=-160) region which 
according to MacArthur and Thornton is not observed in the crystal structures if followed 
by proline. It becomes the case in PTP1B/V184P mutation (Table 5-1) which introduces 
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analogous to VHZ   The P184-P185 diproline segment in its WPD-loop significantly 
reduces kcat and at the same time raises KM. However, in contrast to the case of PTP1B/ 
W179A mutant when the loop was locked in a semi-open state thus abolishing general 
acid catalysis, the pH rate profile of PTP1B/V184P mutant remained bell-shaped (Figure 
5-2,C)  indicating  no loss of  general acid catalysis which in turn indicates that the loop 
has to be locked in the closed conformation. These data indicates that because IPD-loop 
is non-movable in VHZ and SsoPTP, introduction of additional proline residues in these 
proteins results in no significant kinetic alteration. On the other site, in PTP1B containing 
a movable WPD-loop introduction of an additional proline residue imposes 
conformational constraints on the loop increasing its rigidity. Hereby we can conclude 
that additional proline residue in VHZ and SsoPTP contributes to its rigidity but it is not 
the major factor which stipulates it.  In search for additional positions which can explain 
the rigidity of IPD-loop we found that Q73 residue in VHZ and corresponding Q77 in 
SsoPTP provide stabilization to the IPD-loop not previously observed in other PTPs. This 
residue makes two hydrogen bonds to the backbone of IPD-loop which stabilizes the 
IPD-loop in the closed conformation (Figure 5-1). Despite being distal from the active 
site, the VHZ/Q73V substitution decreases kcat four-fold and results in a 50 % increase in 
KM indicating it plays important role in stabilization of the IPD-loop (Table 5-1). 
 
Effect of the distal residues on WPD-loop mobility 
VHZ and SsoPTP contain E44 and E37, respectively, in close proximity to the active site 
pocket.  Analysis of WPD-loop motion in classical PTPs (Figure 5-3) indicates that the 
residues from the corresponding region (S287 in YopH and R112 in PTP1B) stabilize the 
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Table 5-2. Enzyme inhibition by inorganic phosphate. Classical PTPs with movable 
WPD-loop have lower Pi inhibition constants due to the 90 
o 
rotation of phosphate 
binding catalytic arginine associated with the loop motion which helps to release product. 
Rigid IPD-loop permanently holds the R101 in VHZ in the favorable for binding 
conformation reflected by significant reduction of Ki.  The same holds true for SsoPTP 
with a rigid IPD-loop. Inhibition for inorganic phosphate hereby can serve as a useful 
reporter to probe the dynamical state of the WPD-loop.  
 
Name Ki, μM 
YopH/WT 4385 ± 126 
YopH/S287A 3500 ± 119 
PTP1B/WT 3642 ± 110 
VHZ/WT 678.5 ± 54 
VHZ/E44N 714 ± 98 
VHZ/I63W 663 ± 72 
Sso/WT 494 ± 45 
 
 
Figure 5-2. The effect of the PTP1B/V172P substitution. A) Dihedral angle changes for 
the G183 residue in the WPD-loop of PTP1B. Green planes correspond to the φ and ψ of 
G183 residue in PTP1B when WPD-loop is closed, whereas red planes correspond to the 
φ and ψ angles when the loop is in the open conformation. B) The change of 
Ramachandran angles for G183 which accompany WPD-loop transition between open 
and closed conformations in PTP. When G183 is followed by proline in PTP1B/V184P 
mutant this transition becomes disfavored, forcing the loop to occupy predominantly 
closed position. C) kcat vs pH profile for PTP1B/V184P mutant. As expected the plot 
indicates the closed conformation of the loop is not affected by mutation and general acid 
catalysis is fully operational.     
 
 
loop in its open conformation.  We made the YopH/S287A substitution which results in 
the 3 fold reduction of kcat with no significant effect on KM (Table 5-1) and accompanied 
124 
 
by a moderate reduction in Ki for inorganic phosphate (Table 5-2). It is suggested this 
stabilization indeed plays a catalytic role in WPD-loop motion, possibly changing the 
open-closed loop dynamic equilibrium. The VHZ/E44Q, VHZ/E44S and VHZ/E44R 
substitutions resulted in no significant effect on kinetic parameters, indicating the IPD-
loop does not interact with this residue regardless of the charge or bulkiness of its side 
chain. The data suggests that because mutated position did not bring any significant effect 
on VHZ activity but affected YopH the presence of bulkier negatively charged residues at 
this position is only a secondary factor which may or may not contribute to the IPD-loop 
mobility.     
 
Conclusions and further directions 
Preliminary data suggested that the rigidity of the IPD-loops in VHZ and SsoPTP 
is stipulated by several factors rather than a single one. It may not be plausible, however, 
to change the rigidity of the stable IPD-loop to infer about the effect of the WPD-loop 
mobility, for as it was revealed by the VHZ/Q73L substitution, some structural factors 
can be affected as well. However, information obtained about IPD-loop rigidity can be  
used to impose certain restriction on the movable WPD-loop and use catalytic 
consequences of such substitution to infer about the importance of this motion. 
PTP1B/V172P mutant was designed based on the information obtained from VHZ 
studies and revealed significant deterioration of kinetic properties with general acid 
catalysis which remained intact. A crystal structure of this mutant will reveal the 
structural effect brought about by this substitution. If, consistent with the kinetic pH rate 
profile which remained bell shaped in the PTP1B/V184P mutant, the loop will be found 
in the predominantly closed conformation, then it can serve as  solid evidence to show 
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Figure 5-3. General acid loop interactions in the open state.  A) Open and closed WPD-
loop conformations in YopH WT. Stabilization of the WPD-loop in the open 
conformation is provided by S287.  The YopH/S287A mutation result in the three fold 
reduction of kcat (Table 5-1). Analogous stabilization in PTP1B and hematopoetic PTP 
(HePTP) is provided by the arginine side chain in the similar position (data not shown). 
B) Superimposition of VHZ (PDBID 4ERC) with apo YopH (open loop) reveals a steric 
clash which is thought to be one of the factors preventing IPD-loop from occupying an 
open conformation. Mutation of E44 to different residues (Table 5-1) shows no 
significant effect on catalytic parameters.  
 
that the WPD-loop closure is a catalytically relevant event. Kinetic isotope effects and 
pre-steady state kinetics of the PTP1B/V72P mutant will provide additional information 
and help to reveal what step of the reaction is mostly affected by this mutation, and if the 
structure of the transition state is affected in relation to the wild type.  
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Table A-1.  The substrate screen table from the manufacturer. Column 1 refers to the well 
# in the 384 well-format plate. Column 2 shows the phosphorylated peptide sequence. 
Column 3 summarizes the proteins in vivo where each phosphopeptide occurs. The 
UniProt code is given for the easy identification of the protein target.  
 
A1 (pS)DIEEVVEEYE TRT2_HUMAN (P45379) 
A2 (pS)DEEVEQVEEQ TRT3_HUMAN (P45378) 
A3 RRGGV(pS)AEVYT KAP1_HUMAN (P31321) 
   KAP1_MOUSE (P12849) 
   KAP1_RAT (P81377) 
A4 KPFKL(pS)GLSFK MRP_HUMAN (P49006) 
   MRP_MOUSE (P28667) 
   MRP_RABIT (P35566) 
A5 RRGAI(pS)AEVYT KAP0_BOVIN (P00514) 
   KAP0_HUMAN (P10644) 
   KAP0_PIG (P07802) 
   KAP0_RAT (P09456) 
A6 PTRKI(pS)ASEFD CN5A_BOVIN (Q28156) 
   CN5A_CANFA (O77746) 
   CN5A_HUMAN (O76074) 
A7 ARVLE(pS)YRSCY MINK_HUMAN (P15382) 
   MINK_HUMAN (P15382) 
A8 NSVSP(pS)PLMLL ESR1_HUMAN (P03372) 
   ESR1_MESAU (Q9QZJ5) 
   ESR1_MOUSE (P19785) 
   ESR1_RAT (P06211) 
A9 P(pS)DKERLTSDA ITA6_CHICK (P26007) 
A10 KHVPD(pS)GATAT PPB1_HUMAN (P05187) 
   PPB2_HUMAN (P06861) 
   PPB3_HUMAN (P05188) 
   PPBN_HUMAN (P10696) 
A11 NVDKHVPD(pS)GA PPB1_HUMAN (P05187) 
   PPB2_HUMAN (P06861) 
   PPB3_HUMAN (P05188) 
A12 TKRNS(pS)PPPSP ATB1_HUMAN (P20020) 
   ATB1_RABIT (Q00804) 
   ATB1_RAT (P11505) 
A13 PPPQL(pS)PFLQP ESR1_HUMAN (P03372) 
A14 RHLDI(pS)RELND LGN_HUMAN (P81274) 
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A15 VFTSR(pS)AAFSG K2C7_HUMAN (P08729) 
A16 VPLDR(pS)SHCQR INSR_HUMAN (P06213) 
   INSR_HUMAN (P06213) 
   INSR_MOUSE (P15208) 
   INSR_RAT (P15127) 
   INSR_RAT (P15127) 
A17 APKKG(pS)KKAVT H2BA_HUMAN (P02278) 
   H2BC_HUMAN (Q99880) 
   H2BD_HUMAN (Q99877) 
   H2BH_HUMAN (Q93078) 
   H2BJ_HUMAN (Q93079) 
   H2BL_HUMAN (Q93080) 
   H2BN_HUMAN (P23527) 
   H2BQ_HUMAN (Q16778) 
   H2BR_HUMAN (P06899) 
   H2BS_HUMAN (P57053) 
   H2B1_MOUSE (P10853) 
   H2B2_MOUSE (P10854) 
   H2B_RAT (Q00715) 
   H2B_CAIMO (P14001) 
   H2B_CHICK (P02279) 
   H2B_CRONI (P02280) 
   H2B_SALTR (P02282) 
   H2B1_XENLA (P02281) 
   H2B2_XENLA (P06900) 
A18 AKKED(pS)DEEED NUCL_HUMAN (P19338) 
A19 L(pS)DQEKRKQIS PHS2_HUMAN (P11217) 
   PHS2_RABIT (P00489) 
A20 SEGEE(pS)TVRFA KPC1_HUMAN (P05771) 
   KPC1_RABIT (P05772) 
   KPC1_RAT (P04410) 
   KPC2_BOVIN (P05126) 
   KPC2_HUMAN (P05127) 
   KPC2_RABIT (P05773) 
   KPC2_MOUSE (P04411) 
A21 AKSFG(pS)PNRAY CDK7_HUMAN (P50613) 
   CDK7_MOUSE (Q03147) 
A22 LSRMP(pS)PGGRI MPP9_HUMAN (Q99550) 
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   MPP9_HUMAN (Q99550) 
A23 GSRRG(pS)FDATG PLE1_CRIGR (Q9JI55) 
   PLE1_CRIGR (Q9JI55) 
   PLE1_HUMAN (Q15149) 
   PLE1_RAT (P30427) 
   DESP_HUMAN (P15924) 
A24 LTRDS(pS)ILGPH CCAA_HUMAN (O00555) 
   CCAA_MOUSE (P97445) 
   CCAA_RABIT (P27884) 
   CCAA_RAT (P54282) 
   CCAB_HUMAN (Q00975) 
   CCAB_MOUSE (O55017) 
   CCAB_RABIT (Q05152) 
   CCAB_RAT (Q02294) 
   CCAB_DISOM (P56698) 
   CCAE_HUMAN (Q15878) 
   CCAE_MOUSE (Q61290) 
   CCAE_RABIT (Q02343) 
   CCAE_RAT (Q07652) 
   CCAE_DISOM (P56699) 
B1 PQRAT(pS)NVFAM MLRM_CHICK (P02612) 
   MLRN_CHICK (P24032) 
   MLRM_HUMAN (P19105) 
   MLRN_HUMAN (P24844) 
   MLRN_PIG (P29269) 
   MLRA_RAT (P13832) 
   MLRB_RAT (P18666) 
   MLRH_CAEEL (Q09510) 
B2 VTVAY(pS)PKRSP MPP9_HUMAN (Q99550) 
B3 RDLSS(pS)PPGPY AAKC_HUMAN (O43741) 
   AAKC_RAT (Q9QZH4) 
B4 AAAPA(pS)EDEDD NUCL_HUMAN (P19338) 
B5 YYEILN(pS)PEKA 143B_BOVIN (P29358) 
   143B_HUMAN (P31946) 
   143B_RAT (P35213) 
   143Z_HUMAN (P29312) 
   143Z_MOUSE (P35215) 
   143Z_SHEEP (P29361) 
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   1433_XENLA (P29309) 
B6 PMVDQ(pS)PSVST Z145_HUMAN (Q05516) 
B7 KKRPQRAT(pS)NV MLRM_CHICK (P02612) 
   MLRN_CHICK (P24032) 
   MLRM_HUMAN (P19105) 
   MLRN_HUMAN (P24844) 
   MLRN_PIG (P29269) 
   MLRA_RAT (P13832) 
   MLRB_RAT (P18666) 
B8 FFPFH(pS)PSRLF CRAB_BOVIN (P02510) 
   CRAB_HUMAN (P02511) 
   CRAB_MESAU (P05811) 
   CRAB_MOUSE (P23927) 
   CRAB_RABIT (P41316) 
   CRAB_RAT (P23928) 
   HSBY_HUMAN (O43416) 
B9 AAARL(pS)LTDPL GPBB_HUMAN (P13224) 
B10 GAGDG(pS)DEEVD MYH9_HUMAN (P35579) 
B11 SWGTA(pS)PYSAM PMX1_HUMAN (P54821) 
   PMX1_HUMAN (P54821) 
   PMX1_MOUSE (P43271) 
   PMX1_MOUSE (P43271) 
   PMX1_CHICK (Q05437) 
   PMX1_CHICK (Q05437) 
B12 GLSAM(pS)PTKAA Z145_HUMAN (Q05516) 
B13 SLGRRA(pS)FHLE CCAC_HUMAN (Q13936) 
   CCAC_MOUSE (Q01815) 
   CCAC_RABIT (P15381) 
   CCAC_RAT (P22002) 
B14 RSGYS(pS)PGSPG TAU_BOVIN (P29172) 
   TAU_CAPHI (O02828) 
   TAU_HUMAN (P10636) 
   TAU_MACMU (P57786) 
   TAU_MOUSE (P10637) 
   TAU_PAPHA (Q9MYX8) 
   TAU_RAT (P19332) 
B15 LRQLR(pS)PRRTQ RB4A_HUMAN (P20338) 
   RB4A_MOUSE (P56371) 
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   RB4A_RAT (P05714) 
B16 VDYVN(pS)TEAET FA9_HUMAN (P00740) 
B17 TKSG(pS)TTKNRF IF4E_HUMAN (P06730) 
   IF4E_MOUSE (P20415) 
   IF4E_RABIT (P29338) 
   IF4E_XENLA (P48597) 
B18 MIGAD(pS)SEEKF STAT_HUMAN (P02808) 
   STAT_HUMAN (P02808) 
B19 RSRTP(pS)LPTPP TAU_BOVIN (P29172) 
   TAU_CAPHI (O02828) 
   TAU_HUMAN (P10636) 
   TAU_MACMU (P57786) 
   TAU_MOUSE (P10637) 
   TAU_PAPHA (Q9MYX8) 
   TAU_RAT (P19332) 
B20 SRGLK(pS)GLKTD A1AA_BOVIN (P18130) 
   A1AA_CANFA (O77621) 
   A1AA_HUMAN (P35348) 
   A1AA_MOUSE (P97718) 
   A1AA_RABIT (O02824) 
   A1AA_RAT (P43140) 
B21 RRKYR(pS)NKGES CD27_HUMAN (P26842) 
   CD27_HUMAN (P26842) 
B22 AETRVPTMRP(pS) COA2_HUMAN (O00763) 
B23 PTMRP(pS)MSGLH COA2_HUMAN (O00763) 
B24 PTTPL(pS)PTRLS LAM1_HUMAN (P20700) 
C1 AWTAD(pS)GEGDF FIBA_HUMAN (P02671) 
C2 SSTPL(pS)PTRIT LAMA_HUMAN (P02545) 
   LAMA_MOUSE (P48678) 
   LAMC_MOUSE (P11516) 
   LAMA_RAT (P48679) 
C3 YSPKR(pS)PKENL MPP9_HUMAN (Q99550) 
C4 SGQLID(pS)MANS MPK1_CRIGR (Q63980) 
   MPK1_HUMAN (Q02750) 
   MPK1_MOUSE (P31938) 
   MPK1_RABIT (P29678) 
   MPK1_RAT (Q01986) 
   MPK1_SERCA (Q91447) 
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   MPK1_XENLA (Q05116) 
   MPK2_HUMAN (P36507) 
   MPK2_MOUSE (Q63932) 
   MPK2_RAT (P36506) 
   MPK2_CHICK (Q90891) 
   MPK2_CYPCA (Q90321) 
   DSOR_DROME (Q24324) 
C5 MRPSM(pS)GLHLV COA2_HUMAN (O00763) 
   COAC_CHICK (P11029) 
C6 DSMAN(pS)FVGTR MPK1_CRIGR (Q63980) 
   MPK1_HUMAN (Q02750) 
   MPK1_MOUSE (P31938) 
   MPK1_RABIT (P29678) 
   MPK1_RAT (Q01986) 
   MPK1_SERCA (Q91447) 
   MPK1_XENLA (Q05116) 
   MPK2_HUMAN (P36507) 
   MPK2_MOUSE (Q63932) 
   MPK2_RAT (P36506) 
   MPK2_CHICK (Q90891) 
   MPK2_CYPCA (Q90321) 
   DSOR_DROME (Q24324) 
C7 SGPYE(pS)DEDKS TLE2_HUMAN (Q04725) 
C8 RDKEV(pS)DDEAE HS9A_CRIGR (P46633) 
   HS9A_HUMAN (P07900) 
   HS9A_MOUSE (P07901) 
   HS9A_PIG (O02705) 
   HS9A_CHICK (P11501) 
   HS90_BRUPA (O61998) 
C9 RTPPK(pS)PSSAK TAU_HUMAN (P10636) 
   TAU_MACMU (P57786) 
   TAU_PAPHA (Q9MYX8) 
C10 SSHYD(pS)DGDKS TLE1_HUMAN (Q04724) 
C11 FELIL(pS)PRSKE STHM_HUMAN (P16949) 
   STHM_MOUSE (P54227) 
   STHM_RAT (P13668) 
C12 KVRKS(pS)TQEEI COF2_HUMAN (Q9Y281) 
   COF2_MOUSE (P45591) 
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C13 SSLRA(pS)TSKS RS6_CHICK (P47838) 
   RS6_HUMAN (P10660) 
   RS6_XENLA (P39017) 
C14 ASTSK(pS)ESSQK RS6_CHICK (P47838) 
   RS6_HUMAN (P10660) 
   RS6_XENLA (P39017) 
C15 NKRRG(pS)VPILR 42_HUMAN (P16452) 
C16 PIDME(pS)QERIK AP1_HUMAN (P05412) 
   AP1_MOUSE (P05627) 
   AP1_PIG (P56432) 
   AP1_RAT (P17325) 
   AP1_CHICK (P18870) 
   AP1_COTJA (P12981) 
   AP1_SERCA (P54864) 
   TJUN_AVIS1 (P05411) 
C17 PSEPP(pS)PATTP TLE2_HUMAN (Q04725) 
C18 PSAYG(pS)VKAYT ANX2_BOVIN (P04272) 
   ANX2_HUMAN (P07355) 
C19 TKRSG(pS)VYEPL KPBB_HUMAN (Q93100) 
   KPBB_RABIT (P12798) 
C20 KSKIG(pS)TENLK TAU_BOVIN (P29172) 
   TAU_CAPHI (O02828) 
   TAU_HUMAN (P10636) 
   TAU_MACMU (P57786) 
   TAU_PAPHA (Q9MYX8) 
C21 SSPRA(pS)PAHSP TLE1_HUMAN (Q04724) 
C22 ATPRV(pS)PAHSP TLE3_HUMAN (Q04726) 
   TLE3_MOUSE (Q08122) 
C23 QLRRP(pS)DQEVS REL_CHICK (P16236) 
   REL_MELGA (P01125) 
   REL_HUMAN (Q04864) 
   REL_MOUSE (P15307) 
C24 VSPAH(pS)PPENG TLE3_HUMAN (Q04726) 
   TLE3_MOUSE (Q08122) 
D1 QTVKS(pS)KGGPG ANX1_HUMAN (P04083) 
D2 QLRRP(pS)DRELS TF65_HUMAN (Q04206) 
   TF65_MOUSE (Q04207) 
D3 PAKRI(pS)GKMAL CC2_BOVIN (P48734) 
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   CC2_HUMAN (P06493) 
   CC2_MOUSE (P11440) 
   CC2_RAT (P39951) 
   CC2_CHICK (P13863) 
D4 HESME(pS)YELNP MGP_HUMAN (P08493) 
D5 SSND(pS)TSVSAV ACM2_BOVIN (P41985) 
   ACM2_HUMAN (P08172) 
   ACM2_MOUSE (Q9ERZ4) 
   ACM2_PIG (P06199) 
   ACM2_RAT (P10980) 
D6 SSNDSTSV(pS)AV ACM2_BOVIN (P41985) 
   ACM2_HUMAN (P08172) 
   ACM2_MOUSE (Q9ERZ4) 
   ACM2_PIG (P06199) 
   ACM2_RAT (P10980) 
D7 ESSND(pS)TSVSA ACM2_BOVIN (P41985) 
   ACM2_HUMAN (P08172) 
   ACM2_MOUSE (Q9ERZ4) 
   ACM2_PIG (P06199) 
   ACM2_RAT (P10980) 
D8 AKKRL(pS)VERIY TP2A_HUMAN (P11388) 
D9 APPRR(pS)SIRNA NCF1_BOVIN (O77774) 
   NCF1_HUMAN (P14598) 
D10 DENTV(pS)TSLGH ACM2_HUMAN (P08172) 
   ACM2_MOUSE (Q9ERZ4) 
   ACM2_PIG (P06199) 
   ACM2_RAT (P10980) 
D11 SIHQR(pS)RKRLS NCF1_BOVIN (O77774) 
   NCF1_HUMAN (P14598) 
   NCF1_MOUSE (Q09014) 
D12 SRKRL(pS)QDAYR NCF1_HUMAN (P14598) 
D13 AYRRN(pS)VRFLQ NCF1_HUMAN (P14598) 
D14 PWIMQ(pS)TKVPQ MKK2_CRILO (P49136) 
   MKK2_HUMAN (P49137) 
   MKK2_MOUSE (P49138) 
   MKK2_RABIT (P49139) 
D15 LAQRAR(pS)PSDV GPRC_HUMAN (P47775) 
D16 RIGHH(pS)TSDDS ODBA_BOVIN (P11178) 
137 
 
   ODBA_HUMAN (P12694) 
   ODBA_MOUSE (P50136) 
   ODBA_RAT (P11960) 
D17 RGQRD(pS)SYYWE KMIL_AVIMH (P00531) 
   KMIL_CHICK (P05625) 
   KRAF_HUMAN (P04049) 
   KRAF_RAT (P11345) 
   KRAF_XENLA (P09560) 
D18 QTQST(pS)GRRRR ATF2_HUMAN (P15336) 
D19 RPGPQ(pS)PGSPL NCF1_HUMAN (P14598) 
   NCF1_HUMAN (P14598) 
D20 KHLEI(pS)REVGD LGN_HUMAN (P81274) 
D21 PQSPG(pS)PLEEE NCF1_HUMAN (P14598) 
   NCF1_HUMAN (P14598) 
D22 MEFSR(pS)KSDNS EDG1_HUMAN (P21453) 
   EDG1_HUMAN (P21453) 
   EDG1_MOUSE (O08530) 
   EDG1_RAT (P48303) 
D23 GNGYS(pS)NGNTG B2AR_HUMAN (P07550) 
D24 SKVPFR(pS)RSPS GPR6_HUMAN (P46095) 
   GPR6_HUMAN (P46095) 
   GPR6_RAT (P51651) 
E1 SKVPFRSR(pS)PS GPR6_HUMAN (P46095) 
   GPR6_RAT (P51651) 
E2 RSRKE(pS)YSVYV H2BA_HUMAN (P02278) 
   H2BC_HUMAN (Q99880) 
   H2BD_HUMAN (Q99877) 
   H2BE_HUMAN (Q99879) 
   H2BH_HUMAN (Q93078) 
   H2BJ_HUMAN (Q93079) 
   H2BS_HUMAN (P57053) 
   H2B1_MOUSE (P10853) 
   H2B2_MOUSE (P10854) 
   H2B_RAT (Q00715) 
E3 VPFRSR(pS)PSEV GPR6_HUMAN (P46095) 
   GPR6_RAT (P51651) 
E4 VPFRSRSP(pS)EV GPR6_HUMAN (P46095) 
   GPR6_RAT (P51651) 
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E5 SNRKP(pS)KDKDK GAC2_BOVIN (P22300) 
   GAC2_CHICK (P21548) 
   GAC2_HUMAN (P18507) 
   GAC2_MOUSE (P22723) 
   GAC2_RAT (P18508) 
E6 PKSKQ(pS)PISTP DCX_HUMAN (O43602) 
   DCX_MOUSE (O88809) 
   DCX_MOUSE (O88809) 
E7 PEFPL(pS)PPKKK STHM_HUMAN (P16949) 
   STHM_RAT (P13668) 
   STHM_CHICK (P31395) 
E8 ISTPT(pS)PGSLR DCX_HUMAN (O43602) 
   DCX_MOUSE (O88809) 
   DCX_MOUSE (O88809) 
E9 STRTY(pS)LGSAL VIME_BOVIN (P48616) 
   VIME_HUMAN (P08670) 
   VIME_MOUSE (P20152) 
   VIME_PIG (P02543) 
   VIME_RAT (P31000) 
E10 AER(pS)LKDMEES G19P_BOVIN (Q28034) 
   G19P_HUMAN (P14314) 
E11 KDMEE(pS)IRNLE G19P_BOVIN (Q28034) 
   G19P_HUMAN (P14314) 
E12 ARKAV(pS)MHEVN NAC1_BOVIN (P48765) 
   NAC1_CANFA (P23685) 
   NAC1_CAVPO (P48766) 
   NAC1_FELCA (P48767) 
   NAC1_HUMAN (P32418) 
   NAC1_MOUSE (P70414) 
   NAC1_RAT (Q01728) 
E13 LKLSP(pS)PSSRV LAM2_CHICK (P14732) 
   LAM1_HUMAN (P20700) 
   LAM1_MOUSE (P14733) 
   LAM2_HUMAN (Q03252) 
E14 LMFKTEGPD(pS)D P53_HUMAN (P04637) 
   P53_TUPGB (Q9TTA1) 
E15 SPSPS(pS)RVTVS LAM2_CHICK (P14732) 
   LAM1_HUMAN (P20700) 
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   LAM1_MOUSE (P14733) 
   LAM2_HUMAN (Q03252) 
E16 NSRRP(pS)RATWL VTNC_HUMAN (P04004) 
E17 LGRRH(pS)MENME LGN_HUMAN (P81274) 
E18 SRGRA(pS)SHSSQ LAMA_HUMAN (P02545) 
   LAMA_MOUSE (P48678) 
   LAMC_MOUSE (P11516) 
   LAMA_RAT (P48679) 
E19 VSGDT(pS)PRHLS TAU_BOVIN (P29172) 
   TAU_BOVIN (P29172) 
   TAU_CAPHI (O02828) 
   TAU_HUMAN (P10636) 
   TAU_MACMU (P57786) 
   TAU_MOUSE (P10637) 
   TAU_PAPHA (Q9MYX8) 
   TAU_RAT (P19332) 
E20 RGRAS(pS)HSSQT LAMA_HUMAN (P02545) 
E21 SRASS(pS)RSVRT LAM1_CHICK (P14731) 
   LAM1_HUMAN (P20700) 
   LAM1_MOUSE (P14733) 
E22 SKNES(pS)PIRFD MPP9_HUMAN (Q99550) 
E23 DRPRA(pS)GCLAR B1AR_HUMAN (P08588) 
   B1AR_MACMU (P47899) 
   B1AR_MOUSE (P34971) 
   B1AR_RAT (P18090) 
E24 VSNTN(pS)PTKIL TDP2_HUMAN (Q14188) 
F1 ATPQV(pS)DSMRK GLYG_HUMAN (P46976) 
F2 TSTSL(pS)PFYLR CRAB_HUMAN (P02511) 
   CRAB_RABIT (P41316) 
   HSBY_HUMAN (O43416) 
F3 LMRRN(pS)VTPLA F263_HUMAN (Q16875) 
   F263_RAT (O35552) 
F4 MYRRS(pY)VFQTR FILS_BOVIN (Q06002) 
   FILS_HUMAN (Q12934) 
F5 RERRP(pS)YLPTP CIK6_HUMAN (P17658) 
F6 SYPIGEDEE(pS)E VMT2_HUMAN (Q05940) 
F7 SQ(pS)PQYSFESL PRGR_HUMAN (P06401) 
   PRGR_RABIT (P06186) 
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   PRGR_SHEEP (Q28590) 
F8 VQRKV(pS)GSRGS CIK5_HUMAN (P22460) 
F9 PSRGK(pS)SSYSK FIBA_HUMAN (P02671) 
F10 SRGKS(pS)SYSKQ FIBA_HUMAN (P02671) 
F11 PGLRR(pS)PIKKV MYBB_HUMAN (P10244) 
   MYBB_MOUSE (P48972) 
F12 SYSKQFTS(pS)TS FIBA_HUMAN (P02671) 
F13 SKRRN(pS)EFEIF TR5H_HUMAN (P17752) 
   TR5H_RABIT (P17290) 
   TR5H_RAT (P09810) 
   TR5H_CHICK (P70080) 
   TR5H_XENLA (Q92142) 
F14 FLRAP(pS)WFDTG CRAB_HUMAN (P02511) 
   HSBY_HUMAN (O43416) 
F15 GRIHG(pS)PLQKL MP10_HUMAN (O00566) 
F16 PARND(pS)VIVAD ATF2_HUMAN (P15336) 
   ATF2_MOUSE (P16951) 
   ATF2_RAT (Q00969) 
   ATF2_CHICK (O93602) 
F17 ILKPP(pS)PISEA SCG1_HUMAN (Q93045) 
   SCG1_MOUSE (P55821) 
F18 EERRK(pS)HEAEV STHM_HUMAN (P16949) 
   STHM_MOUSE (P54227) 
   STHM_RAT (P13668) 
   STHM_CHICK (P31395) 
F19 GYGSR(pS)LYNLG K2C5_HUMAN (P13647) 
F20 YPRPA(pS)VPPSP GYS1_HUMAN (P13807) 
   GYS1_RABIT (P13834) 
   GYS3_MOUSE (P54859) 
F21 ASVPP(pS)PSLSR GYS1_HUMAN (P13807) 
   GYS1_RABIT (P13834) 
   GYS3_MOUSE (P54859) 
F22 PASVPP(pS)PSLS GYS1_HUMAN (P13807) 
   GYS1_RABIT (P13834) 
   GYS3_MOUSE (P54859) 
F23 SRHS(pS)PHQSED GYS1_HUMAN (P13807) 
   GYS1_MOUSE (Q9Z1E4) 
   GYS1_RABIT (P13834) 
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   GYS3_MOUSE (P54859) 
F24 SRH(pS)SPHQSED GYS1_HUMAN (P13807) 
   GYS1_MOUSE (Q9Z1E4) 
   GYS1_RABIT (P13834) 
   GYS3_MOUSE (P54859) 
G1 SRHSSPHQ(pS)ED GYS1_HUMAN (P13807) 
   GYS1_MOUSE (Q9Z1E4) 
   GYS1_RABIT (P13834) 
   GYS3_MOUSE (P54859) 
G2 LSYAP(pS)PLQKP MPP5_HUMAN (Q99546) 
G3 LSRHS(pS)PHQSE GYS1_HUMAN (P13807) 
   GYS1_MOUSE (Q9Z1E4) 
   GYS1_RABIT (P13834) 
   GYS3_MOUSE (P54859) 
G4 GSQAS(pS)PQSSD GYS2_HUMAN (P54840) 
   GYS2_HUMAN (P54840) 
G5 IGRRQ(pS)LIEDA TY3H_HUMAN (P07101) 
   TY3H_MOUSE (P24529) 
   TY3H_PHASP (P11982) 
   TY3H_RAT (P04177) 
G6 GSKRN(pS)VDTAT GYS1_HUMAN (P13807) 
   GYS1_HUMAN (P13807) 
G7 DLLPM(pS)PSVYA STA4_HUMAN (Q14765) 
G8 NLLPM(pS)PEEFD STA1_HUMAN (P42224) 
   STA1_MOUSE (P42225) 
G9 PDGNK(pS)PAPKP CALD_HUMAN (Q05682) 
   CALD_HUMAN (Q05682) 
   CALD_RAT (Q62736) 
G10 AGALY(pS)GSEGD SRF_HUMAN (P11831) 
G11 RKTTA(pS)TRKVS CFTR_HUMAN (P13569) 
G12 QRMKE(pS)SFYSL PRGR_HUMAN (P06401) 
   PRGR_RABIT (P06186) 
   PRGR_SHEEP (Q28590) 
   PRGR_CHICK (P07812) 
G13 RGRSL(pS)VTSLG GYS2_HUMAN (P54840) 
   GYS2_RAT (P17625) 
G14 IRSSW(pS)GLHLV COA1_HUMAN (Q13085) 
G15 LSRQL(pS)SGVSE HS27_CANFA (P42929) 
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   HS27_HUMAN (P04792) 
G16 GSEGD(pS)ESGEE SRF_HUMAN (P11831) 
G17 GTFRS(pS)IRRL PLM_CANFA (P56513) 
   PLM_HUMAN (O00168) 
   PLM_RAT (O08589) 
G18 EGDSE(pS)GEEEE SRF_HUMAN (P11831) 
G19 EPEKMES(pS)ISS CAS1_HUMAN (P47710) 
G20 KEKIKQS(pS)SSE CIN6_HUMAN (Q01118) 
G21 VEGAG(pS)IAAAT SYUA_HUMAN (P37840) 
   SYUA_HUMAN (P37840) 
G22 MESSI(pS)SSSEE CAS1_HUMAN (P47710) 
G23 TSTLA(pS)SFKRR NMZ1_HUMAN (Q05586) 
   NMZ1_HUMAN (Q05586) 
   NMZ1_MOUSE (P35438) 
   NMZ1_RAT (P35439) 
G24 ESSIS(pS)SSEEM CAS1_HUMAN (P47710) 
H1 SFKRRRS(pS)KDT NMZ1_HUMAN (Q05586) 
   NMZ1_MOUSE (P35438) 
   NMZ1_RAT (P35439) 
H2 KRRRS(pS)KDTST NMZ1_HUMAN (Q05586) 
   NMZ1_MOUSE (P35438) 
   NMZ1_RAT (P35439) 
H3 GRPRTT(pS)FAES KG3B_HUMAN (P49841) 
   KG3B_MOUSE (Q9WV60) 
   KG3B_RAT (P18266) 
H4 FGVER(pS)VRPTD KPB1_HUMAN (P46020) 
   KPB1_MOUSE (P18826) 
   KPB1_RAT (Q64649) 
   KPB1_RABIT (P18688) 
H5 ETPAI(pS)PSKRA DUT_HUMAN (P33316) 
H6 AIAAD(pS)EAEQD IRS1_HUMAN (P35568) 
   IRS1_MOUSE (P35569) 
   IRS1_RAT (P35570) 
H7 RRKKK(pT)PRKAE MPP8_HUMAN (Q99549) 
H8 TYVG(pT)PYYVPP NEK3_HUMAN (P51956) 
   NEK3_MOUSE (Q9R0A5) 
H9 PRRKD(pT)PALHM GSUB_HUMAN (O96001) 
H10 KPVSV(pT)PQGND MPP9_HUMAN (Q99550) 
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H11 KIGEG(pT)YGTVF CDK5_BOVIN (Q02399) 
   CDK5_HUMAN (Q00535) 
   CDK5_MOUSE (P49615) 
   CDK5_RAT (Q03114) 
   CDK5_XENLA (P51166) 
   CDK5_DROME (P48609) 
H12 RTRES(pT)AKKIK RGS1_HUMAN (Q08116) 
   RGS1_HUMAN (Q08116) 
H13 ITSQV(pT)GQIGW A2M1_HUMAN (P20172) 
   AP50_CAEEL (P35603) 
H14 PVSAQ(pT)PKGRR MPP8_HUMAN (Q99549) 
H15 PVRTY(pT)HEVVT CDK2_CRIGR (O55076) 
   CDK2_HUMAN (P24941) 
   CDK2_MESAU (P48963) 
   CDK2_MOUSE (P97377) 
   CDK2_RAT (Q63699) 
   CDK2_CARAU (P43450) 
H16 PIRVY(pT)HEVVT CC2_CAEEL (P34556) 
   CC2_BOVIN (P48734) 
   CC2_HUMAN (P06493) 
   CC2_MOUSE (P11440) 
   CC2_RAT (P39951) 
H17 EGEES(pT)VRFAR KPC1_HUMAN (P05771) 
   KPC1_RABIT (P05772) 
   KPC1_RAT (P04410) 
   KPC2_BOVIN (P05126) 
   KPC2_HUMAN (P05127) 
   KPC2_RABIT (P05773) 
   KPC2_MOUSE (P04411) 
H18 ADAEM(pT)GYVVT MK13_HUMAN (O15264) 
   MK13_PANTR (Q9N272) 
H19 TDDEM(pT)GYVAT MK14_CANFA (O02812) 
   MK14_HUMAN (Q16539) 
   MK14_MOUSE (P47811) 
   MK14_RAT (P70618) 
   MK14_CYPCA (Q90336) 
H20 TPYVV(pT)RYYRA MK08_HUMAN (P45983) 
   MK08_RAT (P49185) 
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   MK09_HUMAN (P45984) 
   MK09_MOUSE (Q9WTU6) 
   MK09_RAT (P49186) 
   MK10_HUMAN (P53779) 
   MK10_MOUSE (Q61831) 
   MK10_RAT (P49187) 
H21 ADEEM(pT)GYVAT MK11_HUMAN (Q15759) 
   MK11_MOUSE (Q9WUI1) 
H22 AQASS(pT)PLSPT LAMA_HUMAN (P02545) 
   LAMA_MOUSE (P48678) 
   LAMC_MOUSE (P11516) 
   LAMA_RAT (P48679) 
H23 DLFKL(pT)PEEKN MPP8_HUMAN (Q99549) 
H24 QEYVQ(pT)VKSSK ANX1_HUMAN (P04083) 
I1 EMPGE(pT)PPLSP AP1_HUMAN (P05412) 
   AP1_MOUSE (P05627) 
   AP1_PIG (P56432) 
   AP1_RAT (P17325) 
   AP1_CHICK (P18870) 
   AP1_COTJA (P12981) 
   AP1_SERCA (P54864) 
I2 NGSPR(pT)PRRGQ RB_HUMAN (P06400) 
   RB_MOUSE (P13405) 
   RB_RAT (P33568) 
I3 NEDPA(pT)PRVSP TLE3_HUMAN (Q04726) 
   TLE3_MOUSE (Q08122) 
   TLE1_BRARE (O13168) 
I4 QRRQRKSRR(pT)I IL2A_HUMAN (P01589) 
I5 PRDPV(pT)ENCVQ ACM2_HUMAN (P08172) 
I6 LPDHKK(pT)LEHL IL7R_HUMAN (P16871) 
I7 KEGPG(pT)PTRSS Z145_HUMAN (Q05516) 
I8 KKIYEEKKKK(pT) VGLN_HUMAN (Q00341) 
   VGLN_CHICK (P81021) 
I9 KISQG(pT)KVPEE KPC1_HUMAN (P05771) 
   KPC2_HUMAN (P05127) 
I10 EKTTN(pT)VSKFD KPC1_HUMAN (P05771) 
   KPC2_HUMAN (P05127) 
I11 TKVPQ(pT)PLHTS MKK2_CRILO (P49136) 
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   MKK2_HUMAN (P49137) 
   MKK2_MOUSE (P49138) 
   MKK2_RABIT (P49139) 
I12 PRHRD(pT)GILDS MBP_BOVIN (P02687) 
   MBP_CAVPO (P25188) 
   MBP_HUMAN (P02686) 
   MBP_MOUSE (P04370) 
   MBP_PANTR (P06906) 
   MBP_RAT (P02688) 
I13 RRRRP(pT)PATLV IPP1_HUMAN (Q13522) 
   IPP1_RABIT (P01099) 
   IPP1_RAT (P19103) 
I14 VIPPH(pT)PVRTV RB_HUMAN (P06400) 
I15 QSPIS(pT)PTSPG DCX_HUMAN (O43602) 
   DCX_MOUSE (O88809) 
   DCX_MOUSE (O88809) 
I16 DQEGD(pT)DAGLK TAU_HUMAN (P10636) 
   TAU_MACMU (P57786) 
   TAU_PAPHA (Q9MYX8) 
I17 NGGIM(pT)PPKST CGE2_HUMAN (O96020) 
   CGE2_MOUSE (Q9Z238) 
I18 PSGLL(pT)PPQSG CGE1_HUMAN (P24864) 
I19 VAAVN(pT)HRDRP F264_HUMAN (Q16877) 
   F264_RAT (P25114) 
I20 LTPKS(pT)PVKTL MYBB_HUMAN (P10244) 
   MYBB_MOUSE (P48972) 
I21 NATFKK(pT)FKHL ACM2_HUMAN (P08172) 
   ACM2_MOUSE (Q9ERZ4) 
   ACM2_PIG (P06199) 
   ACM2_RAT (P10980) 
   ACM2_CHICK (P30372) 
   ACM4_CHICK (P17200) 
   ACM4_XENLA (P30544) 
I22 NA(pT)FKKTFKHL ACM2_HUMAN (P08172) 
   ACM2_MOUSE (Q9ERZ4) 
   ACM2_PIG (P06199) 
   ACM2_RAT (P10980) 
   ACM2_CHICK (P30372) 
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   ACM4_CHICK (P17200) 
   ACM4_XENLA (P30544) 
I23 ATFKK(pT)FRHLL ACM4_HUMAN (P08173) 
   ACM4_MOUSE (P32211) 
   ACM4_RAT (P08485) 
I24 RTFRK(pT)FKMLL ACM5_HUMAN (P08912) 
   ACM5_MACMU (P56490) 
J1 ALGKR(pT)AKYRW NPT2_HUMAN (Q06495) 
   NPT2_MOUSE (Q60825) 
   NPT2_RABIT (Q28620) 
   NPT2_RAT (Q06496) 
   NPT2_SHEEP (O97704) 
J2 AGGPL(pT)PRRVS ERF_HUMAN (P50548) 
   ERF_HUMAN (P50548) 
J3 ADQTP(pT)PTRFL ATF2_HUMAN (P15336) 
   ATF2_MOUSE (P16951) 
   ATF2_RAT (Q00969) 
   ATF2_CHICK (O93602) 
   ATF7_HUMAN (P17544) 
J4 ARAGE(pT)RFTDT EF2_CHICK (Q90705) 
   EF2_CRIGR (P09445) 
   EF2_HUMAN (P13639) 
   EF2_MESAU (P05086) 
   EF2_RAT (P05197) 
J5 QKKRV(pT)MILQS ADDB_HUMAN (P35612) 
   ADDB_MOUSE (Q9QYB8) 
   ADDB_RAT (Q05764) 
J6 GETRF(pT)DTRKD EF2_CAEEL (P29691) 
   EF2_CHICK (Q90705) 
   EF2_CRIGR (P09445) 
   EF2_DROME (P13060) 
   EF2_HUMAN (P13639) 
   EF2_MESAU (P05086) 
   EF2_RAT (P05197) 
J7 FDKEF(pT)RQPVE KPC1_HUMAN (P05771) 
   KPC1_HUMAN (P05771) 
   KPC1_RABIT (P05772) 
   KPC1_RAT (P04410) 
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J8 HPPVL(pT)PPDQE KPC2_BOVIN (P05126) 
   KPC2_BOVIN (P05126) 
   KPC2_HUMAN (P05127) 
   KPC2_HUMAN (P05127) 
   KPC2_RABIT (P05773) 
   KPC2_MOUSE (P04411) 
J9 AAPAL(pT)PPDRL KPCG_BOVIN (P05128) 
   KPCG_BOVIN (P05128) 
   KPCG_HUMAN (P05129) 
   KPCG_MOUSE (P05697) 
J10 KIRKY(pT)MRRLL ERB2_HUMAN (P04626) 
   ERB2_MESAU (Q60553) 
   ERB2_RAT (P06494) 
J11 LVEPL(pT)PSGEA KERB_ALV (P00534) 
   KERB_AVIER (P00535) 
   KERB_AVIEU (P11273) 
   EGFR_HUMAN (P00533) 
   EGFR_MOUSE (Q01279) 
J12 EEPVL(pT)LVDE KPCE_HUMAN (Q02156) 
   KPCE_RABIT (P10830) 
J13 IDEPS(pT)PYHSM IPP2_HUMAN (P41236) 
   IPP2_RABIT (P11845) 
J14 PTAAG(pT)PNKET CALD_HUMAN (Q05682) 
J15 HVTRR(pT)LSMDK K6PL_HUMAN (P17858) 
J16 PQDKE(pY)YKVKE JAK2_HUMAN (O60674) 
   JAK2_MOUSE (Q62120) 
   JAK2_RAT (Q62689) 
J17 RGEEV(pY)VKKTM TIE1_BOVIN (Q06805) 
   TIE1_HUMAN (P35590) 
   TIE1_MOUSE (Q06806) 
J18 VKRRD(pY)LDLAA RET_HUMAN (P07949) 
J19 VDADE(pY)LIPQQ EGFR_HUMAN (P00533) 
   EGFR_MOUSE (Q01279) 
J20 EGDND(pY)IIPLP PGDR_HUMAN (P09619) 
J21 ETDKE(pY)YTVKD JAK1_HUMAN (P23458) 
   JAK1_MOUSE (P52332) 
J22 SPQPE(pY)VNQPD ERB2_HUMAN (P04626) 
J23 KPKQE(pY)LNPVE ERB4_HUMAN (Q15303) 
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   ERB4_RAT (Q62956) 
J24 ENGLN(pY)IDLDL IRS1_HUMAN (P35568) 
K1 EEEHV(pY)SFPNK PAXI_CHICK (P49024) 
   PAXI_HUMAN (P49023) 
K2 MTRDI(pY)ETDYY IG1R_BOVIN (Q05688) 
   IG1R_HUMAN (P08069) 
   IG1R_MOUSE (Q60751) 
   IG1R_RAT (P24062) 
   INSR_HUMAN (P06213) 
   INSR_MOUSE (P15208) 
   INSR_RAT (P15127) 
   MIPR_LYMST (Q25410) 
   ILPR_BRALA (O02466) 
   INSR_DROME (P09208) 
   INSR_AEDAE (Q93105) 
K3 LDNPE(pY)HNASN ERB4_HUMAN (Q15303) 
K4 AENAE(pY)LRVAP EGFR_HUMAN (P00533) 
   EGFR_MOUSE (Q01279) 
K5 FDNLY(pY)WDQDP ERB2_HUMAN (P04626) 
   ERB2_MESAU (Q60553) 
K6 MYDKE(pY)YSVHN MET_HUMAN (P08581) 
   MET_MOUSE (P16056) 
   MET_RAT (P97523) 
K7 AENPE(pY)LGLDV ERB2_HUMAN (P04626) 
   ERB2_MESAU (Q60553) 
   ERB2_RAT (P06494) 
K8 FESR(pY)QQPFED PIG1_HUMAN (P19174) 
   PIG1_HUMAN (P19174) 
K9 LQHPD(pY)LQEYS ERB4_HUMAN (Q15303) 
K10 AENPE(pY)LSEFS ERB4_HUMAN (Q15303) 
K11 EDKAK(pY)DAIFD EP15_HUMAN (P42566) 
   EP15_MOUSE (P42567) 
K12 GFKRS(pY)EEHIP INSR_HUMAN (P06213) 
   INSR_HUMAN (P06213) 
K13 LLGDH(pY)VQLPA RON_HUMAN (Q04912) 
   RON_HUMAN (Q04912) 
K14 SSGAD(pY)PDELQ TRY1_HUMAN (P07477) 
   TRY2_HUMAN (P07478) 
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K15 CTNFMMTP(pY)VV MK09_HUMAN (P45984) 
   MK09_MOUSE (Q9WTU6) 
   MK09_RAT (P49186) 
K16 ELVNN(pY)GKGWS RAPS_HUMAN (Q13702) 
K17 NEEQE(pY)VQTVK ANX1_HUMAN (P04083) 
K18 LEQEE(pY)EDPDI B3AT_HUMAN (P02730) 
K19 IYKND(pY)YRKRG KROS_AVISU (P00529) 
   KROS_HUMAN (P08922) 
   KROS_CHICK (P08941) 
K20 PEPGP(pY)AQPSV CRK_HUMAN (P46108) 
   CRK_MOUSE (Q64010) 
   CRK_RAT (Q63768) 
   CRK_XENLA (P87378) 
K21 TDEGI(pY)DVPLL EFS_HUMAN (O43281) 
K22 HVTRRTPD(pY)FL P2AA_HUMAN (P05323) 
   P2AA_MOUSE (P13353) 
   P2AA_CHICK (P48463) 
   P2AB_HUMAN (P11082) 
   P2AB_PIG (P11493) 
   P2AB_RABIT (P11611) 
   P2A_DROME (P23696) 
   P2A1_SCHPO (P23635) 
K23 SEETP(pY)SYPTG PAXI_HUMAN (P49023) 
K24 EEEEE(pY)MPMED TAMI_POVM3 (P03076) 
   TAMI_POVMA (P03077) 
   TAMI_POVMC (P12906) 
L1 GGKGGS(pY)SQAA 1B02_HUMAN (P01889) 
   1B02_HUMAN (P01889) 
   1B04_HUMAN (P30460) 
   1B04_HUMAN (P30460) 
   1B05_HUMAN (P30461) 
   1B05_HUMAN (P30461) 
   1B07_HUMAN (P30462) 
   1B07_HUMAN (P30462) 
   1B08_HUMAN (P30463) 
   1B08_HUMAN (P30463) 
   1B10_HUMAN (P30464) 
   1B10_HUMAN (P30464) 
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   1B11_HUMAN (P30465) 
   1B11_HUMAN (P30465) 
   1B12_HUMAN (P30513) 
   1B12_HUMAN (P30513) 
   1B13_HUMAN (P30466) 
   1B13_HUMAN (P30466) 
   1B14_HUMAN (P03989) 
   1B14_HUMAN (P03989) 
   1B15_HUMAN (P10317) 
   1B15_HUMAN (P10317) 
   1B16_HUMAN (P19373) 
   1B16_HUMAN (P19373) 
   1B18_HUMAN (P10318) 
   1B18_HUMAN (P10318) 
   1B19_HUMAN (Q08136) 
   1B19_HUMAN (Q08136) 
   1B20_HUMAN (P30467) 
   1B21_HUMAN (P30685) 
   1B21_HUMAN (P30685) 
   1B22_HUMAN (P30468) 
   1B22_HUMAN (P30468) 
   1B23_HUMAN (P30469) 
   1B23_HUMAN (P30469) 
   1B24_HUMAN (P30470) 
   1B25_HUMAN (P30471) 
   1B25_HUMAN (P30471) 
   1B26_HUMAN (P30472) 
   1B26_HUMAN (P30472) 
   1B27_HUMAN (P30473) 
   1B28_HUMAN (P30474) 
   1B29_HUMAN (P18463) 
   1B31_HUMAN (P30475) 
   1B32_HUMAN (P30476) 
   1B34_HUMAN (Q04826) 
   1B35_HUMAN (P30477) 
   1B36_HUMAN (P30478) 
   1B38_HUMAN (P30479) 
   1B39_HUMAN (P30480) 
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   1B40_HUMAN (P10320) 
   1B41_HUMAN (P30481) 
   1B42_HUMAN (P30482) 
   1B43_HUMAN (P30483) 
   1B44_HUMAN (P30484) 
   1B45_HUMAN (P30485) 
   1B46_HUMAN (P30486) 
   1B47_HUMAN (P30487) 
   1B48_HUMAN (P30488) 
   1B49_HUMAN (P18464) 
   1B52_HUMAN (P30489) 
   1B54_HUMAN (P30491) 
   1B54_HUMAN (P30491) 
   1B55_HUMAN (P30492) 
   1B56_HUMAN (P30493) 
   1B57_HUMAN (P30494) 
   1B58_HUMAN (P30495) 
   1B59_HUMAN (P30496) 
   1B60_HUMAN (P18465) 
   1B61_HUMAN (P30497) 
   1B62_HUMAN (P10319) 
   1B63_HUMAN (P30498) 
   1B01_GORGO (P30379) 
   1B02_GORGO (P30380) 
   1B02_GORGO (P30380) 
   1B04_GORGO (P30382) 
   1A02_PANTR (P16210) 
   1B01_PANTR (P13750) 
   1B02_PANTR (P13751) 
L2 RKGGS(pY)SQAAS 1A02_HUMAN (P01892) 
   1A23_HUMAN (P30447) 
   1A24_HUMAN (P05534) 
   1A25_HUMAN (P18462) 
   1A26_HUMAN (P30450) 
   1A29_HUMAN (P30512) 
   1A31_HUMAN (P16189) 
   1A32_HUMAN (P10314) 
   1A33_HUMAN (P16190) 
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   1A34_HUMAN (P30453) 
   1A43_HUMAN (P30456) 
   1A66_HUMAN (P30457) 
   1A68_HUMAN (P01891) 
   1A74_HUMAN (P30459) 
   1A80_HUMAN (Q09160) 
   1AXX_HUMAN (P10313) 
   HLAH_HUMAN (P01893) 
   1A01_GORGO (P30375) 
   1A02_GORGO (P30376) 
   1A03_GORGO (P30377) 
   1A04_GORGO (P30378) 
   1OKO_GORGO (P30388) 
   1A04_PANTR (P13749) 
   1A01_PONPY (P16211) 
L3 EEEPV(pY)EAEPE HS1_HUMAN (P14317) 
L4 HAQDT(pY)LVLDK EPOR_HUMAN (P19235) 
   EPOR_MOUSE (P14753) 
L5 IIDSE(pY)TAQEG BLK_HUMAN (P51451) 
   BLK_MOUSE (P16277) 
L6 RGTDE(pY)FIRKP ACHB_BOVIN (P04758) 
   ACHB_HUMAN (P11230) 
   ACHB_MOUSE (P09690) 
   ACHB_RAT (P25109) 
L7 SKAEE(pY)FLLKS ACHD_HUMAN (Q07001) 
L8 RVIEDNE(pY)TAR HCK_HUMAN (P08631) 
   LYN_HUMAN (P07948) 
   LYN_MOUSE (P25911) 
   LYN_RAT (Q07014) 
L9 IKDDE(pY)NPCQG FGR_HUMAN (P09769) 
L1
0 
IEDNE(pY)TARQG FYN_CHICK (Q05876) 
   FYN_HUMAN (P06241) 
   FYN_MOUSE (P39688) 
   FYN_XENLA (P13406) 
   FYN_XIPHE (P27446) 
   SRC1_XENLA (P13115) 
   SRC2_XENLA (P13116) 
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   SRC_AVISR (P00525) 
   SRC_AVIS2 (P15054) 
   SRC_AVIST (P14085) 
   SRC_AVISS (P14084) 
   SRC_CHICK (P00523) 
   SRC_HUMAN (P12931) 
   SRC_MOUSE (P05480) 
   SRC_RAT (Q9WUD9) 
   SRC_RSVP (P00526) 
   SRC_RSVSR (P00524) 
   SRC_RSVH1 (P25020) 
   YES_AVISY (P00527) 
   YES_CANFA (Q28923) 
   YES_CHICK (P09324) 
   YES_HUMAN (P07947) 
   YES_MOUSE (Q04736) 
   YES_XENLA (P10936) 
   YES_XIPHE (P27447) 
   YRK_CHICK (Q02977) 
L11 MKDEE(pY)EQMVK IKBA_HUMAN (P25963) 
   IKBA_PIG (Q08353) 
L12 AASFE(pY)TILDP EPOR_HUMAN (P19235) 
L13 ASTGI(pY)EALEL ENO_ARATH (P25696) 
   ENO1_HEVBR (Q9LEJ0) 
   ENO2_HEVBR (Q9LEI9) 
   ENO_LYCES (P26300) 
   ENO1_MAIZE (P26301) 
   ENO_RICCO (P42896) 
   ENO_PLAFA (Q27727) 
   ENO_ALLMI (P42897) 
   ENO_XENLA (P08734) 
   ENOA_BOVIN (Q9XSJ4) 
   ENOA_HUMAN (P06733) 
   ENOA_MOUSE (P17182) 
   ENOA_RAT (P04764) 
   ENOA_ANAPL (P19140) 
   ENOA_CHICK (P51913) 
   ENOB_HUMAN (P13929) 
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   ENOB_MOUSE (P21550) 
   ENOB_RABIT (P25704) 
   ENOB_RAT (P15429) 
   ENOG_HUMAN (P09104) 
   ENOG_MOUSE (P17183) 
   ENOG_RAT (P07323) 
   ENOG_CHICK (O57391) 
L14 MTGDT(pY)TAHAG ABL1_HUMAN (P00519) 
   ABL1_MOUSE (P00520) 
   ABL2_HUMAN (P42684) 
   ABL_FSVHY (P10447) 
   ABL_MLVAB (P00521) 
L15 QREAE(pY)EPETV SRC8_CHICK (Q01406) 
L16 SSIDE(pY)FSEQP INR1_HUMAN (P17181) 
L17 EPETV(pY)EVAGA SRC8_CHICK (Q01406) 
L18 NVVPV(pY)DLLLE ESR2_BOVIN (Q9XSB5) 
   ESR2_CALJA (Q95171) 
   ESR2_HUMAN (Q92731) 
   ESR2_MACMU (Q9TTE5) 
   ESR2_MOUSE (O08537) 
   ESR2_RAT (Q62986) 
   ESR2_SHEEP (Q9TU15) 
   ESR2_CHICK (Q9PTU5) 
   ESR2_COTJA (O93511) 
   ESR2_STUVU (Q9PVE2) 
L19 IIENPQ(pY)FSDA TRKA_HUMAN (P04629) 
L20 AEENT(pY)DEYEN SRC8_CHICK (Q01406) 
L21 TATEGQ(pY)QPQP LCK_HUMAN (P06239) 
   LCK_MOUSE (P06240) 
L22 TATEGQ(pY)QQQP LCK_CHICK (P42683) 
   LYN_HUMAN (P07948) 
   LYN_MOUSE (P25911) 
   LYN_RAT (Q07014) 
L23 VLDDQ(pY)TSSTG ITK_HUMAN (Q08881) 
   ITK_MOUSE (Q03526) 
L24 LSNPA(pY)RLLLA DDR1_HUMAN (Q08345) 
   DDR1_MOUSE (Q03146) 
   DDR1_RAT (Q63474) 
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M1 IENPQ(pY)FGITN TRKB_HUMAN (Q16620) 
   TRKB_MOUSE (P15209) 
   TRKB_RAT (Q63604) 
   TRKB_CHICK (Q91987) 
M2 FLDDQ(pY)TSSSG TEC_HUMAN (P42680) 
M3 RADEN(pY)YKAQT KSYK_HUMAN (P43405) 
   KSYK_MOUSE (P48025) 
   KSYK_PIG (Q00655) 
   KSYK_RAT (Q64725) 
M4 ED(pY)FTSTEPQY FGR_MOUSE (P14234) 
   SRC_CHICK (P00523) 
   SRC_HUMAN (P12931) 
   SRC_MOUSE (P05480) 
M5 STEPQ(pY)QPGEN SRC_CHICK (P00523) 
   SRC_HUMAN (P12931) 
   SRC_MOUSE (P05480) 
M6 ATEPQ(pY)QPGEN FYN_HUMAN (P06241) 
   FYN_MOUSE (P39688) 
   YES_HUMAN (P07947) 
   YES_MOUSE (Q04736) 
M7 ED(pY)FTATEPQY FYN_CHICK (Q05876) 
   FYN_HUMAN (P06241) 
   FYN_MOUSE (P39688) 
   FYN_XENLA (P13406) 
   SRC2_XENLA (P13116) 
   YES_CHICK (P09324) 
   YES_HUMAN (P07947) 
   YES_MOUSE (Q04736) 
   YES_XENLA (P10936) 
   YES_XIPHE (P27447) 
   YES_XIPHE (P27447) 
   YRK_CHICK (Q02977) 
M8 VMMGP(pY)RQDLL VINC_HUMAN (P18206) 
   VINC_MOUSE (Q64727) 
   VINC_CHICK (P12003) 
M9 RKGHE(pY)TNIKY PTNB_HUMAN (Q06124) 
   PTNB_MOUSE (P35235) 
   PTNB_RAT (P41499) 
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M1
0 
VLDDE(pY)TSSVG BTK_HUMAN (Q06187) 
   BTK_MOUSE (P35991) 
M11 INGNN(pY)VYIDP KKIT_BOVIN (P43481) 
   KKIT_CANFA (O97799) 
   KKIT_CAPHI (Q28317) 
   KKIT_FELCA (Q28889) 
   KKIT_HUMAN (P10721) 
   KKIT_MOUSE (P05532) 
   KKIT_CHICK (Q08156) 
M12 MEDST(pY)YKASK FAK1_CHICK (Q00944) 
   FAK1_HUMAN (Q05397) 
   FAK1_MOUSE (P34152) 
   FAK1_RAT (O35346) 
   FAK1_XENLA (Q91738) 
M13 IEDED(pY)YKASV FAK2_HUMAN (Q14289) 
   FAK2_RAT (P70600) 
M14 DSARV(pY)ENVGL PTNB_HUMAN (Q06124) 
   PTNB_RAT (P41499) 
M15 VDPFT(pY)EDPNQ EPA4_HUMAN (P54764) 
   EPA4_MOUSE (Q03137) 
   EPA4_CHICK (Q07496) 
   EP4A_XENLA (Q91845) 
   EP4B_XENLA (Q91694) 
M16 NTEDQ(pY)SLVED P85A_BOVIN (P23727) 
   P85A_HUMAN (P27986) 
   P85A_MOUSE (P26450) 
M17 HTDDG(pY)MPMSP IRS1_HUMAN (P35568) 
   IRS1_MOUSE (P35569) 
   IRS1_RAT (P35570) 
M18 IDPET(pY)EDPNR EPA7_HUMAN (Q15375) 
   EPA7_MOUSE (Q61772) 
   EPA7_RAT (P54759) 
   EPA7_CHICK (O42422) 
M19 DGENI(pY)IRHSN 41_HUMAN (P11171) 
   41_MOUSE (P48193) 
M20 KGSGD(pY)MPMSP IRS1_HUMAN (P35568) 
M21 KDGRG(pY)VPATI STA6_HUMAN (P42226) 
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M22 GADDG(pY)MPMTP IRS2_HUMAN (Q9Y4H2) 
   IRS2_MOUSE (P81122) 
M23 NNIDY(pY)KKTTN FGR2_HUMAN (P21802) 
   FGR2_MOUSE (P21803) 
   BFR2_HUMAN (Q01742) 
   CEK3_CHICK (P18461) 
M24 RSDD(pY)MPMSPA IRS2_HUMAN (Q9Y4H2) 
N1 IYRAS(pY)YRRGD KLTK_HUMAN (P29376) 
N2 MSRDI(pY)STDYY TRKA_HUMAN (P04629) 
   TRKA_RAT (P35739) 
   TRKA_CHICK (Q91009) 
N3 RGDKG(pY)VPSVF STA4_HUMAN (Q14765) 
   STA4_MOUSE (P42228) 
N4 KAVDG(pY)VKPQI ST5A_BOVIN (Q95115) 
   ST5A_HUMAN (P42229) 
   ST5A_MOUSE (P42230) 
   ST5A_PIG (Q9TUZ1) 
   ST5A_RAT (Q62771) 
   ST5A_SHEEP (P42231) 
   ST5B_BOVIN (Q9TUM3) 
   ST5B_HUMAN (P51692) 
   ST5B_PIG (Q9TUZ0) 
N5 YNGDY(pY)RQGRI UFO_HUMAN (P30530) 
   UFO_MOUSE (Q00993) 
N6 GSAAP(pY)LKTKF STA3_HUMAN (P40763) 
   STA3_MOUSE (P42227) 
   STA3_RAT (P52631) 
N7 YSTDY(pY)RLFNP TRKC_HUMAN (Q16288) 
N8 VYSTD(pY)YRVGG TRKB_HUMAN (Q16620) 
   TRKB_MOUSE (P15209) 
   TRKB_RAT (Q63604) 
   TRKB_CHICK (Q91987) 
   TRKC_PIG (P24786) 
   TRKC_CHICK (Q91044) 
N9 MSRDV(pY)STDYY TRKB_HUMAN (Q16620) 
   TRKB_MOUSE (P15209) 
   TRKB_RAT (Q63604) 
   TRKB_CHICK (Q91987) 
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   TRKC_HUMAN (Q16288) 
   TRKC_PIG (P24786) 
   TRKC_RAT (Q03351) 
   TRKC_CHICK (Q91044) 
N10 YSTDY(pY)RVGGH TRKB_HUMAN (Q16620) 
   TRKB_MOUSE (P15209) 
   TRKB_RAT (Q63604) 
   TRKB_CHICK (Q91987) 
   TRKC_PIG (P24786) 
   TRKC_CHICK (Q91044) 
N11 HLEKK(pY)VRRDS KFMS_FELCA (P13369) 
   KFMS_HUMAN (P07333) 
   KFMS_MOUSE (P09581) 
   KFMS_RAT (Q00495) 
   KFMS_FSVMD (P00545) 
N12 PSAEL(pY)SNALP PGDR_HUMAN (P09619) 
   PGDR_MOUSE (P05622) 
N13 DSTNE(pY)MDMKP KKIT_BOVIN (P43481) 
   KKIT_CANFA (O97799) 
   KKIT_CAPHI (Q28317) 
   KKIT_FELCA (Q28889) 
   KKIT_HUMAN (P10721) 
   KKIT_FSVHZ (P04048) 
N14 LYSGD(pY)YRIQG DDR2_HUMAN (Q16832) 
   DDR2_MOUSE (Q62371) 
N15 TSTDE(pY)LDLSA FGR3_HUMAN (P22607) 
   FGR3_HUMAN (P22607) 
N16 TSNQE(pY)LDLSM FGR1_HUMAN (P11362) 
   FGR1_RAT (Q04589) 
N17 TTNEE(pY)LDLSQ FGR2_HUMAN (P21802) 
   FGR2_HUMAN (P21802) 
N18 IESSN(pY)MAPYD PGDR_HUMAN (P09619) 
N19 TAEPD(pY)GALYE PIG1_BOVIN (P08487) 
   PIG1_HUMAN (P19174) 
   PIG1_RAT (P10686) 
N20 ANNPL(pY)KEATS ITB3_HUMAN (P05106) 
   ITB3_MOUSE (O54890) 
N21 NEDDG(pY)DVPKP CBL_HUMAN (P22681) 
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   CBL_MOUSE (P22682) 
N22 APYDN(pY)VPSAP PGDR_HUMAN (P09619) 
   PGDR_MOUSE (P05622) 
N23 DSNPL(pY)KSAIT ITB7_HUMAN (P26010) 
N24 DFDGT(pY)ETQGG EPA1_HUMAN (P21709) 
   EPA1_MOUSE (Q60750) 
O1 RNPGF(pY)VEANP PIG1_BOVIN (P08487) 
   PIG1_HUMAN (P19174) 
   PIG1_RAT (P10686) 
O2 DPEAV(pY)TTTGG EPA7_HUMAN (Q15375) 
   EPA7_MOUSE (Q61772) 
   EPA7_RAT (P54759) 
   EPA7_CHICK (O42422) 
O3 QAPPV(pY)LDVLG TRKA_HUMAN (P04629) 
O4 YAGDY(pY)RVQGR DDR1_HUMAN (Q08345) 
   DDR1_MOUSE (Q03146) 
   DDR1_RAT (Q63474) 
O5 ELQDD(pY)EDMME B3AT_HUMAN (P02730) 
O6 KASPV(pY)LDILG TRKB_HUMAN (Q16620) 
   TRKB_MOUSE (P15209) 
   TRKB_RAT (Q63604) 
   TRKB_CHICK (Q91987) 
O7 FLDSG(pY)RILGA VINC_HUMAN (P18206) 
   VINC_MOUSE (Q64727) 
   VINC_CHICK (P12003) 
O8 KVGPG(pY)LGSGG RET_HUMAN (P07949) 
O9 MHDSN(pY)VSKGS PGDS_HUMAN (P16234) 
   PGDS_MOUSE (P26618) 
   PGDS_RAT (P20786) 
   PGDS_XENLA (P26619) 
O10 MRDSN(pY)ISKGS PGDR_HUMAN (P09619) 
   PGDR_MOUSE (P05622) 
O11 EEEEA(pY)GWMDF GAST_DIDMA (P33713) 
   GAST_HUMAN (P01350) 
   GAST_MOUSE (P48757) 
   GAST_PIG (P01351) 
   GAST_RAT (P04563) 
O12 KSPGE(pY)VNIEF IRS1_HUMAN (P35568) 
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   IRS1_MOUSE (P35569) 
   IRS1_RAT (P35570) 
O13 IKMGR(pY)EARFA EPB4_HUMAN (P54760) 
O14 IKMDR(pY)KDNFT EPA4_HUMAN (P54764) 
   EPA4_MOUSE (Q03137) 
O15 STNHI(pY)SNLAN KKIT_BOVIN (P43481) 
   KKIT_CANFA (O97799) 
   KKIT_CAPHI (Q28317) 
   KKIT_FELCA (Q28889) 
   KKIT_HUMAN (P10721) 
   KKIT_HUMAN (P10721) 
O16 IKMER(pY)KDNFT EPA4_CHICK (Q07496) 
   EP4A_XENLA (Q91845) 
   EPA7_HUMAN (Q15375) 
   EPA7_MOUSE (Q61772) 
   EPA7_RAT (P54759) 
   EPA7_CHICK (O42422) 
O17 TGTEE(pY)MKMDL IRS1_HUMAN (P35568) 
O18 IKMGR(pY)KESFV EPB3_HUMAN (P54753) 
   EPB3_MOUSE (P54754) 
O19 KDGNG(pY)ISAAE CALM_DICDI (P02599) 
   CALM_ELEEL (P02594) 
   CALM_HUMAN (P02593) 
   CALM_PLECO (P11120) 
   CALM_STIJA (P21251) 
   CALS_CHICK (P02597) 
O20 RGQEV(pY)VKKTM TIE2_BOVIN (Q06807) 
   TIE2_HUMAN (Q02763) 
   TIE2_MOUSE (Q02858) 
O21 DRV(pY)IHPFHL ANGT_HORSE (P01016) 
   ANGT_HUMAN (P01019) 
   ANGT_MOUSE (P11859) 
   ANGT_RAT (P01015) 
   ANGT_SHEEP (P20757) 
O22 EDTLT(pY)ADLD SHS1_BOVIN (O46631) 
   SHS1_HUMAN (P78324 ) 
   SHS1_MOUSE (P97797) 
   SHS1_RAT (P97710) 
161 
 
 
Table A-2.  Phosphopeptides that showed the highest % of phosphate release.  Each of 
the phosphotyrosine (pY)-containing peptides from the library (Table S1) showed some 
degree of hydrolysis by VHZ, yielding on average 50% of hydrolysis, while none of the 
phosphoserine (pS) or phosphothreonine (pT) substrates showed measureable phosphate 
release. 
Substrate source 
(UniProt 
Databank) 
Peptide sequence 
% 
reaction 
Substrate biological role 
Filensin 
(Q06002),(Q12934) 
MYRRS(pY)VFQTR 80% 
Structural constituent of eye 
lens 
Receptor tyrosine-
protein kinase erbB-
4 (Q15303) 
LDNPE(pY)HNASN 80% 
Cell differentiation,  cell 
growth and cell proliferation. 
Belongs to EGF receptor 
superfamily. 
Anion exchange 
protein 1 (P02730) 
ELQDD(pY)EDMM
E 
80% 
Anion exchange; cytoplasmic 
domain provides binding sites 
for cytoskeletal proteins, 
glycolytic enzymes, and 
hemoglobin. 
BDNF/NT-3 growth 
factors 
receptor(Q16620),(P
15209),(Q63604),(Q
91987); 
KASPV(pY)LDILG 80% 
Nervous system development 
and/or maintenance. 
VYSTD(pY)YRVGG 75% 
Protein 4.1 
(P11171)(P48193) 
DGENI(pY)IRHSN 80% 
Structural element of the 
erythrocyte membrane 
skeleton;  mechanical stability 
and deformability of 
membranes 
Src substrate protein 
p85 (Q01406) 
QREAE(pY)EPETV 100% 
Organization of the actin 
cytoskeleton and cell structure; 
regulation of cell migration, 
and transformation. 
Tyrosine-protein 
kinase JAK2 
(O60674)(Q62120)(
Q62689) 
PQDKE(pY)YKVKE 70% 
Cell growth, development, 
differentiation, and histone 
modifications. 
Tyrosine-protein 
kinase receptor Tie-
1 (Q06805), 
(P35590), (Q06806); 
RGEEV(pY)VKKT
M 
70% 
Protein tyrosine-kinase 
transmembrane receptor. 
Proto-oncogene 
tyrosine-protein 
kinase receptor Ret 
(P07949) 
VKRRD(pY)LDLAA 75% 
Tyrosine-protein kinase 
activity; important for 
development. 
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Figure A-2.  Selective alignment of VHZ-VO3 (white) with YopH WT (1YPT, green). 
To align the structures the P-loop of YopH was selectively aligned to the analogous 
region in VHZ with (RMSD=0.238). The steric environment of the open WPD loop was 
analyzed using the MolProbity server. The analysis revealed a steric clash of E44 (VHZ) 
residue with the side chain of D65 if the IPD-loop of VHZ were to assume an open 
conformation analogous to that of YopH, PTP1B. In YopH the negatively charged E44 is 
occupied by the smaller, neutral S287. General acid has always been observed in this 
particular rotamer due to the hydrogen bond with the backbone carbonyl of invariant W 
when the WPD-loop occupies its open conformation (not shown in the figure). E44 can 
occupy several conformations; however the present clash cannot be avoided regardless of 
E44 side chain position.  This figure illustrates that the general acid loop oscillation in 
VHZ cannot follow the classical pathway which is to best of our knowledge the only one 
exclusively observed in PTP family. 
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APPENDIX B 
 
SUPPORTING INFORMATION FOR “UNUSUSAL AND UNACCOUNTED  
PROPERTIES OF LDP3(VHZ) PROTEIN TYROSINE PHOSPHATASE 
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Table B-1. Ionization constants of  catalytic residues in VHZ/WT and VHZ/D65A 
obtained from non-linear least squares fit of equation derived in Section B-4 to the 
experimental data presented in the Figure 3-3. pK1E – is assigned to the ionization of 
nucleophilic cysteine whereas pK2E – is attributed to the general acid catalysis.  
 
kcat kcat/KM 
 pK1E pK2E pK1E pK2E 
VHZ/WT 5.16 ± 0.43 5.54 ± 0.21 4.84 ± 0.11 5.02 ± 0.31 
VHZ/E134Q 5.18 ± 0.6 5.30 ± 0.52 5.17 ± 0.42 5.61 ± 0.34 
VHZ/D65A 4.71 ± 0.63 5.06 ± 0.42 4.21 ± 0.52 5.61 ± 0.28 
 
B-1. Validation of the continuous spectrophotometric assay method for PTP activity 
with pNPP 
p-Nitrophenyl phosphate (Acros) was recrystallized from 100 % ethanol and dried 
under high vacuum. A set of buffered standard solutions of p-nitrophenol was prepared in 
the range pH 4.5-9.0 (in steps of 0.12). The buffers used were 50mM acetate (pH 4.5-
5.5), 50 mM succinate (pH 5.75-6.5), 50 mM 3,3-dimethylglutarate (6.75-7.25), 50 mM 
glycyl-glycine (pH7.5-8.5 ). Ionic strength was adjusted to 150 mM with NaCl. For each 
pH at least eight dilutions of the buffered standard solution were prepared with the same 
buffer containing no chromophore and pNP concentration was plotted vs A 400 nm  and 
10 mM path length (Figure C-1 A). The inverse values of the slopes were plotted vs 
corresponding pH values (Figure C-1 B) and fitted to the equation using least squares 
linear regression. 
pNPpNP pNP
400 tot tot+
pNP
pNP pNP400
totpNP +
tot pNP
K
A =α×C ×ε= ×C ×ε
K +[H ]
KA 1
×C ×ε
C Slopes K +[H ]
 
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Where α is the fraction of deprotonated p-nitrophenol, ε is extinction coefficient 
of p-nitrophenolate, pNP
totC  is the total concentration of p-nitrophenol,   KpNP  is the p-
nitrophenol ionization constant.  
The acid dissociation constant obtained from the fit was 
8
pNPK 7.73 10
     and 
extinction coefficient of 
-1 -1ε=18.59 mM ×sm  . 
   
 
 
 
 
 
 
 
Figure B-1. Validation of the partial extinction coefficients method.  A) A set of p-
nitrophenol dilution at each  pH has been prepared and total concentration of each 
dilution is plotted vs corresponding absorbance at 400 nm yielding a set of slopes. 
Steeper slopes correspond to lower pH.  B) In order to validate the approach the inverse 
of the slopes has been plotted vs pH. The plot was fitted to the p-nitrophenol titration 
curve which yields a pKa of p-nitrophenol (7.11) and extinction coefficient of fully 
deprotonated  p-nitrophenolate (18.5) (equation 3). 
 
B-2. Derivation of Expression for steady-state kinetics of PTP catalyzed hydrolysis 
of phosphate monoester substrates 
Protein tyrosine phosphatases catalyze hydrolysis of phosphate monoester 
substrates via two-step Ping-Pong mechanism represented by the following scheme: 
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Scheme B-1 . Kinetic scheme of classical PTP mechanism. All forward rates constant are 
given odd subscripts whereas all the reverse rate constants given are even subscripts. 
 
To derive the kinetic rate law for the mechanism presented in scheme B-1 we 
write a series of equations describing the rate of change of each enzyme form. Under 
steady state assumption concentration of each intermediate remains constant (the rate of 
change is set to 0): 
total
3 5
1 2 3
2 1 5
E =E+ES+EP
dEP
=0=k ×[ES]-k ×[EP]
dt
dES
=0=k ×[E]×[S]-(k +k )×[ES]
dt
dE
=0=k ×[ES]-k ×[E]×[S]+k ×[EP]
dt









  
We can re-arrange each equation as follows: 
total
5
3
1
2 3
2 5
1
[EP]=[E ]-[E]-[ES]
k
[ES]= ×[EP]
k
k
[ES]= ×[E]×[S]
k +k
k ×[ES]+k ×[EP]
[E]=
k ×[S]











 
Substituting [ES] from equation 3 into equation 4 we can find: 
2 1
5
2 3
1
5 5 2 3 5
2 1 2 1 1 3
1 1
2 3 2 3
k ×k
×[E]×[S]+k ×[EP]
k +k
[E]=
k ×[S]
k ×[EP] k ×[EP] (k +k )×k ×[EP]
[E]= = =
k ×k k ×k k ×k ×[S]
k ×[S]- ×[S] k ×[S]- ×[S]
k +k k +k
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Substituting expression for ES and obtained expression for E into equation 1 we 
obtain: 
2 3 5 5 2 3 5 1 5
total total
1 3 3 1 3
total 1 3 total
2 3 5 1 5 1 3 2 3 5 1 5
1 3
1 3 t
(k +k )×k ×[EP] k (k +k )×k +k ×k ×[S]
[EP]=[E ]- - ×[EP]=[E ]- ×[EP]
k ×k ×[S] k k ×k ×[S]
[E ] k ×k ×[S]×[E ]
[EP]= = =
(k +k )×k +k ×k ×[S] k ×k ×[S]+(k +k )×k +k ×k ×[S]
1+
k ×k ×[S]
k ×k ×[S]×[E
=
 
otal
2 3 5 1 3 5
]
(k +k )×k +k × k +k ×[S]
 
Reaction rate corresponds to the rate of product release: 
 
 
 
 
5 1 3 5 3
total total
1 3 5 3 5 cat total
5
2 3 5 2 3 5 M
1 3 5 1 3 5
k ×k ×k k k
×[S]×[E ] ×[S]×[E ]
k × k +k k +k k ×[S]×[E ]
V=k ×[EP]= =
(k +k )×k (k +k )×k K +[S]
+[S] +[S]
k × k +k k × k +k


 
We can see now that: 
 
 
 
 
 
 
Where Ks is the enzyme substrate complex ([ES]) dissociation constant.  
The obtained expressions are equally valid for native VHZ and its mutants. The 
following conclusions can be drawn: 
1. kcat/KM characterizes the events from substrate trapping by free enzyme E up until the 
first irreversible step k3 regardless of what step (k3 or k5) is a rate limiting. The kcat 
 
5 3
cat
3 5
2 3 5 5
M S
1 3 5 3 5
3 5
cat 5 3 3
5M S
S
5 3
k ×k
k
k +k
(k +k )×k k
K K
k × k +k k +k
k ×k
k k +k k
=
kK K
K ×
k +k

  

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parameter reports on the chemical behavior of enzyme-substrate complex and when 
k3>>k5 (dephosphorylation is much slower than phosphorylation) we write: 
5 3 5 3
cat 5
3 5 3
5 5
M S S
3 5 3
3 5
cat 5 3 5 3
5 5M S
S S
5 3 3
k ×k k ×k
k k
k +k k
k k
K K K
k +k k
k ×k
k k +k k k
=
k kK K
K × K
k +k k
  
   
 

 
2. KM values are determined by two major terms:  Ks and 
5
3 5
k
k +k
 . 
Residues which affect Ks (substrate binding) as well as the relative kinetic ratio 
5
3 5
k
k +k
  will have a measurable effect on KM.  
In the presence of two substrate binding modes earlier presented in Figure 3-9 of 
the main text,  
 
The general law will be affected as it will contain a fractional terms Aα  and Bα   
modulating Vmax and the calculated kcat will depend on which of the two conformations 
has catalytic viability (which in turn will depend on which general acid, E134 or D65, is 
available). 
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 
AB
A WT max
max max A
AB
B WT max
max max B
AB
A B WT WT WT WT
max max max A max B max A B max
[B]
K =
[A]
V
V =V ×α =
1+K
V
V =V ×α =
1
1+
K
V V V ×α V ×α V (α α ) V
 
 
 
      
 
 
B-3. Derivation of expression for the steady-state kinetics of PTP-catalyzed 
hydrolysis in the presence of alternative nucleophilic acceptors. 
Although native classical PTPs generally cannot transfer phosphate to acceptors 
other than water (hydrolysis of enzyme phosphate intermediate), atypical DSPs, Low 
Molecular Weight PTPs, as well as VHZ/WT revealed an ability to phosphorylate 
alcohols (alcoholysis of phosphoenzyme intermediate), when such alternative 
nucleophiles are added. In this case the breakdown of the phosphoenzyme intermediate 
proceeds via two simultaneous (additive, not competing) pathways according to Scheme 
B-2:  
To derive the kinetic expression for the PTP-catalyzed reaction of phosphoester 
hydrolysis in the presence of an alternative nucleophilic agent, the algorithm developed 
by King and Altman will be used (JPC 60, 1375). The reaction mechanism (Panel A) is 
presented in a closed cyclic form (Panel B). 
The appropriate rate constants are multiplied by their corresponding concentration 
factors ([S] for k1 and [ROH] for k7). Three open loop patterns (Panel C) are obtained 
from the catalytic triangle of Panel B by erasing one side at a time because none of the 
pattern should contain open loops.   
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Scheme B-2. King-Altman derivation of kinetic law for PTP catalyzed reaction in the 
presence of alternative nucleophilic acceptors.  
 
We need to write down distribution equation for each enzyme form (e.g., E, ES 
and EP). From each of the three open patterns (Panel C) we write a product of elementary 
constants (e.g., k1, k2, k3, k5) that point towards an enzyme form from the breach in the 
cycle (clockwise and counterclockwise).  If some elementary step on the way from the 
breach to an enzyme form is absent due to irreversibility, then the rate constant of the 
step in reverse direction is considered to be  0 (for example, the reverse rate of k3 is 
k4=0).  Now starting from left to right we can write for each enzyme form:  
 
 
 
 
 
3 5 7 2 2 5 7 3 2 5 7
total
1 1 5 7 1 5 7
total
3 1 3
total
k ×(k +k [ROH])+0×k +k ×(k +k [ROH]) (k +k )×(k +k [ROH])[E]
= =
[E ] ([E]+[ES]+[EP])
0×0+k [S]×0+k [S]×(k +k [ROH]) k [S]×(k +k [ROH])[ES]
= =
[E ] ([E]+[ES]+[EP])
k ×0+k [S]×k +k[EP]
=
[E ]
  

    

 2 1 3×0 k [S]×k=
([E]+[ES]+[EP])
[E]+[ES]+[EP]


 
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By adding all three equations together we find: 
 
 
 
The rate of the process is described by last irreversible step associated with 
release of the reaction product and liberation of free enzyme form:  
5 7V=(k +k [ROH])×[EP] . 
1 3 1 3
total 3 2 5 7 1 5 7 3
5 7 1 3 total
5 7
3 2 5 7 1 5 7 3
k [S]×k k [S]×k[EP]
= =
[E ] Δ (k +k )×(k +k [ROH])+k ×(k +k [ROH])+k ) [S]
(k +k [ROH])×k ×k ×[S] E
V=(k +k [ROH])×[EP]=
(k +k )×(k +k [ROH])+k ×(k +k [ROH])+k ) [S]
 
  
 

  
 
Finally we divide the numerator and denominator by coefficient before [S] to 
obtain: 
 
3 5 7
total
5 7 3 cat total
3 2 5 7 M
1 5 7 3
3 5 7
cat
5 7 3
3 2 5 7 5
M S
1 5 7 3
k ×(k +k [ROH])
×[S]×[E ]
(k +k [ROH])+k k ×[S]×[E ]
V= =
(k +k )×(k +k [ROH]) K +[S]
+[S]
k ×((k +k [ROH])+k )
k × k +k [ROH])
k =
k +k [ROH]+k
k +k k +k [ROH] k +k
K = × =K ×
k k +k [ROH])+k




  
 
 
 
 
7
5 7 3
3 5 7cat
M S 5 7
[ROH]
k +k [ROH])+k
k × k +k [ROH]k
K K × k +k [ROH]





 
total
[Enz.Form] PatternC1+PatternC2+PatternC3
=
[E ] [E]+[ES]+[EP]
3 2 5 7 1 5 7 1
total total total
3 2 5 7 1 5 7 1 3
(k +k )×(k +k [ROH])+k [S]×(k +k [ROH])+k [S]×k3[E] [ES] [EP]
+ =1=
[E ] [E ] [E ]
(k +k )×(k +k [ROH])+k [S]×(k +k [ROH])+k [S]×k
   


     
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We have two potential interpretations of kcat in the presence of an alternative 
nucleophile  depending on whether the second step (k5) of the process is rate limiting, or 
both steps (k3 and k5) simultaneously contribute to the overall rate of the process. 
In the case (k3>>( 5 7k +k [ROH]  ) – the second step is the rate limiting one, we 
can simplify: 
 
3 5 3 7
cat 5 7
5 7 3
k ×k +k ×k [ROH]
k = k +k [ROH]
k +k [ROH] +k

 
 
This expression indicates that kcat values should increase linearly with 
concentration of  [ROH]  . Then plotting kcat vs [ROH] will yield a linear plot with the 
slope equal to k7. 
However, when k3 and ( 5 7k +k [ROH] ) are comparable, the plot will be linear at 
low nucleophile concentration when [ROH] << 5 3
7
k +k
k
  : 
3 5 3 7
7 3 5 3 7
cat
5 3 3 5 3 5
7
k ×k +k ×k
[ROH]
k k ×k k ×k
k = + [ROH]
k +k k k k k
+[ROH]
k

 
 
 
In the broad range of alcohol concentrations and eventually at 5 3
7
k +k
<<[ROH]
k
 
reaction will become independent of [ROH]:   
3 5 3 7
7 3 5 3 7
cat
5 3 7
7
k ×k +k ×k
[ROH]
k k ×k +k ×k
k =
k +k k
+[ROH]
k

  
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Because concentration of ethylene glycol in our experiment was too low to reach 
saturation (as revealed by linear dependence of experimental kcat values on [ROH], we 
can simplify  as earlier (considering 5 3
7
k +k
ROH<<
k
 ) 
3 5 3 7
3 5 3 7 7 7 3 5 3 7
cat
5 35 7 3 5 3 5 3
7
k ×k k ×k
+ [ROH]
k ×k +k ×k [ROH] k k k ×k k ×k
k = [ROH]
k +kk +k [ROH]+k k +k k +k
+[ROH]
k


   

 
In this case the slope of the plot of kcat vs  [ROH] is no longer the rate of 
alcoholysis but the ratio of three rate constants.  However, we can still define enzymatic 
preference for alcoholysis over hydrolysis rate by looking at the ratio:  
3 7
5 3 7
3 5 5
5 3
k ×k
k +k kSlope
S =
k ×kIntercept k
k +k
 
 
We can see that in the absence of alcohol ([ROH]=0), the expression for kcat 
reduces to the ordinary steady-state expression algebraically derived in B-2: 
3 5 3 7 3 5
cat
[ ] 0
5 3 5 3 5 3
k ×k k ×k k ×k
k lim [ROH] =
k +k k +k k +kROH 
 
   
   
Likewise for KM: 
5 7 5
M S S
5 7 3 5 3
k +k [ROH] k
K =K × K ×
k +k [ROH])+k k +k



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B-4. Derivation of expression for pH dependence of steady-state kinetics of PTP 
catalyzed hydrolysis of phosphate monoester. 
PTPs utilize a cysteine residue which attacks the phosphate moiety of the 
substrate monoester in the first step and therefore must be deprotonated for catalytic 
activity. At the same time a catalytic general acid must be protonated to donate a proton 
to the leaving group of the substrate. Additionally, phosphate monoester substrate 
protonation state changes from mono-ionic to di-ionic, which is known to affect binding. 
Because of this the reaction rate of the PTP-catalyzed reaction is affected by pH which 
controls the protonation state of catalytically relevant residues.  
The following protonation events can occur: 
 
Scheme B-3.  Intermediates in PTP catalyzed reaction affected by pH  
Scheme B-3contains the following assumptions: 
1. Substrate can bind to each of the three enzyme forms.  
2. Binding to EH1 (cysteine deprotonated, general acid protonated) produces a 
reactive enzyme-substrate complex. EH1 hereby is considered as an optimal ionization 
state of enzyme.  
3. Binding to E (general acid deprotonated, cysteine deprotonated) produces 
essentially unreactive enzyme-substrate complex, which, however, can gain a proton 
from solution producing a reactive EH1S complex. It is possible because unlike catalytic 
cysteine in EH2 the general acid remains exposed to the solvent environment. 
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4. Binding to EH2 (protonated cysteine and general acid) produces a completely 
unreactive enzyme-substrate complex which cannot lose proton to produce EH1 because 
of the shielding of the catalytic cysteine by the substrate.  
5. Substrate binding does not affect the pKA (KA1=KA2) of the general acid, and it 
follows from the thermodynamic box that affinity of E and ES for the substrate are 
identical.  
The scheme can be simplified: 
 
Scheme B-4. Simplified from Scheme B-3representation of pH effect on PTP catalyzed 
reaction.  
 
The three enzyme forms in the box can be reduced to one (analogous to Cha 
approximation). We account for protonation states by multiplying the rate constant k1 by 
the fraction of EH1 in the box, and by the fraction of substrate in the correct (dianionic) 
form.  The mechanism can be further simplified:  
 
Scheme B-5.  pH effect on PTP catalyzed reaction.The  dashed box as a single 
intermediate. It is justified by Cha approximation. X represents the species present in the 
box; fx is the fraction of correctly protonated enzyme form (E H1);  fs is the fraction of 
correctly protonated substrate (di-anionic form of pNPP). 
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To find the expression for the fraction of the correctly protonated form present we 
write: 
 
 
 
 
 
pNPP has two ionizable sites (K1S,K2S). However, because K1S is outside of the 
experimental pH range (experimental pH range is higher than K1S ) we can simplify the 
expression by assuming that the first stage is 100% deprotonated (setting K1S ). 
The initial rates method developed by W. W. Cleland will be used. The 
mechanistic scheme is re-written to contain only the net rate constants: 
 
Scheme B-6.  Net rate constant representation of PTP catalyzed reaction according to the 
W.W. Cleland. 
 
 
Net rate constants are used to represent only the forward flux through each step of 
the mechanism. In other word it represents the fraction of the overall transformation 
through each step that proceeds forward (the net flux) to the next step rather than 
returning back via a reverse rate constant.  For irreversible steps we can write equalities 
like 5 5k' =k  and 3 3k' =k   because 100% of the transformation moves on to the next step 
and reverse rate constants for these steps equal 0. However, for the k’1 step we need to 
write: 
1S
+
1E
x 2 ++ +
2
1E 1E 2E 2E
+
1E
1S 2S 2S
s 2 2 +K+ + +
2
1S 1S 2S +
2S
2S1S
H ×KHE 1
f = =
H E+HE+E HH + H ×K +K ×K K
1
K H
K ×K KS 1
f = = lim
H S+HS+S HH + H ×K +K ×K H
1+ H +K
KK

   
           
  
 
 
 
  
                  
 
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   3 31 1 x s 1 x s
3 2 3 2
k' k
k' =k × × S ×f ×f k × × S ×f ×f
k' +k k +k

 
According to the net rate constant method, we write: 
 
 
 
 
 
 
 
 
 
 
3 5 3 5
cat5 3 5 3
+ +
S 5 M
5 S 2E
+x s 5 3
5 3 1E 2S
3 5
cat
5 3
S 5
M
x s 5 3
k ×k × S k ×k × S
k × Sk +k k +k
= = =
K k K + SH Hk ×K K+ S
× 1+ + × 1+f ×f × k +k k +k K KH
k ×k
k =
k +k
K k
K =
f ×f × k +k
            
        
  
 
Substituting the previously derived expressions for fx and fs we obtain.  
3
cat S
+ +
M
2E
+
1E 2S
k
k K
=
K H HK
1+ + × 1+
K KH
            
          
Because the expression for kcat does not contain k1 we multiply it only by fx (not fs).     
3 5
5 3
cat +
2E
+
1E
k ×k
k +k
k
H K
1+ +
K H

    
      
 
 
 
     
1 3 5 x s
3 2t 5 3 2 1 x s 5 3
1 3 5 1 3 x s 3 5
k ×k ×k × S ×f ×fV 1 1
= = = =
1 1 1 k +k 1 1E k × k +k +k ×f ×f × k +k × S+ + + +
k' k' k' k ×k × S ×f ×f k k
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B-5. Derivation of the pre-steady state kinetics expressions for PTP-catalyzed pNPP 
hydrolysis: 
 
Scheme B-7.  Schematic representation of PTP catalyzed pNPP hydrolysis. 
 
Let’s write the system of first order differential equations for each enzyme form 
as follows: 
2 1 5
1 2 3
3 5
total
S
dE
=k ×[ES]-k ×[E]×[S]+k ×[EP]
dt
dES
=k ×[E]×[S]-(k +k )×[ES]
dt
dEP
=k ×[ES]-k ×[EP]
dt
E =E+ES+EP
[E] [S]
K
[ES]











 

  
These equations  are identical to the ones previously derived for steady-state in 
the section B-2, except for the rate for each enzyme form (intermediate) is not 0 
(assumption we made for steady state).  
First, we need to find the dependence of [E-P] (formation of [E-P] accompanies 
chromophore release) on time. To do this we need to integrate the corresponding 
differential equation, but before we derive the expression connecting [E-P] and [ES].  
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 
 
 
S
total
total
S S
total
totalS
S
S
[E] [S]
K
[ES]
[E]=[E ]-[ES]-[EP]
[S] [S]
[ES]= ×[E]= × [E ]-[ES]-[EP]
K K
[S]
× [E ]-[EP]
[S]× [E ]-[EP]K
ES=
[S]+K[S]
1+
K



 
 
 
 
Substitution into equation for [EP] enzyme form we obtain: 
 3 total
3 5 5
S
3 total 3
5
S S
k ×[S]× [E ]-[EP]d[EP]
=k ×[ES]-k ×[EP]= -k ×[EP]=
dt [S]+K
k ×[S]×[E ] k ×[S]
= - +k ×[EP]=A-B×[EP]
[S]+K [S]+K
 
 
 
  
Integration of both sides yields: 
    
d[EP] 1 dA-B×[EP]
=- = dt
A-B×[EP] B A-B×[EP]
1 1 1
t=- ln A-B×[EP] +C =- ×ln A-B×[EP] - C
B BB

  
  
The value of integration constant C can be calculated at t=0 
   t=0,[EP]=0C =-ln A-B×[EP] =-ln A  
Substitution of C expression into equation yields: 
    
-B×t
1 1 A-B×[EP]
t=- × ln A-B×[EP] -ln A =- ln
B B A
A-B×[EP]
=e
A
 
 
   
Substitution of A and B back into the equation will yields: 
 
3 3
5 5
S S
k ×[S] k ×[S]
- +k ×t - +k ×t
[S]+K [S]+K3 total
3 total
-B×t
S
S3
3 55
S
k ×[S]×[E ]
× 1-e k ×[E ]× 1-e
[S]+KA× 1-e
[EP]= = =
B Kk ×[S]
k +k × 1++k
[S][S]+K
   
   
   
   
   
   
   
   
   
  
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Now let’s substitute it to the expression for the rate of pNP release and rearrange 
prior to integration in order to separate the time-dependent and time-independent parts:  
 
 
 
 
 
 
 
 
As can be seen after re-arrangement the only part dependent on time is the one 
included under the exponential term, whereas C and D are t-independent constants. 
By integrating the expression we obtain: 
3 3
5 5
S S
k ×[S] k ×[S]
- +k ×t - +k ×t
[S]+K [S]+K
3
5
S
D
[pNP]= C+D×e ×dt=C×t- ×e +F
k ×[S]
+k
[S]+K
   
   
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Where F is the constant of integration. We obtain its value by setting t=0.  
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Substitution of the expression for F , C and D into the equation yields after a series of re-
arrangements: 
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3 3
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S S
k ×[S] k ×[S]
- +k ×t - +k ×t
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The first two terms in the obtained expression correspond to a straight line with the slope 
of cat total max
M M
k ×[S]×[E ] V ×[S]
=
[S]+K [S]+K
  which corresponds to the steady-state rate of product pNP 
release and Y intercept 
 
2
cat
total
5 M
k ×[S]
×[E ]
k × [S]+K
 
 
 
 
  which corresponds to the amplitude 
of the burst proportional to the total enzyme concentration. We can notice that when 
[S]>>KM, and k3>>k5 (such that kcat = k5 – de-acylation of enzyme is the rate limiting 
step), the expression can be simplified and the magnitude of the burst is equal to the 
[Etotal]: 
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When one of the conditions (either [S]>>KM or  k3>>k5) is not satisfied  
 
cat
5 M
k ×[S]
1
k × [S]+K
  and the magnitude of the burst rapidly reduces because of the square 
power of the term. This term can be viewed as a product of two terms:  
   
cat cat
5 M5 M
k ×[S] k [S]
k [S]+Kk × [S]+K
   
The first one depends exclusively on the nature of the enzyme at hand and totally 
determined by the ratio: 
3 5
cat 3 5 3
5 5 3 5
k ×k
k k +k k
k k k +k
  . The ratio shows that if k3>>k5 condition 
is not satisfied, the ratio cat
5
k
1
k
  . The second term 
 M
[S]
[S]+K
corresponds to the fraction 
of enzyme-substrate complex which forms upon rapid mixing from the total enzyme 
present in solution. This term can be experimentally maximized and approached to unity 
by using saturated ([S]>>KM ) substrate concentrations. If such concentration is not 
achievable it is possible a set of lower substrate concentrations can be used to construct a 
saturation curve. Finally, the exponential term or burst rate constant 
k ×[S]
3 +k
5[S]+K
S
can be 
simplified if we use a saturating amount of substrate (or its values can be obtained from 
saturating curve at lower substrate concentrations). In this case the expression of the 
Burst rate constant simplifies to the simple sum  
k ×[S]
3 +k k +k
5 3 5[S]
 .  
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SUPPORTING INFORMATION FOR “METAVANADATE AT THE ACTIVE 
SITE OF THE PHOSPHATASE VHZ” 
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Below are the absolute energies (in Hartrees) and the atomic coordinates of the structures that 
were computationally analyzed.  The coordinates were obtained from the x-ray structure. 
Complex shown in Figure 4-2, A: 
E(B3LYP/6-31G*) = -5421.28129098 
C           -2.564078    6.097605   -2.147937 
C           -2.074282    4.809721   -2.298077 
C           -2.828828    3.841212   -2.936995 
C           -4.073112    4.184683   -3.423734 
C           -4.564762    5.465201   -3.268804 
C           -3.806093    6.421611   -2.631369 
C           -2.315088    2.454911   -3.101813 
C           -3.178162    1.397957   -2.402183 
C           -2.845657    0.007788   -2.952113 
O           -3.652161   -0.583823   -3.667401 
N           -3.103828    1.543927   -0.941127 
C           -4.186200    1.758800   -0.201678 
O           -5.342292    1.748475   -0.648949 
C           -3.991763    2.009069    1.284148 
N           -2.643245    2.312415    1.734752 
C           -2.156038    3.555649    1.711129 
O           -2.811871    4.525966    1.325986 
C           -0.711852    3.757697    2.159414 
C            0.139054    4.047198    0.919841 
C            1.604621    4.421267    1.126244 
C            1.817242    5.327482    2.313061 
N           -0.168211    2.644116    2.945790 
C            0.065405    2.731680    4.255662 
O           -0.222864    3.729175    4.930432 
C            0.702578    1.486602    4.903246 
C            2.208904    1.429259    4.622323 
N            0.038880    0.261248    4.467666 
C           -1.157248   -0.032245    4.961671 
O           -1.698806    0.657185    5.826250 
C           -1.853628   -1.304514    4.472887 
N           -3.291855   -1.056816    4.482188 
C           -1.360245   -1.841526    3.108760 
S           -1.835093   -0.855900    1.673917 
V            0.198156   -0.347226    0.543004 
O            0.639040   -1.848475   -0.195223 
O           -0.408457    0.847159   -0.483213 
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O            1.124727    0.154276    1.848070 
C            2.170170    5.052550   -0.139512 
N           -1.666263   -0.511593   -2.655395 
C           -1.184227   -1.724278   -3.297674 
C           -1.768774   -2.997412   -2.727347 
O           -2.611233   -3.650042   -3.354617 
N           -1.342354   -3.346069   -1.520591 
C           -1.856383   -4.536348   -0.860530 
C           -3.360347   -4.421715   -0.633147 
O           -4.108995   -5.362964   -0.917708 
C           -1.090184   -4.757891    0.449855 
C            0.388416   -5.150963    0.229796 
C            1.215266   -5.066767    1.501703 
N            1.551456   -3.683642    1.851085 
C            2.250850   -3.333675    2.930953 
N            2.518622   -2.051964    3.179963 
N           -3.798787   -3.260691   -0.156681 
C           -5.209695   -3.008286    0.089763 
C           -6.025967   -3.105870   -1.196346 
O           -5.655896   -2.518798   -2.199737 
N            2.690387   -4.265005    3.773083 
C           -5.405523   -1.614876    0.724107 
O           -4.935639   -1.659815    2.073267 
C           -6.865303   -1.197231    0.749411 
O           -7.063408   -3.773521   -1.242127 
N            2.912325    0.452939   -0.974720 
C            3.663337    1.545394   -0.919259 
N            3.545988    2.482147   -1.856543 
N            4.546597    1.707043    0.060695 
C            5.422844    2.869734    0.166581 
C            6.387897    2.756612    1.330761 
C            5.706988    3.008483    2.669403 
O            1.942221    2.044727   -4.103413 
C            1.503987    0.880095   -4.282680 
O            1.615513   -0.025316   -3.430465 
C            0.834520    0.551134   -5.594611 
C            1.533546   -0.579303   -6.317362 
O            5.363528   -0.578767    1.505494 
C            4.959816   -1.690444    1.095837 
O            3.993422   -1.819585    0.308681 
C            5.710443   -2.922476    1.561836 
C            5.098360   -4.224968    1.051585 
C            6.216263    0.643233   -2.934691 
C            5.598078    0.022967   -4.005037 
C            5.633930   -1.358612   -4.119179 
C            6.283716   -2.134160   -3.165843 
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C            6.888214   -1.500961   -2.090181 
C            6.853870   -0.113721   -1.971079 
C            6.302191   -3.623501   -3.287680 
H            4.104848   -4.115862    1.069705 
H            5.705043   -2.939110    2.561872 
H            6.652879   -2.864288    1.233526 
H            7.051832   -3.978678   -2.729838 
H            6.457311   -3.861909   -4.245958 
H            5.186899   -1.802454   -4.896487 
H            5.126250    0.570192   -4.696387 
H            6.201896    1.640568   -2.858431 
H            7.289773    0.333493   -1.190166 
H            7.353614   -2.046095   -1.393309 
H           -3.643441   -0.240423    4.024463 
H           -1.614621   -2.044477    5.102165 
H           -0.361489   -1.884784    3.136593 
H           -1.730929   -2.761978    2.987507 
H            0.479126   -0.347375    3.807347 
H            0.577042    1.562436    5.892545 
H            2.638512    2.278941    4.929531 
H            2.361494    1.314877    3.640217 
H            2.611146    0.656060    5.113326 
H            0.035401    1.783030    2.479621 
H           -0.689231    4.534758    2.788130 
H            0.119238    3.227482    0.348217 
H           -0.294972    4.804410    0.431812 
H            2.097503    3.573545    1.323611 
H            3.129897    5.293020    0.007048 
H            1.650798    5.877830   -0.361966 
H            2.101692    4.401797   -0.895880 
H            2.790171    5.539210    2.400579 
H            1.500385    4.869409    3.143309 
H            1.301839    6.174811    2.182856 
H           -2.064508    1.569458    2.071884 
H           -4.294251    1.188573    1.769831 
H           -4.574509    2.780846    1.538133 
H           -2.213194    1.479784   -0.490838 
H           -4.146067    1.536835   -2.610536 
H           -1.391624    2.412522   -2.721526 
H           -2.283865    2.242885   -4.078364 
H           -4.625643    3.496791   -3.894918 
H           -5.471948    5.698254   -3.619004 
H           -4.159995    7.350616   -2.521352 
H           -2.011251    6.791787   -1.686771 
H           -1.168424    4.578711   -1.942246 
H           -1.091731   -0.060059   -1.973113 
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H           -1.417379   -1.679104   -4.269589 
H           -0.190397   -1.761200   -3.194248 
H           -0.657733   -2.782962   -1.057527 
H           -1.714022   -5.334325   -1.445667 
H           -1.118162   -3.911535    0.981588 
H           -1.540473   -5.489146    0.961545 
H            0.421523   -6.090689   -0.111435 
H            0.785364   -4.534370   -0.450413 
H            0.693399   -5.470835    2.253064 
H            2.062903   -5.580716    1.369386 
H            1.236286   -2.956607    1.241177 
H            3.215010   -3.999812    4.582146 
H            2.496436   -5.230006    3.596297 
H            3.043513   -1.800004    3.992505 
H            2.194125   -1.342341    2.554012 
H           -3.136784   -2.537093    0.038861 
H           -5.535402   -3.709472    0.723539 
H           -4.898375   -0.953515    0.172399 
H           -6.946564   -0.291886    1.166792 
H           -7.392686   -1.858153    1.283460 
H           -7.220029   -1.165572   -0.185109 
H           -5.056209   -0.762827    2.498372 
H            1.618130   -1.351587   -5.687042 
H            2.445032   -0.265536   -6.585061 
H            0.847665    1.364528   -6.177001 
H           -0.111991    0.284000   -5.416235 
H            5.229480    2.176840    2.954108 
H            5.048045    3.753336    2.565536 
H            7.118584    3.428507    1.210372 
H            6.778580    1.835889    1.336898 
H            4.860315    3.686151    0.293082 
H            5.947913    2.954557   -0.679509 
H            4.614491    0.996552    0.761104 
H            2.883617    2.367963   -2.596805 
H            4.120282    3.300496   -1.820645 
H            2.249991    0.338708   -1.715007 
H            3.008410   -0.256297   -0.276513 
H            6.455486    3.281923    3.411631 
H            5.403442   -5.046927    1.697518 
H            5.442600   -4.414406    0.035941 
H            5.354065   -4.028215   -2.936703 
H            0.947721   -0.870826   -7.187849 
H           -3.921634   -1.728595    4.072121 
H           -3.778547   -0.946061    5.357932 
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Complex shown in Figure 4-2, B: 
 
E(B3LYP/6-31G*) = -4901.42875623 
 
C            1.727809   -3.634447    0.694462 
C            1.534656   -4.937697    1.214981 
C            0.789643   -5.177939    2.374034 
C            0.238858   -4.058681    2.966769 
C            0.418934   -2.772195    2.447145 
C            1.150954   -2.505815    1.300343 
O            1.313912   -1.191292    0.823651 
V           -0.178825   -0.082110   -0.199831 
O            0.015483   -1.328264   -1.610982 
S           -2.033199    1.040534   -1.380700 
C           -1.580835    1.265999   -3.139307 
C           -2.523536    0.665752   -4.191768 
C           -2.444495   -0.853382   -4.300928 
O           -3.332658   -1.451832   -4.889324 
N           -3.916007    0.860783   -3.859496 
N           -1.421330   -1.509442   -3.782888 
C           -1.438805   -2.971294   -3.828894 
C           -2.382298   -3.551682   -2.733723 
O           -3.269642   -4.376542   -3.023285 
C           -0.018669   -3.537010   -3.749231 
O           -0.032582   -4.954399   -3.726518 
N           -2.207915   -3.096254   -1.491983 
C           -3.023011   -3.542385   -0.374403 
C           -4.176822   -2.591690   -0.082012 
O           -5.166811   -2.987161    0.536400 
C           -2.175192   -3.706508    0.870188 
N           -4.051352   -1.339991   -0.513731 
C           -5.115785   -0.363870   -0.316466 
C           -5.189436    0.276766    1.052562 
O           -6.260771    0.730773    1.450842 
N           -4.063602    0.316066    1.772424 
C           -4.009606    0.924449    3.106474 
C           -2.926851    1.995037    3.258521 
O           -3.181200    3.058049    3.800787 
C           -3.807687   -0.170324    4.171845 
C           -5.075728   -0.993166    4.336565 
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C           -2.669698   -1.107453    3.763119 
C           -2.385786   -2.198536    4.771378 
N           -1.725030    1.718731    2.757149 
C           -0.593441    2.611285    2.950550 
C           -0.587122    3.913613    2.200356 
O           -0.758003    4.989356    2.786739 
N           -0.371502    3.818488    0.884910 
C           -0.359712    4.989654    0.048258 
C           -1.798885    5.451274   -0.083670 
O           -2.078995    6.663586   -0.095901 
C            0.266551    4.703487   -1.318377 
C            1.740247    4.338870   -1.261433 
C            2.198336    3.688475   -2.556632 
N            1.849414    2.270835   -2.611525 
C            2.355226    1.411695   -3.489091 
N            1.977220    0.140861   -3.463878 
N           -2.724702    4.501564   -0.182743 
C           -4.139673    4.869363   -0.237593 
N            3.236832    1.822744   -4.389483 
O           -1.454465   -0.472374    1.160609 
O            0.787256    1.523491   -0.015362 
O            3.576364   -0.701956   -0.384177 
C            4.157960   -1.433388   -1.207098 
O            3.872275   -2.649856   -1.357554 
C            5.237784   -0.789508   -2.049276 
C            5.362564    0.714788   -1.785704 
C            6.130834    0.988061   -0.491544 
O            7.341321    0.818263   -0.438913 
N            6.036255    1.386014   -2.880664 
N            5.415129    1.440272    0.534521 
C            5.998837    1.741698    1.850364 
C            6.736438    0.524842    2.429018 
C            5.822616   -0.498080    3.076973 
C            5.221561   -1.484802    2.327408 
C            4.383723   -2.419125    2.910239 
C            4.148191   -2.380328    4.244300 
C            4.764458   -1.420793    5.024519 
C            5.592356   -0.480179    4.434102 
H            5.018500   -0.929077   -3.014395 
H            6.112356   -1.226017   -1.838695 
H            4.432811    1.072626   -1.701020 
H            5.541278    1.213516   -3.732450 
H            6.970479    1.037538   -2.961593 
H            4.433709    1.582367    0.405585 
H            5.244703    1.962981    2.469019 
H            7.234000    0.076320    1.686751 
191 
 
 
H            7.385253    0.848849    3.117842 
H            5.394406   -1.526631    1.343459 
H            3.951665   -3.122955    2.346899 
H            3.529242   -3.045253    4.663222 
H            4.613424   -1.405066    6.012781 
H            6.027344    0.219745    4.999956 
H           -4.101129    1.838264   -3.758141 
H           -4.122666    0.392196   -3.001056 
H           -2.229159    1.130634   -5.027187 
H           -0.680034    0.853199   -3.272545 
H           -1.525781    2.249642   -3.311284 
H           -0.654331   -1.019008   -3.369770 
H           -1.813222   -3.259208   -4.710505 
H            0.499921   -3.228665   -4.546117 
H            0.420141   -3.202036   -2.915675 
H            0.905050   -5.296945   -3.674268 
H           -1.488633   -2.422431   -1.323354 
H           -3.412870   -4.425399   -0.637266 
H           -2.751233   -4.013590    1.627892 
H           -1.753884   -2.829963    1.105029 
H           -1.460050   -4.384495    0.700287 
H           -3.211877   -1.063271   -0.981607 
H           -4.988591    0.365725   -0.987907 
H           -5.987766   -0.824879   -0.484752 
H           -3.230657   -0.082586    1.388945 
H           -4.885642    1.389256    3.235763 
H           -3.582558    0.280148    5.036399 
H           -2.912463   -1.536753    2.893828 
H           -1.838998   -0.562515    3.646415 
H           -1.634547   -2.770261    4.441513 
H           -3.203766   -2.760738    4.893921 
H           -2.131140   -1.785952    5.646347 
H           -4.928209   -1.698246    5.030770 
H           -5.307427   -1.426487    3.465997 
H           -5.826356   -0.397099    4.622366 
H           -1.597189    0.876399    2.234315 
H           -0.549340    2.829740    3.925307 
H            0.228993    2.109908    2.683817 
H           -0.216312    2.919681    0.474956 
H            0.203953    5.706047    0.458214 
H           -0.229242    3.942905   -1.737380 
H            0.166730    5.520203   -1.886524 
H            2.275584    5.168960   -1.106957 
H            1.888861    3.700674   -0.505735 
H            1.762803    4.158193   -3.325160 
H            3.191574    3.778888   -2.629466 
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H            1.187679    1.925576   -1.945533 
H            3.616833    1.174727   -5.049857 
H            3.521633    2.780681   -4.408593 
H            2.357268   -0.507184   -4.124196 
H            1.311902   -0.169868   -2.784674 
H           -2.455256    3.539183   -0.219361 
H           -4.709168    4.054027   -0.342018 
H           -4.423733    5.392402    0.565986 
H           -4.262434    5.458260   -1.036423 
H            0.603659   -6.068417    2.789313 
H           -0.308115   -4.171757    3.796790 
H           -0.002806   -2.003651    2.929052 
H            2.288940   -3.515455   -0.124973 
H            1.945159   -5.714058    0.736932 
H            6.687273    2.582278    1.776871 
H            6.062033    2.377705   -2.701919 
H           -4.492953    0.484042   -4.595202 
 
 
Complex shown in Figure 4-2, C: 
 
E(B3LYP/6-31G*) = -5203.76225829 
 
C           -4.650931   -3.875018    3.942494 
C           -5.278665   -4.241590    2.771297 
C           -5.628832   -3.288152    1.825213 
C           -5.322039   -1.959816    2.070362 
C           -4.697310   -1.589556    3.237779 
C           -4.359132   -2.550930    4.174980 
C           -6.284062   -3.692621    0.544783 
C           -5.305790   -3.787446   -0.629041 
N           -5.017139   -2.467767   -1.186787 
C           -5.973152   -1.657321   -1.629435 
O           -7.177812   -1.931931   -1.565809 
C           -5.500137   -0.338456   -2.237071 
N           -6.163584   -0.116872   -3.514996 
C           -5.767077    0.823982   -1.273457 
C           -4.801517    0.836201   -0.084474 
O           -3.860552    0.006070   -0.059148 
O           -4.988004    1.679369    0.825546 
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N           -5.392620    4.285088    0.301963 
C           -6.239458    5.176589    1.133674 
O           -1.546300   -0.181465    1.461650 
V           -0.002954    0.388743    0.152605 
O            1.311197   -0.168568    1.419883 
S            1.883731    1.195505   -1.300103 
C            1.208610    2.388941   -2.470610 
C            1.920465    3.745262   -2.495497 
C            1.432286    4.689840   -1.404799 
O            1.992607    5.762388   -1.233670 
N            3.354112    3.612265   -2.305461 
N            0.404434    4.319671   -0.657937 
C            0.014065    5.166578    0.458862 
C            0.902312    4.882213    1.672577 
O            1.519655    5.791369    2.227934 
C           -1.465620    4.985311    0.808062 
O           -1.861487    5.957286    1.759792 
N            0.964358    3.611880    2.064897 
C            1.771541    3.172265    3.200785 
C            3.186869    2.735966    2.792450 
O            4.121871    2.765025    3.603494 
C            1.068468    2.038414    3.921931 
N            3.337482    2.318050    1.540878 
C            4.626439    1.864789    1.049711 
C            4.976289    0.426998    1.386249 
O            6.152042    0.064384    1.412984 
N            3.975371   -0.413965    1.629518 
C            4.275810   -1.824306    1.899476 
C            3.534785   -2.870116    1.073520 
O            4.082805   -3.938281    0.783314 
C            4.090591   -2.141754    3.407836 
C            5.089950   -1.360034    4.238041 
C            2.661827   -1.829555    3.865084 
C            2.407522   -2.153398    5.337411 
N            2.294956   -2.574437    0.699756 
C            1.439084   -3.573991    0.082003 
C            1.648074   -3.702581   -1.408919 
O            2.220247   -4.689406   -1.894179 
N            1.173176   -2.704263   -2.142942 
C            1.410533   -2.656178   -3.575901 
C            2.909037   -2.485172   -3.877756 
O            3.450556   -3.122013   -4.782873 
C            0.573782   -1.536479   -4.206497 
C           -0.927415   -1.791855   -4.116157 
C           -1.746686   -0.549739   -4.437622 
N           -1.814711    0.358230   -3.288516 
194 
 
 
C           -2.547265    1.465695   -3.259972 
N           -2.552921    2.237516   -2.173840 
N            3.573528   -1.628623   -3.107339 
C            5.015125   -1.452502   -3.238876 
C            5.727304   -2.785290   -3.045624 
O            6.614370   -3.139465   -3.819558 
N           -3.277831    1.800308   -4.323512 
C            5.530193   -0.417249   -2.232223 
O            4.848441    0.817683   -2.400596 
O           -0.697240    2.166232    0.117176 
O           -0.568146   -0.901112   -1.140502 
O           -1.164762   -2.564030    2.235684 
C           -0.830482   -3.039655    3.282536 
N           -0.894025   -2.379140    4.389191 
C           -0.278291   -4.423922    3.363198 
H           -5.748066    3.351992    0.344755 
H           -4.453702    4.299654    0.646145 
H           -5.404347    4.602445   -0.646377 
H           -5.850005    0.746974   -3.908246 
H           -7.153058   -0.080039   -3.375735 
H           -4.513944   -0.387651   -2.393155 
H           -5.669438    1.683865   -1.774605 
H           -6.701274    0.743544   -0.926433 
H           -4.065558   -2.163636   -1.236964 
H           -5.654901   -4.403767   -1.334921 
H           -4.447898   -4.165462   -0.280780 
H           -6.985674   -3.017049    0.319389 
H           -6.711525   -4.587106    0.674982 
H           -5.556666   -1.263727    1.391916 
H           -4.487521   -0.627303    3.409995 
H           -3.901734   -2.281806    5.023000 
H           -4.408424   -4.569225    4.619935 
H           -5.484169   -5.205704    2.600969 
H            3.727454    2.998177   -3.000647 
H            3.536822    3.236383   -1.396381 
H            1.709023    4.118632   -3.399094 
H            0.249832    2.546096   -2.234880 
H            1.266173    1.991617   -3.386077 
H           -0.092955    3.475655   -0.856736 
H            0.140702    6.120018    0.185889 
H           -2.016180    5.089091   -0.020439 
H           -1.605605    4.071582    1.190062 
H           -2.828644    5.831964    1.982016 
H            0.435568    2.929220    1.560421 
H            1.873334    3.958060    3.810922 
H            1.624671    1.741290    4.697841 
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H            0.938567    1.272414    3.292161 
H            0.178194    2.353723    4.251129 
H            2.549237    2.315142    0.925327 
H            4.628541    1.958913    0.054706 
H            5.331769    2.455236    1.442603 
H            3.029509   -0.089428    1.628632 
H            5.229613   -1.908390    1.609701 
H            4.253308   -3.119656    3.540769 
H            2.490027   -0.854892    3.721499 
H            2.026732   -2.366568    3.308817 
H            1.461918   -1.928047    5.570072 
H            3.028409   -1.616306    5.909138 
H            2.566753   -3.127920    5.497141 
H            4.959415   -1.573274    5.205971 
H            4.951048   -0.380460    4.091747 
H            6.018820   -1.609694    3.964486 
H            1.944732   -1.649048    0.845280 
H            1.628393   -4.459370    0.505942 
H            0.485833   -3.321684    0.247514 
H            0.645612   -1.976296   -1.704648 
H            1.125806   -3.523679   -3.982658 
H            0.780271   -0.679528   -3.734504 
H            0.825847   -1.455244   -5.170492 
H           -1.169719   -2.513980   -4.764697 
H           -1.147580   -2.090247   -3.187529 
H           -1.323171   -0.070568   -5.206211 
H           -2.674087   -0.827270   -4.687512 
H           -1.277116    0.130157   -2.476867 
H           -3.831372    2.633465   -4.307986 
H           -3.272268    1.218533   -5.137359 
H           -3.105821    3.071208   -2.155430 
H           -2.004845    1.983040   -1.376724 
H            3.074695   -1.095027   -2.424139 
H            5.210521   -1.114577   -4.159945 
H            5.375555   -0.755031   -1.303650 
H            6.509128   -0.275296   -2.377123 
H            5.193876    1.482250   -1.738686 
H            5.470502   -3.377594   -2.281498 
H           -0.171569   -4.665364    4.328090 
H            0.615967   -4.433411    2.915992 
H           -1.255759   -1.447015    4.394571 
H           -0.581884   -2.799489    5.241174 
H           -0.964588   -5.117275    2.879277 
H           -6.226210    4.830426    2.166107 
H           -5.851777    6.193157    1.086655 
H           -7.261623    5.160183    0.758400 
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H           -5.941132   -0.872080   -4.144471 
H           -1.402170   -1.074746    1.751090 
H            3.789450    4.517629   -2.388291 
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American Chemical Society’s Policy on Theses and Dissertations 
If your university requires you to obtain permission, you must use the RightsLink 
permission system.  
See RightsLink instructions at http://pubs.acs.org/page/copyright/permissions.html.  
This is regarding request for permission to include your paper(s) or portions of text from 
your paper(s) in your thesis. Permission is now automatically granted; please pay special 
attention to the implications paragraph below. The Copyright Subcommittee of the Joint 
Board/Council Committees on Publications approved the following:  
Copyright permission for published and submitted material from theses and dissertations  
ACS extends blanket permission to students to include in their theses and dissertations 
their own articles, or portions thereof, that have been published in ACS journals or submitted to 
ACS journals for publication, provided that the ACS copyright credit line is noted on the 
appropriate page(s).  
 
Publishing implications of electronic publication of theses and dissertation material  
Students and their mentors should be aware that posting of theses and dissertation 
material on the Web prior to submission of material from that thesis or dissertation to an ACS 
journal may affect publication in that journal. Whether Web posting is considered prior 
publication may be evaluated on a case-by-case basis by the journal’s editor. If an ACS journal 
editor considers Web posting to be “prior publication”, the paper will not be accepted for 
publication in that journal. If you intend to submit your unpublished paper to ACS for 
publication, check with the appropriate editor prior to posting your manuscript electronically.  
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Reuse/Republication of the Entire Work in Theses or Collections 
 Authors may reuse all or part of the Submitted, Accepted or Published Work in a thesis 
or dissertation that the author writes and is required to submit to satisfy the criteria of degree-
granting institutions. Such reuse is permitted subject to the ACS’ “Ethical Guidelines to 
Publication of Chemical Research” (http://pubs.acs.org/page/policy/ethics/index.html); the 
author should secure written confirmation (via letter or email) from the respective ACS journal 
editor(s) to avoid potential conflicts with journal prior publication*/embargo policies. 
Appropriate citation of the Published Work must be made. If the thesis or dissertation to be 
published is in electronic format, a direct link to the Published Work must also be included using 
the ACS Articles on Request author-directed link − see 
http://pubs.acs.org/page/policy/articlesonrequest/index.html 
  
* Prior publication policies of ACS journals are posted on the ACS website at  
http://pubs.acs.org/page/policy/prior/index.html  
 
If your paper has not yet been published by ACS, please print the following credit line on 
the first page of your article: "Reproduced (or 'Reproduced in part') with permission from 
[JOURNAL NAME], in press (or 'submitted for publication'). Unpublished work copyright 
[CURRENT YEAR] American Chemical Society." Include appropriate information.  
If your paper has already been published by ACS and you want to include the text or 
portions of the text in your thesis/dissertation, please print the ACS copyright credit line on the 
first page of your article: “Reproduced (or 'Reproduced in part') with permission from [FULL 
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REFERENCE CITATION.] Copyright [YEAR] American Chemical Society." Include 
appropriate information.  
 
Submission to a Dissertation Distributor 
If you plan to submit your thesis to UMI or to another dissertation distributor, you should 
not include the unpublished ACS paper in your thesis if the thesis will be disseminated 
electronically, until ACS has published your paper. After publication of the paper by ACS, you 
may release the entire thesis (not the individual ACS article by itself) for electronic 
dissemination through the distributor; ACS’s copyright credit line should be printed on the first 
page of the ACS paper.  
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